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Structures of synthesized compounds reported in chapters 4 and 5 
 
Quinoxaline-amino acid A6a-n 


































*Fragment fused with the quinoxaline framework. N belongs to the quinoxaline skeletal framework. 
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No. R R1 
B5a val - 
B5b met - 
B5c tyr - 
B6a val H 
B6b val F 
B6c val OMe 
B6d val NO2 
B6e met H 
B6f met F 
B6g met OMe 
B6h met NO2 
B6i tyr H 
B6j tyr F 
B6k tyr OMe 
B6l tyr NO2 
                                                  R = amino acid side chain;   
 






Structures of synthesized compounds reported in Chapter 7 
 
 
2-Substituted benzimidazoles C5a-v 
No. R No. R 
 
C5a Ph C5l 4-S(CH3) Ph  
C5b 4-F Ph C5m 2-Naphthyl 
C5c 4-Cl Ph C5n α-(E)-prop-1-en-1-yl Ph  
C5d 4-Br Ph C5o 2-(6-Chloroquinolinyl) 
C5e 4-CF3 Ph C5p 2-OH-4,6-(OCH3)2 Ph 
C5f 4-NO2 Ph C5q 3,4-(OH)2 Ph 
C5g 4-CH3 Ph C5r 2,3,4-(OH)3 Ph 
C5h 4-OCH3 Ph C5s 2-Thiophenyl 
C5i 4-NH2 Ph C5t 2-Furanyl 
C5j 4-OH Ph C5u n-Butyl 





A total of 51 compounds, including 17 quinoxaline-amino acid hybrids (A6a-n and B5a-c), 12 
quinoxaline-amino acid-thiazolidine hybrids (B6a-l) and 22 2-phenyl substituted 
benzimidazoles (C5a-v) were successfully synthesized in yields in excess of 75%.  Of these 
compounds, only 8 of the quinoxaline-amino acid hybrids were previously reported.  All the 
other compounds synthesized in this work were novel.  A thermal study was carried out on the 
quinoxaline-amino acid hybrids A6a-n to determine the hydrogen bonding capabilities of the 
molecules, important in deciding whether or not the molecules can act as good ligands.  It was 
found that of the three centers studied for their hydrogen bonding, NH-1 and NH-4 had very 
poor hydrogen bonding capability whereas the best hydrogen bonding capability was seen by 
H-2.  This study was supported by DFT and MD calculations on A6d since a crystal structure 
was also obtained for this molecule.  The results supported the thermal study in showing that 
H-2 was highly involved in hydrogen bonding.   
Certain steps in the synthesis of compounds B6a-l and C5a-v were carried out under 
microwave conditions, which have the advantage of short reaction times and good yields 
compared to conventional methods.  We report here for the first time the synthesis of 
thiazolidines with quinoxaline-amino acids under microwave conditions.  All the synthesized 
compounds were characterized using instrumental techniques such as 1D and 2D NMR and 
Mass spectrometry.  X-Ray crystallography was carried out on selected samples to confirm the 
structures and to determine the configuration of stereocentres in the molecules.  The crystal 
structures indicated that the quinoxaline-amino acid hybrids were synthesized in the S-
configuration at C-2, while the quinoxaline-amino acid-thiazolidine hybrids were all 
synthesized as racemates. 
The synthesized compounds were tested in three different assays; antimicrobial, antioxidant 
and antidiabetic.  Compounds B6f, B6j and B6k, showed broad spectrum activity in the 
xiii 
antimicrobial assays with minimum bactericidal concentration (MBC) values comparable to 
that of ciprofloxacin.  B6f and B6j was active at <100 µM against all the strains tested against 
and B6k were active at <100 µM against Staphylococcus aureus, Methicillin-resistant S. aureus 
(MRSA) and Escherichia coli as well as the fungal strain, Candida albicans.  B6f was highly 
active against S. aureus (23.4 µM) and Klebsiella pneumonia (11.7 µM), B6j against 
Pseudomonas aeruginosa (21.7 µM) and B6k against S. aureus (15.9 µM) and E. coli (21.2 
µM).  The thiazolidine moiety was essential for antimicrobial activity.  In the first series of 
compounds without the thiazolidine group, the activity was much less (in the mM range), with 
only A6g having a MBC of 80 µM against E. coli.  The antimicrobial activity of the 
benzimidazoles was also not good, with only C5p and C5r being notably active against K. 
pneumoniae (MBCs of 14.5 and 25.5 µM). 
The quinoxaline amino acids A6a, A6d and A6f showed better α-glucosidase inhibitory 
activity with IC50 values of 0.056, 0.012 and 0.042 mM, respectively compared to acarbose 
IC50 of 0.088 mM.  Their activity against α-amylase was not as good, being higher than that 
for acarbose.  The thiazolidine hybrids were less active than the quinoxaline amino acids in the 
antidiabetic assay with only a few compounds being 2-3 fold higher than the acarbose standard.  
Molecular docking of the two most active anti-diabetic compounds (A6d and A6f) in the 
binding site of Saccharomyces cerevisiae α-glucosidase indicated predominant hydrophobic 
and hydrogen bonding interactions, which could be responsible for their activity in the 
antidiabetic assay.  The best antioxidant activity was shown by B6k and B6l with IC50 values 
of 19.60 and 10.53 µM respectively in comparison to ascorbic acid (IC50 16.86 µM). 
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Chapter 1. Introduction 
Quinoxalines and benzimidazoles are two important classes of heterocyclic compounds, with 
major applications in the pharmaceutical industry.  Currently, there are several drugs 
containing a quinoxaline core unit such as echinomycin, levomycin and quinacillin 
(antibiotics), varenicline (nicotinic receptor agonist), brimonidine (eye drop), 
chloroquinoxaline sulfonamide (CQS, NSC 339004), XK469 (NSC697887) (anticancer 
agents), and sulfaquinoxaline (used in veterinary medicine) (Figure 1-1) (Bailly et al., 1999; 
Campbell et al., 2008; Baumann et al., 2013; Nageswar et al., 2013; Ali et al., 2015).  In 
addition, there are several other quinoxaline compounds presently used as AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists such as YM90K, CNQX, 
DNQX, YM872, LU112313 and NBQX (Figure 1-2) (Sasaki and Kaneko, 1996; Kodama et 
al., 1999; Loscher et al., 1999; Takahashi et al., 2002; Olayiwola et al., 2007; Seidl et al., 2014; 
Deng et al., 2016; Zuo et al., 2016). 
 
Several drugs used in the pharmaceutical industry also contain a benzimidazole scaffold in 
their structure.  Examples of these are omeprazole (used for gastric ulcers and acid reflux), 
clemizole and astemizole (antihistamines), mebendazole and thiabendazole (anthelmintics), 
pimobendan (inodilator), bezitramide (analgesic), cambendazole (veterinary anthelmintic), 
Imet-3393 (cancer), pimozide (antipsychotic drug) and diabazole (diabetes) (Figure 1-3) 
(Lieberman et al., 2009; Ingle and Magar, 2011; Khokra et al., 2011; Raghunath et al., 2014; 
Zhang et al., 2015).  In addition, benomyl, thiabendazole and carbendazim are used as 




Figure 1-1  Drugs containing a quinoxaline scaffold 
 
 










Quinoxaline is isomeric with other naphthyridines including quinazoline, phthalazine and 
cinnoline (Figure 1-4).  It consists of two aromatic rings; a benzene ring fused to a second six 
membered ring containing two nitrogen atoms. 
 
 
Figure 1-4  Structures isomeric with quinoxaline 
 
The quinoxaline scaffold occurs in many naturally occurring compounds such as riboflavin 
(Vitamin B2) (Figure 1-5), flavoenzymes, molybdopterines and antibiotics of Streptomyces 
(Saito et al., 1967; Yoshida and Katagiri, 1969; Cornish et al., 1985; Hirose et al., 2011; Mu et 
al., 2014; Sheraz et al., 2014).  Riboflavin is involved in a variety of biochemical processes in 
the body such as antibody production and red blood cell formation (Hardwick et al., 2004).  In 
addition, they have potential industrial application, being able to inhibit metal corrosion, being 
used as dyes, and in organic semiconductors, cavitands and dehydroannulenes (O’Brien et al., 
1996; Koti et al., 2000; Dailey et al., 2001; Sessler et al., 2002; Castro et al., 2004; Sascha and 
Faust, 2004; Chang et al., 2011; Zarrok et al., 2012; Tayebi et al., 2014).  They have also been 
used as a ligand in a catalytic system (Wu et al., 2007). 
 
The first report of a quinoxaline compound having antimalarial activity was reported by 
Haworth in 1948 (Haworth et al., 1948).  In 1949, Crowther and his co-workers synthesized a 
series of dialkylaminoquinoxaline derivatives and tested them for their antimalarial activity.  
They obtained results similar to that of Haworth (Crowther et al., 1949).  The antitumoral 
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properties of quinoxaline compounds was first noticed by Renault in 1981 (Renault et al., 
1981). 
 
Figure 1-5  Biologically active quinoxaline scaffold containing compounds 
 
Subsequently, there has much interest in the synthesis and bioactivity of quinoxaline 
derivatives.  This is elaborated on further in Chapter 2. 
 
1.2 Benzimidazoles 
Benzimidazoles consist of a benzene ring fused to a diazole ring, where both nitrogen atoms 
are adjacent to the benzene ring (Figure 1-6).  They are also known as 1,3-benzodiazoles, 
benziminazoles or benzoglyoxalines.  In 1948, benzimidazole was recognised as an integral 
part of vitamin B12 (α-(5,6-dimethylbenzimidazolyl)cobamidcyanide) available in nature 
(Barker et al., 1960).   
 
 
Figure 1-6  Benzimidazole core structure 
 
Benzimidazole-derived alkaloids are rare in nature, and only a few examples of these natural 
products can be found in the literature such as kealiiquinone (Figure 1-7) (Faulkner et al., 
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1992; Jin, 2011).  In 1889, Fischer reported the bacteriostatic and fungicidal properties of the 
parent benzimidazole (Fischer et al., 1889).   
 
 
Figure 1-7  Structure of kealiiquinone 
 
Beside their pharmaceutical application, benzimidazoles have played a role in organocatalysis, 
ligands for organometallic reactions, in semiconductors, the textile industry, dyes, the 
photographic industry, cosmetics and materials (Johnson et al., 1966; Overman, 1974; Hegngi 
et al., 1999; Berrada et al., 2002; Robert et al., 2004; Malathi et al., 2009; Mamada et al., 2011; 
Kim et al., 2012; Jain et al., 2013; Tozlu et al., 2013; Ahmed et al., 2014; Fleischmann et al., 
2015; Mănescu et al., 2015; Nájera et al., 2015; Bodedla et al., 2016; Sánchez et al., 2016).  5-
Methyl benzimidazole has also been used as camphor substitute (Wright, 1951).  A number of 
salts of benzimidazole sulfonic acid are said to be of value in preparations for dental care 
(Rehman et al., 2013).   
 
The first benzimidazole was prepared by Hobreck in 1872 (Wright, 1951), who obtained a 
mixture of 2,5- and 2,6-dimethyl-benzimidazole (1 and 2) by the reduction of 2-nitro-4-
methylacetanilide (Scheme 1-1).  Three years later Ladenburg obtained the same 




Scheme 1-1.  Synthesis of benzimidazole (1 and 2)  
 
The traditional synthesis of benzimidazoles (3) involves the reaction between an o-
phenylenediamine and a carboxylic acid or its derivatives under harsh dehydrating reaction 
conditions (Scheme 1-2) (Phillips, 1928).  As such, this is known as the “Phillips method”. 
 
 
Scheme 1-2  Benzimidazole synthesized by the “Phillips method” 
 
The first use of triethyl orthoformate for the preparation of 2-substituted benzimidazoles (4) 
was done by Walther and Kessler in 1906 (Scheme 1-3) (Wright, 1951). 
 
 
Scheme 1-3  Benzimidazole (4) synthesized using triethyl orthoformate  
 
Subsequent to these early studies, a range of synthetic pathways and reactions to synthesize 
benzimidazole derivatives were carried out.  This is elaborated on further in chapter 3. 
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This thesis focuses on the synthesis and bioactivity of derivatives of these two scaffolds.  The 
quinoxalines are combined with amino acids and thiazolidines resulting in hybrid molecules 
and the benzimidazoles contain substituted benzene moieties in their core structure.  Hybrid 
molecules can either enhance or diminish the activity of either of the two scaffolds alone 
(Aiyelabola et al., 2012; Saxena et al., 2014; Tripathi et al., 2014; Demmer et al., 2015; 
Mickevičienė et al., 2015; Srivastava et al., 2015; Napoleon et al., 2016).  Both amino acids 
and thiazolidines, are each bioactive molecules in their own right and hence are both capable 
of enhancing the effect of the quinoxalines (Hughes et al., 2007; Singh et al., 2011; Vinay and 
Lakshika, 2011; Bayram et al., 2015; Camacho et al., 2016; Gupta et al., 2016; Pânzariu et al., 
2016).  Different substituents attached to the core structure of many organic molecules alter 
their bioactivity.  Hence derivatising benzimidazoles with aromatic groups containing different 
substituents can be used to identify lead compounds for the pharmaceutical industry.  
 
1.3 Hypothesis 
It is hypothesized that since quinoxalines and benzimidazole scaffolds are contained in known 
drugs, new molecules based on these scaffolds may lead to new drugs with either enhanced 
bioactivity or fewer side effects.  Furthermore, it is hypothesized that the activity of each of the 




To identify lead compounds with quinoxaline and benzimidazole core structures, which can be 




1.5 Objectives  
Broad objective:  To synthesize novel hybrid frameworks of amino acid tethered quinoxalines, 
amino acid-quinoxaline-thiazolidine hybrids and fluorinated benzimidazole derivatives and 
test them for their antimicrobial, antidiabetic and antioxidant activities. 
 
Specific objective 
1. To synthesize a small library of novel: 
a) amino acid tethered quinoxalines;  
b) amino acid-quinoxaline-thiazolidine hybrids and  
c) fluorinated benzimidazoles.  
2. To carry out a structural elucidation of all the synthesized compounds by 2D NMR 
spectroscopy and X-ray crystallography.   
3. To screen the synthesized hybrid compounds for their antibacterial, antifungal, 
antioxidant and antidiabetic activities. 
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Quinoxalines, including those with additional fused heterocyclic rings are an important class 
of compounds with diverse pharmacological properties such as anticancer, antiviral, 
antibacterial and antifungal properties amongst others.  This review reports on the different 
methods used to synthesize quinoxalines and comments on the reactants used to produce 
different types of quinoxalines, together with proposed mechanisms for their synthesis.  
Modification at the 2, 3 and 6 positions of the basic quinoxaline core structure demonstrated 
good antibacterial and antifungal activity.   
 





Quinoxaline is a heterocyclic molecule containing a benzene ring fused to a pyrazine ring 
(Figure 2-1).  It is also known as 1,4-diazanaphthalene or benzopyrine.  The chemistry and 
pharmacological activity of quinoxalines have been recently reviewed (Ajani et al., 2014), 
which shows their potential to be used widely in the field of pharmacy and medicine.  In 
addition, there have also been reports of them used in industrial applications (Kono et al., 2012; 
Keshtov et al., 2015). 
 
 
Figure 2-1  The general structure of a quinoxaline with nomenclature included 
 
Quinoxaline derivatives possess a wide range of pharmacological properties such as 
antimicrobial (Alasmari et al., 2015; Chaudhary et al., 2015; Issa et al., 2015; Manchal et al., 
2015), antifungal (Castro et al., 2015; Issa et al., 2015; Manchal et al., 2015), antioxidant 
(Manta et al., 2014; Burguete et al., 2011), anticancer (Neckel et al., 2015; Thabit et al., 2015; 
Ma et al., 2014, 2015), antidiabetic (Kulkarni et al., 2015), antitubercular (Puratchikody et al., 
2011; Achutha et al., 2013), antimalarial (Chandra Shekhar et al., 2014), anti-inflammatory 
(Burguete et al., 2011), antiviral (Selvam et al., 2011; Henen et al., 2012), and anti-HIV (Gris 
et al., 2008).  The quinoxaline framework was also part of various antibiotics such as 
echinomycin, levomycin and actinolutin, known to inhibit growth of Gram +ve bacteria 
(Katagiri et al., 1975). 
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In this review, we focus on the different routes for synthesizing quinoxaline molecules and 
highlight the reactants used in each of these routes.  We also attempt to provide some 
mechanistic information on the formation of these molecules from their precursors. 
 
2.2 Synthesis 
A common procedure for the synthesis of these molecules makes use of ortho diamines, which 
undergo substitution or addition reactions with dicarbonyl compounds or carbonyl derivatives 
forming the quinoxalines (Ingle and Wadher, 2014; Chandra Shekhar et al., 2014; Alasmari et 
al., 2015; Demmer et al., 2015).  Various carbonyl compounds such as oxalic acid (Pradeep et 
al., 2015; Thabit et al., 2015), pyruvic acid (Noolvi et al., 2011) and acetic acid (Kumar et al., 
2013; Neckel et al., 2015) all result in different quinoxalines being formed, each with different 
groups at C-2 and C-3.  In addition, quinoxalines were synthesized from α,β-unsaturated 
carbonyl compounds (Arimondo et al., 2001; Vekariya et al., 2003; Karki et al., 2009; Hossain 
et al., 2012; Manta et al., 2014), α-chloro carbonyl compounds (Gavara et al., 2010) and 1,4-
dialdehydes (Diana et al., 2008; Parrino et al., 2015), all using o-phenylenediamines.  There 
are also some miscellaneous routes to synthesizing quinoxalines, which involve nucleophilic 
substitution reactions of fluorinated nitrobenzenes and fluorinated amines (Moarbess et al., 
2008; Khier et al., 2010).  Quinoxaline N-oxides were also reported to be synthesized from 
benzofurazan (Ismail et al., 2010; Barea et al., 2013; Torres et al., 2013; Gil et al., 2014).  
 
2.2.1 Quinoxalines synthesized from o-phenylenediamines and 1,2-dicarbonyl 
compounds 
In this particular synthesis, the amino group first reacts with one carbonyl group by either a 
substitution reaction (if the leaving group is good) or an addition reaction (with a poor leaving 
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group).  A second nucleophilic addition to the second carbonyl group in an intramolecular 
reaction leads to the formation of the quinoxaline. 
 
2.2.2 The reaction of ortho diamines with 1,2-dicarbonyl compounds with leaving 
groups at both carbonyl centers 
There have been several reports of quinoxalines being synthesized from oxalic acid resulting 
in quinoxaline-2,3-dione (5) (Alasmari et al., 2015; Thabit et al., 2015; Pradeep et al., 2015).  
These intermediates was synthesized en route to other quinoxaline derivatives, which make use 
of the reactivity of the two amide bonds formed in the reaction.  The lone pair of the amine of 
the diamine initially adds to the carbonyl carbon of the carboxylic acid, forming the alkoxide 
anion, followed by the same mechanism occurring with the other amino group and carboxylic 
group, the latter being an intramolecular reaction.  The hydroxyl group in the intermediate then 
picks up a proton, and reformation of the carbonyl group at C-2 occurs forming the quinoxaline-
2,3-diones (5) (Scheme 2-1).  The same mechanism takes place with diethyloxalate and this 
reagent can be used for the synthesis of quinoxaline-2,3-dione instead of oxalic acid (Demmer 
et al., 2015). 
 
 
Scheme 2-1  Mechanism of synthesis of quinoxaline-2,3-diones (5) 
 
Once formed, the intermediate 5 can be chlorinated at both C-2 and C-3 with phosphoryl 
chloride (POCl3) in DCM or with POCl3 and thionyl chloride (SOCl2) leading to the 3-chloro-
2-ketoquinoxaline (6) or dihalogenated quinoxaline (7).  These halogenated quinoxalines can 
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then be substituted with strong bases for example hydrazine hydrate resulting in the hydrazine 
derivative 8 and 9 (Scheme 2-2) (Suresh et al., 2010; Galal et al., 2011, 2013; Alswah et al., 
2013; Alasmari et al., 2015). 
 
Scheme 2-2  Derivatization of quinoxaline-2,3-diones (5) 
 
2.2.3 The reaction of ortho diamines with 1,2-dicarbonyl compounds with leaving 
groups at only one carbonyl centre 
Pyruvic acid (Noolvi et al., 2011; Andres et al., 2013; Chaudhary et al., 2015), 2-oxoacetic acid 
(Rodrigues et al., 2014), 2-oxo-2-phenylacetic acid (Corona et al., 2008, 2009), ethyl-2-
oxopropanoate (Andres et al., 2013), ethyl 2-(1-benzoyl-1H-indol-3-yl)-2-oxoacetate (El-Sawy 
et al., 2010) and ethyl oxamate (Galal et al., 2011) all have one good leaving group (or a 
hydroxyl group capable of being protonated) and one poor leaving group attached to each of 
the carbonyl centres (Scheme 2-3).  After nucleophilic attack by the amino group of the 
diamino phenyl reagent, the leaving group departs from the tetrahedral intermediate after a 
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proton is abstracted from the secondary amine, forming an amide bond.  Nucleophilic attack of 
the second amine intramolecularly results in a tetrahedral hydroxy intermediate, which 
undergoes elimination of water after a base abstracts a proton from the secondary amine, 
forming the imine.  The product of the reaction with 1,2-dicarbonyl compounds with one 
leaving group is a 3-substituted quinoxaline-2-one (14) (Scheme 2-4). 
 
 
Scheme 2-3  Reactions of o-diamine with one leaving group containing compound 
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Scheme 2-4  Mechanism for synthesis of 3-aminoquinoxalin-2(1H)-one (14) 
 
2.2.4 The reaction of ortho diamines with 1,2-dicarbonyl compounds with two poor 
leaving groups (1,2-diketones and 1,2-dialdehyde) 
Two types of 1,2-diketones are reported to react with the diamines.  The first consists of alkyl 
groups which are not joined together (open chain diketones) (Gavara et al., 2010; Isikdag et 
al., 2011; Rajule et al., 2012; Chandra Shekhar et al., 2014; Piras et al., 2014) and the second 
contains the diketone as part of a ring (mainly five membered and six membered rings) (Gavara 
et al., 2010; Isikdag et al., 2011; Alasmari et al., 2015). 
 
Examples of these precursors to the quinoxalines include simple 1,2-diketones such as hexane-
3,4-dione (Gavara et al., 2010) as well as aromatic diketones such as substituted benzils (Ingle 
and Marathe, 2012; Ingle et al., 2013; Ingle and Wadher, 2014).  The substituents on the 
dicarbonyl compound could even be heterocyclic rings such as pyrrolopyridine (Leboho et al., 
2015).  When the diacarbonyl compounds are contained in heterocyclic rings such as indoline-
2,3-dione (Arimondo et al., 2001; Karki et al., 2009; Sridevi et al., 2011; Hossain et al., 2012; 
Srinivas et al., 2013) or carboxcylic rings such as cyclopentane-1,2-diones (Gavara et al., 2010; 
Alasmari et al., 2015), a heterocyclic or carbocyclic ring occurs at the 2 and 3 positions of the 
quinoxaline molecule after addition of the diamine (Scheme 2-5).   
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The mechanism for these reactions consist of the amino groups adding to the carbonyl carbon, 
forming an alcohol after which the same mechanism occurs intramolecularly to form the 
quinoxalines.  Elimination of two water molecules results in the formation of the substituted 
quinoxaline molecule (15) (Scheme 2-6), with both substituents adjacent to the carbonyl 
groups retained after imine formation.  With glyoxal (Melero et al., 2004; Huang et al., 2009; 
Mielcke et al., 2012; Neckel et al., 2015), butenedioane (Melero et al., 2004), a two-carbon 
compound containing two aldehyde groups (Melero et al., 2004), an unsubstituted quinoxaline 
occurs where R1 and R2 is hydrogen (Scheme 2-6).   
 
 





Scheme 2-6 Mechanism of formation of quinoxaline (15) 
 
2.2.5 The reaction of diamines with α,β-unsaturated carbonyl compounds 
There are two reports of quinoxalines forming from α,β-unsaturated carbonyl compounds, 
however the mechanisms for these reactions are not clear.  In the first instance, bromoacetic 
acid is used together with the α,β -unsaturated carbonyl compound producing a quinoxaline 
where the two nitrogen atoms from the diamine add across the double bond and the carbonyl 
group is reduced in the process.  It is reported that the product forms through a dibromo 
intermediate, but this is not further clarified (Vekariya et al., 2003).  This leads to the 
quinoxalines 21-29 in Scheme 2-7. 
 
 
Scheme 2-7  Synthesis of benzimidazole fused quinoxaline compounds (21-29) 
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The second example contains an α,β-unsaturated amide group reacting with a hydroxy and ester 
substituted double bond in the reagent.  A complete mechanism is not reported in the literature 
(Manta et al., 2014), however it is proposed that 30 occurs through a nucleophilic attack on the 
α-carbon of the double bond, resulting an enolate ion, which eliminates H2O on reformation of 
the α,β-unsaturated group, placing the double bond adjacent to the ester carbonyl.  A second 
nucleophilic attack on the amide carbonyl and elimination of water leads to the quinoxalines 
30 (Scheme 2-8).  Compound 31 is formed by reduction since this is energetically favourable 
due to the formation of a fully conjugated system.   
 
Scheme 2-8  Synthesis and mechanism of pyrrolo quinoxaline 
 
25 
2.2.6 The reaction of diamines with α-chloro ketones 
The reaction of diamines with α-chloro ketones probably occurs via a direct nucleophilic 
substitution of the chloro group with an amino group of the diamine followed by nucleophilic 
attack by the second amino group on the carbonyl carbon producing an aminol, which 
dehydrates to an imine forming the quinoxaline 32.  PTSA is used as a catalyst in the reaction.  
The products reported in Gavara et al. (2010) is speculated to be due to a subsequent reduction 
step after formation of the quinoxaline, since formation of 32 leads to aromaticity into the 
nitrogen-containing ring (Scheme 2-9) (Gavara et al., 2010). 
 
 
Scheme 2-9  Synthesis and mechanism of pyrazolo quinoxalines 
 
2.2.7 Formation of quinoxalines by nucleophilic substitution of ortho 
nitrofluorobenzenes and ortho aminofluorobenzenes 
Ortho nitrofluorobenzenes were subjected to a nucleophilic substitution reaction with 
imidazole.  Reduction of the nitro group to the amine follows and then formation of the 
quinoxaline with di-imidazolylmethanone.  This occurred by attack of the amine on the di-
imidazolylmethanone carbonyl group with a concomitant loss of one imidazole group and then 
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an intramolecular attack on the same carbonyl group by the imidazolyl group ortho to the amide 
resulting in formation of the quinoxaline (34) and departure of the second imidazole group 
(Scheme 2-10) (Moarbess et al., 2008).   
 
With imidazole and pyrazole dimers formed through their carboxylic acids, the amino group 
of the ortho aminofluorobenzene attacks the carbonyl group of the dimer resulting in cleavage 
of the imidazole group.  Attack at the other carbonyl group in a similar fashion leads to two 
molecules of the fluorinated intermediate being formed.  The imidazole nitrogen then replaces 
the fluorine on the aromatic ring leading to formation of the quinoxalines (35) (Scheme 2-11) 
(Moarbess et al., 2008; Khier et al., 2010). 
 
 
Scheme 2-10  Mechanism of formation of imidazole quinoxaline (34) 
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Scheme 2-11  Synthesis and mechanism of pyrazolo quinoxaline (35) 
2.2.8 Reaction of azalactones with diamines 
The cinnamate azalactone was prepared by the reaction of N-acetyl glycine with 
benzaldehydes, which when added to the ortho diamine forms quinoxaline (36) (Issa et al., 
2015).  It is speculated that the reaction occurs through a nucleophilic attack by the amine on 
the lactone carbonyl, which rearranges to the keto tautomer before attack on the imine carbon 
occurs by a pictet-spengler like reaction.  Removal of an acetonitrile group then leads to the 
quinoxaline 36 (Scheme 2-12). 
 
2.2.9 Reaction of 1,2-dialdehydes with diamines 
Diamines react with 1,2-dialdehydes in the presence of a cyanide ion and acid, producing a 
cyano intermediate (39) which further cyclises to three different quinoxalines (40-43) (Scheme 
2-13) (Diana et al., 2008; Parrino et al., 2015).  In the synthesis of the intermediate, one of the 
amino groups first adds to the aldehyde forming an imine, which is activated by acid and 
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attacked by a cyanide ion.  The secondary amine formed then attacks the second aldehyde 
resulting in pyrrole formation to which a nitrile is attached (39) (Scheme 2-14). 
 
Scheme 2-12  Reaction and mechanism of quinoxaline via azalactones with diamines 
 
Scheme 2-13  Synthesis of quinoxalines from 1,2-dialdehydes with diamines 
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In formation of the first quinoxaline (40), H2O adds to the nitrile carbon and the nitrile nitrogen 
is protonated by acid, resulting in an imide, which is further protonated, resulting in collapse 
of the imide to the amide.  Intramolecular amide formation then occurs under acidic conditions, 
hydrolysing the free amide and forming a cyclic amide resulting in the quinoxaline (40) 
(Scheme 2-15).  In the second quinoxaline (41), collapse of the imide to the amide does not 
occur, but instead the second amino group adds to the activated iminium carbon, forming the 




Scheme 2-14  Mechanism of preparation of intermediate (39) 
 
 
Scheme 2-15  Mechanism of formation of quinoxaline (40) 
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Scheme 2-16  Mechanism of formation of quinoxaline (41) 
 
The third quinoxaline forms by the amine of the nitrile intermediate (39) reacting with formic 
acid and producing a protonated intermediate to which a water molecule adds resulting in ring 
closure.  Loss of two water molecules leading to the stable aromatic quinoxaline (43) then 
occurs  (Scheme 2-17). 
 
 
Scheme 2-17  Mechanism of formation of quinoxaline (43) 
 
2.2.10 Reaction of diamines with 3-chloro-2-oxopropanal and iodoxybenzoic acid 
3-chloro-2-oxopropanal and iodoxybenzoic acid first reacts to activate the aldehydic carbonyl 
group.  Thereafter the two amino groups attack each of the carbonyl groups forming a hydroxy 
31 
intermediate (44).  The first double bond forms when the iodo complex is eliminated and the 
quinoxaline (45) forms after the elimination of water (Scheme 2-18) (Elshihawy et al., 2013). 
 
 
Scheme 2-18  Mechanism for synthesis of quinoxaline using IBX 
 
2.2.11 Synthesis of 1,4-di-N-oxide quinoxaline derivatives 
The benzofurazan oxide 46 is an important intermediate in the synthesis of 1,4-di-N-oxide 
quinoxaline derivatives, which can react with nitrile, carbonyl or dicarbonyl compounds with 
acidic α hydrogens or with conjugated double bonds.  This benzofurazan oxide (46) 
intermediate was synthesized from 2-nitroaniline by reacting it with either sodium nitrite, 
sodium azide (Monge et al., 1995) or sodium hypochlorite (Sheng et al., 2007) (Scheme 2-19).  
2-Nitroaniline is commercially available, however it can also be synthesized from aniline by 
first protecting the aniline and then nitrating it.  Depending on the reagent used, different 
functionalities become available on the quinoxaline ring, which can be reacted further to create 




Scheme 2-19  Synthesis of benzofurazan oxide (46) 
 
By the reaction of 46 with malonitrile, N-oxide quinoxalines 47 (Monge et al., 1995) with 
cyano and amino groups result where the amino group is reacted further with dimethyl 
sulphoxide producing N-methyl derivatives 48 (Ismail et al., 2010), acid chlorides producing 
N acyl derivatives 49 (Barea et al., 2013) and acetic anhydride producing N acetyl derivatives 
50 (Ismail et al., 2010) (Scheme 2-20).  With styrene imines, the intermediate 46 produces N-
oxide quinoxalines with imino groups 51, which can be reduced with LiBH4 to yield amines 
52 (Scheme 2-20) (Ismail et al., 2010). 
 
Scheme 2-20  Synthesis of N-oxide quinoxaline derivatives 
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Substituted 2-keto-3-methylquinoxaline-1,4-dioxides (53) were prepared by the Beirut reaction 
(reacting 1,3-dicarbonyl compounds, ethanol, morpholine and the benzofurazan oxide 46).  
These intermediates were further reacted with DMA (a strong base) and DMF in xylene 
yielding the enamines (54) or the enaminone derivative (55).  The intermediate quinoxaline-N-
oxide acetophenone (53b) underwent Claisen-Schmidt condensation reactions with various 
substituted aldehydes yielding chalcones (56) which were used as precursors for the synthesis 
of three, five and six membered cyclic compounds 57, 58 and 59 respectively (Amin et al 2006; 
Gil A et al., 2014) (Scheme 2-21). 
 
Scheme 2-21  Synthesis of different N-oxide quinoxaline derivatives 
 
The mechanism of the Beirut reaction involves the enol form of the 1,3-dicarbonyl compound 
attacking the electrophilic N-oxide nitrogen of the benzofurazan N-oxide (46), forming an 
anion on the other nitrogen, which subsequently adds to the carbonyl of the ketone forming an 
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alcohol intermediate.  Rearrangement of the benzofurazan N-oxide and elimination of water 
results in the 1,4-di-N-oxides (53) (Scheme 2-22). 
 
 
Scheme 2-22  Mechanism of the Beirut reaction 
 
The benzofurazan N-oxide 46 reacts with various other 1,3-dicarbonyl reagents or a β-
cyanocarbonyl reagent yielding quinoxaline alkyl esters 60, ketones (61-63) or caboxamides 
(64) (Zarranz et al., 2004; Amin et al., 2006; Solano et al., 2007; Torres et al., 2013) (Scheme 
2-23).  The bubbling of ammonia gas in a warm alcoholic solution of 46 and substituted 
acetophenones for 3 h yielded 65, a phenylene quinoxaline derivative in high yields (Amin et 
al., 2006) (Scheme 2-23). 
 
The reaction of 46 with hydrazine hydrate and ethyl acetoacetate produced the intermediate 66, 
which upon treatment with sodium nitrite produced the keto azides 67, which were reacted 
further with aryl amines and alkyl alcohols to produce quinoxaline N-oxide ureas (68) or 




Scheme 2-23  Reactions of benzofurazan oxide with different dicarbonyl compounds 
 
 




2.2.12 Synthesis of quinoxaline ligands starting with phenanthroline and subsequent 
complex formation 
Quinoxaline based ligands were synthesized by oxidation of phenanthroline (70) using 
sulphuric and nitric acids along with sodium bromide to yield 2,10-phenanthroline-5,6-dione 
(71).  This diketo intermediate, 71 was further reacted with various di-amino compounds such 
as ethylene diamine, o-phenylenediamine and cyclohexane-1,2-diamine to yield dipyrido[3,2-
d:2',3'-f] quinoxaline (72), dipyrido[3,2-a:2',3'-c]phenazine (73) and dipyrido[3,2-a:2',3'-
c](6,7,8,9-tetrahydro)phenazine (71) respectively (Scheme 2-25).  These derivatives 72, 73 and 
74 were bidentate ligands, which were shown to co-ordinate to Cu and Pd metals via the 
nitrogen lone pairs of the phenanthroline ring resulting in the quinoxaline metal complexes 75-
82 (Nagaraj et al., 2015; Ma et al., 2014, 2015) (Scheme 2-26 and Scheme 2-27).  
 
Scheme 2-25  Synthesis of different quinoxaline ligands 
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Scheme 2-26  Synthesis of metal complexes of quinoxaline 
 
 
Scheme 2-27  Synthesis of quinoxaline metal complexes 
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Manchal et al. (2015) reported various metal complexes (84-87) prepared from the quinoxaline 
schiff base (83) obtained from commercially available 3-chloro-2-hydrazinequinoxaline (8) and 
furfuraldehyde (Manchal et al., 2015).  This ligand 83 co-ordinates to the metal via the nitrogen 
atoms of the quinoxaline and imine and the oxygen atom of the furan ring (Scheme 2-28). 
 
 
Scheme 2-28  Metal complexes prepared from quinoxaline schiff bases 
 
Quinoxaline dione (5) treated with substituted hydrazine carbothioamides (88) yielded the 
thiosemicarbazide ligand 89-90 which was shown to complex with various metals via both 
sulfur and nitrogen to form the complexes 91 (Kulkarni et al., 2012) (Scheme 2-29).  
 
 
Scheme 2-29  Quinoxaline metal complexes prepared from thiosemicarbazide ligand 
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2.3 Pharmacological Importance of Quinoxaline Derivatives 
Derivatives of quinoxaline have shown activity in a vast array of biological assays including 
antioxidant, antimicrobial, anticancer, antitubercular, antimalarial, analgesic, anti-
inflammatory, anticonvulsant, anti-epileptic and anti-HIV and have been reviewed extensively 
in the last three years (Ajani et al., 2014; Ali et al., 2015; Newahie et al., 2016).  Synthetic 
quinoxalines form part of antibiotics such as echinomycin, levomycin and actinomycin 
(Katagiri et al., 1975).  This short review focusses on the antimicrobial and antidiabetic 
activities of quinoxalines, since these two biological assays were carried out in this thesis. 
 
2.3.1 Antimicrobial activity  
Table 2-1 to Table 2-4 contains quinoxaline derivatives with reported MIC values of <100 µg 
mL-1 and zones of inhibition >25 mm.  These quinoxalines fall into several classes of 
substituted quinoxalines ranging from simple quinoxalines to more complex dimers.  
 
The simple quinoxalines contain substituents at the nitrogen, C-2 and C-3 and various positions 
on the aromatic ring (Figure 2-2).  These quinoxalines contain thioketo groups at C-2 and alkyl 
groups at N-1 (92, 93) (Caleb et al., 2011), carboxylic acids at C-3 along with methoxy or 
ethoxy groups (94-96) (Kumar et al., 2013), a 2-chloro-3-alkyl-3-carboxylate (97) (Kumar et 
al., 2013), C-6 amino acid linked quinoxalines (98-109) (Chaudhary et al., 2015), and a 6-
methyl-2-piperidinyl quinoxaline (110) (Henen et al., 2012), 2,3-diphenyl-6-sulphonyl 
quinoxalines (111-118) (Ingle and Wadher, 2014), 3-hydrazino-2-benzylquinoxaline (119) 
(Issa et al., 2015) and 2-hetrocyclic-3-alkyl or aromatic substituted quinoxalines (21-29, 120-
124) (Vekariya et al., 2003; El-Sawy et al., 2010; Issa et al., 2015).  Among these compounds, 
the best antimicrobial activity was seen by the C-6 amino acid linked quinoxalines 98-109 
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(Table 2-1 and Table 2-2) ranging from 6 to 25 µg mL-1 and 96-97 and 121-122 showing zones 
of inhibition > 30 mm (Table 2-1 and Table 2-2). 
 
 
Figure 2-2  Biologically active simple quinoxaline compounds 
 
The second class of bioactive quinoxalines are the 2-substituted C-3-N-4 fused triazolo 
quinoxalines.  Compounds 125-133 contain a benzyl-substituted group at C-2 and a triazolo 
group fused at C-3-N-4 (Issa et al. 2015).  The triazolo moiety in turn has C-3' substituted alkyl 
(126), phenyl (127, 128), keto (129), ester (130, 131), alkyl acid (132) or phenyl acid (133) 
group attached to it, providing further variation within this class.  Further compounds 134-145 
contains chloro, methoxy, thioacids, piperazine, anilines and thiotriazoles at the 2-position 
(Figure 2-3) (Suresh et al., 2010; Henen et al., 2012). 
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Gram Negative Fungi 
S.A B.S 
 
B.M R.F E.C P.V K.P P.A C.A A.N M.A P.C 
DD MIC 
 
DD MIC DD MIC DD DD MIC MIC MIC DD MIC MIC DD 
21 18-25 - - - - - 18-25 - - - - - - - - 
22 18-25 - - - 18-25 - 18-25 18-25 - - - - - - - 
23 - - - - 18-25 - - - - - - 18-25 - - - 
24 18-25 - - - - - - - - - - 18-25 - - - 
25 18-25 - - - - - - - - - - 18-25 - - - 
26 - - - - - - 18-25 18-25 - - - 18-25 - - - 
27 - - - - - - 18-25 - - - - 18-25 - - - 
28 - - - - - - - 18-28 - - - - - - - 
29 - - - - - - - 18-25 - - - - - - - 
92* - 32 - - - 16 - - - - - - - - - 
93* - 64 - - - - - - - - - - - - - 
94 - - - - - - - - - - - 29 - - - 
95 - - - - - - - - - - - 27 - - - 
96 - - 35 - - - - - - - - 33 - - - 
97           - 30 - - - 
98 - 12.5 - 6 - - - - 12.5 6 6 - 12.5 25 6 
99 - 25 - 12.5 - - - - 12.5 6 12.5 - 12.5 12.5 12.5 
100 - 12.5 - 6 - - - - 12.5 6 6 - 25 25 6 
101 - 12.5 - 6 - - - - 25 12.5 12.5 - 12.5 25 6 
102 - 25 - 12.5 - - - - 25 6 6 - 12.5 12.5 6 
103 - 12.5 - 6 - - - - 12.5 6 25 - 25 6 25 
S.A = Staphylococcus aureus; B.S = Bacillus subtilis; B.C = Bacillus cereus; B.M = Bacillus magaterium; R.F = Rhodococcus fascians; E.C = Escherichia 
coli; P.V = Proteus vulgaris; K.P = Klebsiella pneumoniae; P.A = Pseudomonas aeruginosa; C.A = Candida albicans; A.N = Aspergillus niger; M.A = 
Microsporum audouinii; P.C = Penicillium chrysogenum; DD = Disc diffusion method, zone of inhibition in mm; MIC = Minimum inhibitory concentration 
in µg ML-1; * = MIC value in mg ML-1.  Highlighted values show the most best results. 
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MIC MIC DD 
 
MIC MIC DD MIC DD MIC MIC MIC DD 
104 12.5 6 - - 6 - 6 - 6 12.5 25 6 
105 12.5 6 - - 6 - 6 - 6 25 12.5 6 
106 25 6 - - 6 - 12.5 - 6 12.5 12.5 6 
107 12.5 12.5 - - 6 - 6 - 6 12.5 12.5 6 
108 25 6 - - 6 - 6 - 6 12.5 12.5 6 
109 12.5 6 - - 6 - 6 - 6 12.5 12.5 6 
110 - - - 85 - - - - - - - - 
111 23 - - 36 - - - - - - - - 
112 32 - - 35 - - - - - - - - 
113 50 - - 40 - - - - - - - - 
114 12 - - 67 - - - - - - - - 
115 35 - - 25 - - - - - - - - 
116 19 - - 21 - - - - - - - - 
117 22 - - 27 - - - - - - - - 
118 24 - - 29 - - - - - - - - 
119 100 50 - 50 - - 100 - 50 - - - 
120 100 100 - 100 - - 50 - 50 - - - 
121 - - - - - - - 32 - - - - 
122 - - - - - - - 32 - - - - 
123 - - 28 - - 25 - - - - - - 
124 - - 28 - - 25 - - - - - - 
DD = Disc diffusion method, zone of inhibition in mm; MIC = Minimum inhibitory concentration in µg ML-1.  Highlighted values show the most  
best results.
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Compounds 125, 127, 132 and 133 showed MIC values of 25 µg mL-1 or less against bacterial 
strains, whilst 128, 130-131 and 133 showed MICs of 25 µg mL-1 against C. albicans.  Compounds 
136, 139 and 142 showed zones of inhibition of > 30 mm against bacterial strains with 136 showing 
a broad spectrum of activity being active against both Gram +ve and Gram –ve bacteria.  
Compounds 138, 140-143 all showed zones of inhibition > 30 mm against the fungal species, A. 
niger and P. chrysogenum (Table 2-3). 
 
 
Figure 2-3  Second class of quinoxaline compounds  
 
A set of unique quinoxalines with a C-2-C-3 fused imidazo thiadiazo group also showed good 
bioactivity (146-152) (Teja et al., 2013).  Compounds 146-147 showed MICs of 15.63 µg mL-1 
against Gram +ve and Gram –ve bacteria as well as the fungal A. fumigatus.   
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A. niger P.  
chrysogenum 
DD MIC DD 
 
MIC MIC DD DD MIC MIC DD DD 
125 - 50 - 50 25 - - 50 100 - - 
126 - 50 - 50 50 - - 100 100 - - 
127 - 100 - 25 25 - - 50 100 - - 
128 - 50 - 100 100 - - 50 25 - - 
129 - 100 - 100 100 - - 100 50 - - 
130 - 50 - 50 50 - - 100 25 - - 
131 - 50 - 100 100 - - 100 25 - - 
132 - 25 - 12.5 12.5 - - 25 50 - - 
133 - 100 - 100 25 - - 100 25 - - 
134 - - - - 87 - - - 89 - - 
135 - 84 - - - - - - - - - 
136 31 - 30 - - 31 35 - - - - 
137 25 - - - - - - - - 26 26 
138 - - - - - - - - - 31 - 
139 32 - 27 - - - 36 - - - 25 
140 26 - 26 - - - - - - 25 30 
141 - - - - - - - - - 30 26 
142 28 - 31 - - - - - - 31 28 
143 25 - - - - - - - - 33 34 
144 - 94 - - 67 - - - - - - 
145 - - - 91 98 - - - 78 - - 
DD = Disc diffusion method, zone of inhibition in mm; MIC = Minimum inhibitory concentration in µg ML-1.  Highlighted values show the best results.  
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The best activity was seen by the 2-hydroxyphenyl derivative 149, which showed MIC values of 
7.81 µg mL-1 against these same bacterial and fungal strains (Table 2-4).  Three molecules with a 
six membered triazine ring fused at C-3-N-4 (153-155) also showed activity < 100 μg mL-1 with 
153 showing a MIC of 25 µg mL-1 against P. aeruginosa and 12.5 µg mL-1 against C. albicans 
(Figure 2-4; Table 2-4) (Issa et al., 2015). 
 
Compounds 156-158 contained a methylene linker bridging two quinoxalines (Srinivas et al., 
2013) (Figure 2-4).  The para chloro and fluoro derivatives 157 and 158 showed MIC values of 
8-16 µg mL-1 against both Gram +ve and –ve bacterial strains (Table 2-4). 
 
Two metal chelated quinoxalines (75, 76) synthesized from phenanthroline and ethylenediamine 
precursors (discussed above, Scheme 2-27) showed zones of inhibition of 26 and 29 mm 
respectively against an unspecified fungal Aspergillus species (Table 2-4) (Nagaraj et al., 2015).   
 
 
Figure 2-4  Unique quinoxaline compounds 
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A. niger A. 
fumigatus 
Aspergillus 
MIC (µg ML-1) 
 
DD 
75 - - - - - - - - - 26 
76 - - - - - - - - - 29 
146 31.25 - 15.63 31.25 - 15.63 - 31.25 15.63 - 
147 31.25 - 15.63 31.25 - 31.25 - 31.25 15.63 - 
148 31.25 - - 31.25 - - - - - - 
149 7.81 - 7.81 31.25 - 7.81 - 31.25 7.81 - 
150 - - 31.25 - - - - 31.25 31.25 - 
151 - - - 31.25 - 31.25 - 31.25 - - 
152 31.25 - 31.25 - - 31.25 - - - - 
153 50 25 - 50 - 25 12.5 - - - 
154 50 100 - 50 - 50 25 - - - 
155 50 50 - 50 - 100 50 - - - 
156 - 64 - - - - - - - - 
157 8 8 - 16 8 - - - - - 
158 8 16 - 16 16 - - - - - 
DD = Disc diffusion method, zone of inhibition in mm; MIC = Minimum inhibitory concentration in µg ML-1.  Highlighted values show the best results.  
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2.3.2 Antidiabetic Activity 
Antidiabetic activity of quinoxalines were limited to the quinoxaline–thiosemicarbazone 
ligands (89-90) and their metal complexes (91) (Kulkarni et al., 2012) (Scheme 2-29).  This 
was evaluated by a blood-glucose and oral glucose tolerance test (OGTT).  These compounds 
showed a notable reduction in the blood glucose level and promising activity in the OGTT.  In 
addition, they posessed low toxicity with a high safety profile (Kulkarni et al., 2012). 
 
2.4 Conclusion 
Quinoxalines can be easily synthesized using a variety of methods, most of which contain an 
ortho-diamine with oxalic acid derivatives.  There are however some other more specific 
syntheses, also contained in this review.  This literature survey identifies many quinoxaline 
molecules with promising antibacterial and antifungal activity such as C-6 amino acid linked 
quinoxalines (MIC 6-12.5 µg mL-1), 7,8-dinitro-2-(2-hydroxy-phenyl)[1,3,4] 
thiadiazolo[2’,3’:2,3]imidazo[4,5-b]quinoxaline (MIC 7.81 µg mL-1), (5-(4-fluorophenyl)-3-
((2-(3-(3-phenylquinoxalin-2-yl)benzyl)-6H-indolo[2,3-b]quinoxalin-6-yl)methyl)-4,5-
dihydro-1H-pyrazol-1-yl)(phenyl)methanone (MIC 8-16 µg mL-1) and 3-(4-benzyl-
[1,2,4]triazolo[4,3-a] quinoxalin-1-yl)propanoic acid (MIC 12.5-50 µg mL-1).  These 
compounds can be considered lead compounds for antibiotics since they show better activity 
than gatifloxacin, ampicillin and clotrimazole (currently used antibiotics).   
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Molecules with a benzimidazole scaffold are regarded as an important class of heterocyclic 
compounds with a wide spectrum of biological activities.  We report on the latest synthetic 
methods and mechanisms of these reactions as well as their antibacterial, antifungal and 
antidiabetic activities.  The present review covers more than 60 of the latest references, which 
focused on the synthesis of the benzimidazole scaffold using various synthetic strategies.   
 




Benzimidazoles are the benzo derivatives of imidazole, also known as 1H-benzimidazole or 
1,3-benzodiazole (Figure 3-1).  Benzimidazole and thiobenzimidazole both exist in two 
equivalent tautomeric forms (Figure 3-2).  In 1944, Woolley proved that benzimidazoles 
showed similar therapeutic potential to purines in eliciting optimum biological responses 
(Woolley et al., 1944).  In recent years, benzimidazoles have gained much importance, having 
applications in the pharmaceutical industry (Chaudhari et al., 2014; Yadav et al., 2015; Preethi 
et al., 2015; Aboul-Enein et al., 2015; Verma et al., 2016), in agriculture as fungicides (Yang 
et al., 2011; Raghunath et al., 2014) and in industry (Tang et al., 2013; Finšgar et al., 2014; 
Zhang et al., 2014).  In addition, benzimidazoles are applied as important intermediates in many 
organic reactions (Sánchez et al., 2016).  There are currently a number of drugs in the market 
containing a benzimidazole scaffold, such as omeprazole (proton pump inhibitors), albendazole 
(anthelmintic), mebendazole (antimicrobial) and enviradine (antiviral) (Bansal et al., 2015; 
Yadav et al., 2015). 
 
Benzimidazoles have been prepared most commonly from the reaction of o-phenylenediamine 
with carbonyl-containing compounds such as carboxylic acids, acid chlorides and aldehydes, 
under harsh dehydrating conditions using strong acids such as polyphosphoric and 
hydrochloric acids (Chen et al., 2014; Fang et al., 2016; Khairunissa et al., 2016; Weijie et al., 
2016).  When o-phenylenediamine was reacted with carbon disulphide (Reddy et al., 2016) or 
hydrazinecarbothioamide (El Ashry et al., 2010), 1H-benzo[d]imidazole-2-thiols were 
produced.  In addition, o-phenylenediamines reacted with cyanogen bromide or urea produced 
1H-benzo[d]imidazol-2-amines and 1H-benzo[d]imidazol-2(3H)-ones respectively (Abbas et 
al., 2013; Reddy et al., 2016). 
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There have also been reports of the preparation of benzimidazole isoindolones from o-
phenylenediamines and phthalic anhydride (Deshmukh et al., 2015; Mehta et al., 2015) as well 
as 2-(o-sulfamoylphenyl) benzimidazoles with o-phenylenediamine and saccharin (Ashraf et 
al., 2016).  Such reactions provide convenient strategies for the synthesis of hybrid 
benzimidazoles, which have the potential to be further derivatized.  Beside o-
phenylenediamines, o-nitro arylamines were also used to synthesize benzimidazoles, 
producing 2-cyclohexyl-1H-benzimidazoles with cyclohexanecarbonyl chloride (Park et al., 
2014). 
 
This mini review covers the literature from 2014 to May 2016 focusing on the various pathways 
for the synthesis of the benzimidazole nucleus under different reaction conditions. In addition, 
we attempt to explain a mechanistic pathway for the formation of the benzimidazole nucleus 
from o-phenylenediamine.  The antibacterial, antifungal and antidiabetic activity of 
benzimidazole derivatives are also highlighted in this review. 
 
Figure 3-1  The general structure of a benzimidazole with nomenclature included 
 
 
Figure 3-2  Tautomeric forms of benzimidazoles 
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3.2 Synthesis 
There are two common methods for the synthesis of benzimidazoles.  The first is the coupling 
of o-phenylenediamine with carboxylic acids or their derivatives and the second involves a 
two-step reaction that includes oxidative cyclo-dehydrogenation of Schiff bases generated from 
the condensation of o-phenylenediamine and aldehydes.  Since a vast number of acids and 
aldehydes are available, a large number of benzimidazoles have been prepared from these 
precursors.   
 
3.2.1 Benzimidazoles synthesized from substituted o-phenylenediamine with 
carboxylic acids 
2-Substituted benzimidazoles (159-174) were prepared in good yields from o-
phenylenediamines and different types of carboxylic acids in the presence of hydrochloric or 
polyphosphoric acid (Scheme 3-1 to Scheme 3-3) (Chinnappadu et al., 2014; Harkala et al., 
2014; Huizhen et al., 2014; Madabhushi et al., 2014; Rao et al., 2014; Alasmary et al., 2015; 
Chandra et al., 2015; Elagab et al., 2015; Gobis et al., 2015; Kankate et al., 2015; Mariappan 
et al., 2015; Rashid et al., 2015; Fang et al., 2016; Gaballah et al., 2016; Govindaraj et al., 




Scheme 3-1  General scheme of synthesis of benzimidazole 
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The mechanism for this reaction involves nucleophilic addition of the amino group to the 
carbonyl carbon of the carboxylic acid, forming the amide, after which a second nucleophilic 
step involving the other amino group resulted in the alcohol addition intermediate (175), which 
formed the benzimidazole (161) upon dehydration (Scheme 3-4).  The reaction is catalysed by 
either polyphosphoric or hydrochloric acid, whose function is to activate the carboxylic acid, 
making the carbonyl group more susceptible to nucleophilic attack. 
 
 




Scheme 3-3  Synthesis of 2-substituted benzimidazoles using various carboxylic acid 
 
 
Scheme 3-4  Mechanism of synthesis of benzimidazole (161) 
 
Benzimidazoles synthesized from substituted o-phenylenediamine and aldehydes  
Aldehydes react with o-phenylenediamines in the presence of a catalyst such as sodium 
dithionite (Kamal et al., 2014; Kumar et al., 2015), sodium metabisulfite (Taha et al., 2014; 
Kamal et al., 2015; Ramprasad et al., 2015; Khairunissa et al., 2016), sodium bisulfite (Weijie 
et al., 2016), copper sulfate (Zhang et al., 2016), ammonium chloride (Al-ebaist et al., 2015), 
zinc oxide or magnesium oxide (Dinparastast et al., 2016), resulting in 2-substituted 




Scheme 3-5  Synthesis of benzimidazole using different reaction conditions 
 
 
Scheme 3-6  Synthesis of 2-substituted benzimidazoles using various aldehydes 
 
Scheme 3-7  Mechanism of synthesis of benzimidazole (184) 
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Eren et al. (2014) reports a plausible mechanism for this reaction in which sodium sulphite 
adds to the aldehyde intermediate forming the hydroxy sulphite, which is then attacked by one 
of the amino groups of the o-phenylenediamine.  This first substitutes the hydroxy group and 
subsequently the sulphite group when the second amino group adds to the same carbon, 
forming the benzimidazole (184) after the release of H2 (Scheme 3-7) (Eren et al., 2014). 
 
3.2.2 1H-benzo[d]imidazole-2-thiols synthesized from substituted o-phenylenediamine 
with carbondisulfide or hydrazinecarbothioamide 
Both carbon disulphide and carbothiamide were used to synthesize benzimidazole-2-thiols with 
o-phenylenediamine, however no mechanisms are reported in the literature (El Ashry et al., 
2010; Reddy et al., 2016).  We postulate mechanisms for each of the reactions below. 
 
With carbon disulphide, the amino group from o-phenylenediamine adds to the carbon of CS2 
forming a thiol intermediate, which is attacked by the second amino group, substituting the 
thiol group, eliminating H2S and forming the benzimidazole thiol (185) (Scheme 3-8). 
 
 
Scheme 3-8  Synthesis of thiobenzimidazole (185) 
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Using hydrazine carbothiamide, the amino group of o-phenylenediamine attacks the 
electrophilic carbon in the usual manner, forming a tetrahedral sulphide intermediate (186), 
which then collapses eliminating hydrazine and forming a trigonal planar thiourea like 
intermediate, which is again attacked by the second amino group forming a tetrahedral sulphide 
intermediate again (187), which this time collapses eliminating ammonia and forming the 
thiobenzimidazole (188-189) (Scheme 3-9). 
 
 
Scheme 3-9  Synthesis with possible mechanism of formation of thiobenzimidazole using 
hydrazine carbothiamide 
 
3.2.3 Benzimidazoles synthesized from o-phenylenediamine or o-nitroaniline and acid 
chlorides 
Benzimidazoles are formed in good yields using o-phenylenediamine with acid chlorides (Chen 
et al., 2014; Park et al., 2014).  This reaction forms via nucleophilic acyl substitution of the 
chloro group with the amino group on the o-phenylenediamine, first forming the amide, which 
is attacked further by the second amino group forming a tetrahedral intermediate, which 
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ultimately forms the benzimidazole (190) by elimination of water (Scheme 3-10).  When o-
nitroanilines are used instead of o-phenylenediamines, an additional reduction step is needed 
after the formation of the amide intermediate (191) (Scheme 3-11).  
 
 
Scheme 3-10 Synthesis with mechanism of benzimidazole (190) 
 
 





3.2.4 Benzimidazoles synthesized from o-phenylenediamine and urea 
O-phenylenediamines react with urea in acidic condition producing 1H-benzo[d]imidazol-
2(3H)-one in good yields (Abbas et al., 2013; Srinivas Rao et al., 2014; Benali et al., 2015).  In 
this mechanism, the lone pair on the amino group attacks the carbonyl group of urea forming 
an amide bond and eliminating ammonia.  The lone pair on the second amine then repeats this 
process to produce the benzimidazol-2(3H)one (193) (Scheme 3-12). 
 
 
Scheme 3-12  Formation of benzimidazole using o-phenylenediamine and urea 
  
3.2.5 Benzimidazoles synthesized from substituted o-phenylenediamine and cyanogen 
bromide 
Benzimidazole-2-amines (194) are synthesized from the reaction of substituted o-
phenylenediamines and cyanogen bromide in the presence of ethanol and water (Garg et al., 
2014; Bansal et al., 2015; Reddy et al., 2016).  The postulated mechanism for this reaction is 
attack of the lone pair of one of the amino groups from o-phenylenediamine on the cyanogen 
carbon.  This occurs with a concomitant loss of HBr.  The lone pair of the second amino group 
then attacks the same nitrile carbon, forming an imine.  Proton transfers then produce the 
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benzimidazole-2-amines (194) (Scheme 3-13).  The presence of an amino group at C-2 makes 
a variety of derivatisation involving amino groups possible.   
 
 
Scheme 3-13  Synthesis of benzimidazole using o-phenylenediamine and cyanogen bromide 
 
3.2.6 Benzimidazo-isoindol-ones synthesized from o-phenylenediamine and phthalic 
anhydride 
Benzimidazole-indole (195) hybrid scaffolds are formed in good yields by the reaction of o-
phenylenediamines and phthalic anhydride (Deshmukh et al., 2015; Mehta et al., 2015).  In this 
mechanism, the anhydride is cleaved after the amine attacks the carbonyl group of the 
anhydride, forming an amide bond at one end and an acid at the other.  The lone pair of the 
second amino group then attacks the amide carbonyl group, forming an imidazole ring with a 
hydroxy group at C-2.  A further attack of the lone pair of one of the NH groups on the 
imidazole moiety then reacts with the carboxylic acid forming the benzimidazo-isoindol-one 




Scheme 3-14  Synthesis of Benzimidazo-isoindol-ones (195) 
 
3.2.7 Benzimidazol-2-benzenesulphonamides synthesized form o-phenylenediamine 
and saccharin 
The reaction of o-phenylenediamine and benzene sulphonamide (saccharin) produced 2-(1H-
benzo[d]imidazol-2-yl)benzenesulfonamide (196) (Ashraf et al., 2016), probably by the lone 
pair of the amino group attacking the carbonyl group of saccharin, hydrolysing the amide bond.  
The second amino group of o-phenylenediamine then reacts with the newly formed amide 
bond, forming the benzimidazol-2-benzene sulphonamide (196) after a dehydration step 
(Scheme 3-15). 
 
3.3 Applications of benzimidazole derivatives as antimicrobial and antidiabetic agents 
Benzimidazole derivatives have shown a number of different biological activities including 
antimicrobial, antidiabetic, antioxidant, anticancer, anti-tubercular, anti-HIV, anti-
inflammatory, antiviral, antihypertensive, antiprotozoal, anticonvulsant and analgesic activity 
(Keri et al., 2015; Singla et al., 2015; Khairunissa et al., 2016; Verma et al., 2016; Zhang et al., 
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2016).  The benzimidazole scaffold can be functionalised at a variety of positions, however the 
most common positions found to be derivatised are N-1, C-2, C-5 and C-6.   
 
 
Scheme 3-15  Synthesis and mechanism of benzimidazol-2-benzenesulphonamides (196) 
 
This short review focus on the antimicrobial and antidiabetic activities of benzimidazole 
derivatives since these two biological assays were carried out in this thesis. 
 
3.3.1 Antimicrobial activity 
Outlined below is a summary of benzimidazole structures with reported MIC values of <10 µg 
mL-1 and >30 mm zones of inhibition against one or more bacterial and fungal strains (Table 
3-1 to Table 3-6).  Essentially, these benzimidazoles were substituted at C-2 and N-1.   
 
Compounds 197-199 contains substitution on N-1 only, with C-2 left unsubstituted.  These 
substituents were propanoate esters.  The benzene ring in these compounds were either 
unsubstituted (199), contained methyl groups at C-5 and C-6 (197) or a chloro group at C-6 
(198) (Figure 3-3).  Compounds 197 and 198 showed strain specific activity to Bacillus. 
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proteus and 199 showed activity against Staphyllococcus aureus, all having MIC values of 8 
µg mL-1 (Wen et al., 2016). 
 
 
Figure 3-3  Biologically active N-1 substituted benzimidazoles 
 
Benzimidazoles 200-204 contain hydroxy, methyl, amino and nitro groups on the phenyl ring 
substituted at C-2 and bromo, nitro and methyl groups on the benzene ring of benzimidazole 
(Al-Ebaisat et al., 2015; Govindaraj et al., 2016).  Compounds 205 and 206 contain a 2-
benzamide group at C-2, with the benzene ring of the benzimidazole being unsubstituted in 
205 and substituted with a bromo group at C-6 in 206 (Govindaraj et al., 2016; Reddy et al., 
2016).  Compound 207 also contained a phenyl group at C-2, but with a phenyl tetrazolo moiety 
attached at the ortho position (Reddy et al., 2016).  Compound 208 contains a fluoro group at 
C-5 and a methyl-5-fluorouracil moiety at C-2, while compounds 209-214 contains a thio-6-
methyl pyrimidine moiety with fluoro, chloro, bromo, methyl, methoxy and trifluoromethyl 
groups (209-214) (Chen et al., 2014; Fang et al., 2016).  Compounds 215-216 contains a phenyl 
substituted thiourea moiety at C-2, with trifluoromethyl groups on the phenyl ring and propyl 
and butyl groups substituted at the nitrogen of the thiourea group (Figure 3-4) (Madabhushi et 
al., 2014).  Compounds 208 and 210 showed excellent MIC values of 2 µg mL-1 against the 
fungal strain (Candida albicans) and Gram –ve strain (Stenotrophomonas maltophilia). 
 
Benzimidazoles 217-327 all contained an imidazo-thiadiazol group attached to C-2 through C-
5' of the imidazole ring in the substitutent.  These substitutents further contained fluoro, chloro 
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and methoxy groups on the phenyl ring at C-4' of the imidazole group (Ramprasad et al., 2015).  
Compounds 238-249 contained thiomethyl-1,2,3-triazol-1-ylarylethylideneaceto-hydrazide 
groups at C-2, where the phenyl group was substituted with halogens, hydroxy, methoxy, 
isopropyl or dimethylamino groups (Youssif et al., 2014).   
 
 
Figure 3-4  Biologically active C-2 substituted simple benzimidazoles 
 
Compounds 250-267 each contained fluoroquinolones attached to C-2 through a piperidine 
linker, either directly (250 and 251) or through a methylene (252-261), ethylene (262-263), 
ethylamine (264-265) or imine group (266-267) (Zhang et al., 2016).  The nitrogen of the 
fluoroquinoline moiety was substituted either with an ethyl group or with a cyclopropyl group 
and the benzene ring of the benzimidazole moiety was either unsubstituted or contained 
halogens (Br, Cl and F) or a nitro group.  In addition, compound 268 contained an ethylidene-
pyridine-6-arylimino-3,5-dicarbonitrile-4-nitrophenyl group at C-2 (Figure 3-5 and Figure 
3-6) (Desai et al., 2014).  Among these, compounds 257 and 259 showed the best antimicrobial 
activity with MIC values ranging from 0.125-1 µg mL-1 against Gram +ve and –ve bacterial 
strains.  The other compounds also showed good MIC values of between 0.5-10 µg mL-1. 
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The next class of benzimidazoles contain substitution at both N-1 and C-2.  Compounds 269-
272 contain ethyl, propyl, butyl and 3-F-benzyl groups at N-1, while C-2 is attached to a 
substituted 5-fluorouracil moiety (Fang et al., 2016).   
 
Figure 3-5  Biologically active C-2 substituted complex benzimidazoles 
 
 
Figure 3-6  Biologically active C-2 substituted complex benzimidazoles 
 
Compounds 273-274 contains a 2,4-difluorobenzyl group at N-1 and a 3,5-ditrifluoromethyl 
methylaminophenyl group at C-2 (Huizhen et al., 2014).  In addition, 275 and 276 has a N-
benzyl-N-methyl-5-fluorouracil group at C-2 and a substituted benzyl group at N-1 (Fang et 
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al., 2016).  Compounds 277-301 all contain a piperidine linked fluoroquinolone linked to C-2 
similar to 250-267, but now with either an ethyl group or a substituted benzyl group at N-1 
(Figure 3-7) (Zhang et al., 2016).  Of these, compounds 292, 295 and 299 showed the best 
activity against Gram +ve and Gram –ve bacterial strains and fungal strains with MIC values 
ranging from 0.03-8 µg mL-1.  Other compounds also showed good antimicrobial activity 
against certain bacteria. 
 
 
Figure 3-7  Biologically active N-1 and C-2 substituted complex benzimidazoles 
 
Compounds 302-316 were slightly different to all the other compounds discussed previously.  
Compounds 302-304 contained an imine at C-2 and either phenylpropyl or 2-oxo-2-
phenylethyl groups at N-1 and N-3 (Mavrova et al., 2015).  Compounds 305-316 contain a 
propyl chain at N-1, a 2,4-dichlorophenyl moiety at C-2 and substituted benzilidene hydrazones 
at C-5 (Figure 3-8) (Kumar et al., 2015).  Most of these compounds showed good activity 
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against the fungal strain, Aspergillus niger with MIC values of 3.12-6.25 µg mL-1.  Compound 
315 showed broad spectrum antimicrobial activity with MIC values of 3.12 to 6.25 µg mL-1. 
 
 
Figure 3-8  Biologically active N-1, N-3 and C-2 substituted complex benzimidazoles 
3.3.2 Antidiabetic activity 
Two types of benzimidazoles showed α-glucosidase inhibition with reported IC50 values of 
<25 µg mL-1 (Table 3-7).  This includes benzimidazole 318 with a 4-cyanophenyl moiety at 
C-2 and a 4-cyanobenzyl moiety at N-1 and compounds 319-333 with methyl groups at C-5 
and C-6 and a substituted benzohydrazide group at C-2 containing hydroxy, methoxy, chloro, 
and methyl groups.  The most active of these compounds were 319, 321, 324-325 and 333 with 
IC50 values of <9 µg mL-1 (Figure 3-9; Table 3-7) (Dinparast et al., 2016; Khairunissa et al., 
2016).  In addition, 2,3-dihydro-3-(4-nitrobenzensulfonyl)-2-oxo-1H-benzimidazole (317) 
(Figure 3-9) coupled to hydroxyethyl starch (HES) resulted in a 67% reduction in blood 
glucose levels of rats (Abbas et al., 2015).   
 
Figure 3-9  Biologically active benzimidazoles 
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MIC MIC DD MIC DD MIC 
197 - - - 8 - - - - - - - 
198 - - - 8 - - - - - - - 
199 - 8 - - - - - - - - - 
200 - - - - - - - - - 6.25 6.25 
201 - - - - - - - - - - 6.25 
202 - - - - - - - - - - 6.25 
203 - - - - - - - - - - 6.25 
204 - - - - 30 - - - - - - 
205 - - - - 30 - - - - - - 
206 - - 32 - 36 - - - - - - 
207 - - 32 - 36 - - - - - - 
208 - 8 - - - - - 2 8 -  
209 - - - - - - - 8 - - - 
210 - 8 - - - - 2 - - - - 
211 - - - - - - 4 8 - - - 
212 - - - - - - 8 - - - - 
213 - - - - - - 8 - - - - 
214 - - - - - - 8 - - - - 
215 - - - - - 6.25 - - - - - 
216 6.25 - - - - - - - - - - 
MIC = Minimum inhibitory concentration in µg mL-1; DD = Disc diffusion method, zone of inhibition in mm  
M. luteus = Micrococcus luteus; E. coli = Escherichia coli; P. aeruginosa = Pseudomonas aerugoinosa; S. cerevisiae = Saccharomyces cerevisiae; C. glabrata = Candida 
glabrata; C. krusei = Candida krusei. 
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A.flavus C.albicans C. 
Keratinophilum 
 
MIC (µg mL-1) 
 
217 6 4 7 3 3 3 4 
218 4 5 4 5 5 4 5 
219 3 4 4 3 3 4 3 
220 4 4 5 6 3 3 4 
221 - - - - 6 6 5 
222 4 4 3 4 5 5 4 
223 3 3 2 3 - - - 
224 7 5 8 3 4 3 4 
225 5 5 6 4 5 5 4 
226 4 5 2 3 4 5 4 
227 3 4 6 4 - 6 - 
228 5 4 3 - 5 2 3 
229 - - - - 2 2 3 
230 2 4 3 2 3 - 4 
231 3 4 1 2 - 9 - 
232 9 - - 10 7 6 8 
233 4 4 5 3 6 - 7 
234 9 6 8 6 - 4 - 
235 3 4 4 4 3 - 5 
236 5 5 3 6 - 4 - 
237 - 8 9 8 3 - 2 
238 - - - - - 6.25* - 
MIC = Minimum inhibitory concentration in µg mL-1; *= MIC in µM  
 
3.4 Conclusion 
Benzimidazoles can easily be prepared from substituted o-phenylenediamine with a variety of 
carboxylic acid or aldehyde derivatives.  Due to the variety of substituted precursors available, 
a vast number of benzimidazoles were able to be prepared, however there is still scope for the 
synthesis of many more.  Many of these compounds showed promising antimicrobial and anti-
diabetic activity and can be considered lead compounds for antibiotics and anti-diabetic agents 
since some have shown better activity than miconazole, fluconazole and acarbose (currently 
used drugs).   
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Gram +ve Gram –ve Fungi 







MIC (µg mL-1) 
239 - - - - - 3.12* - - - 6.25* 
240 - - - - - 6.25* - - - 3.12* 
241 - - - - - - - - - 6.25* 
242 - - - - - - - - - 6.25* 
243 - - - - - 6.25* - - - 6.25* 
244 - - - - - 3.12* - - - 3.12* 
245 - - - - - - - - - 3.12* 
246 - - - - - 6.25* - - - 6.25* 
247 - - - - - - - - - 6.25* 
248 - - - - - - - - - 6.25* 
249 - - - - - 6.25* - - - 6.25* 
250 2 4 4 2 1 2 2 4 2 - 
251 2 0.5 1 1 2 1 0.5 0.5 1 - 
252 1 1 1 2 0.5 0.5 1 2 0.5 - 
253 8 - 0.5 - 2 - 4 8 8 - 
254 - 1 1 2 0.5 0.5 1 1 0.5 - 
255 8 - 2 - 4 - 2 - 8 - 
256 8 8 1 - 2 8 2 4 4 - 
257 0.125 0.125 0.125 0.25 0.125 0.125 0.5 1 0.125 - 
258 0.5 2 2 4 1 1 2 2 1 - 
259 0.5 0.5 0.25 0.5 0.5 0.5 0.5 0.5 0.5 - 
260 - 4 - - 8 8 1 - 4 - 
261 8 2 8 -- 4 4 0.5 4 4 - 
MIC = Minimum inhibitory concentration in µg mL-1; * = MIC in µM; B. subtilis = Bacillus subtilis 
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MIC (µg mL-1) 
 
262 2 - - - - - - - - - - - - - - 
263 - 4 1 4 2 - 4 0.5 0.5 1 - - - - - 
264 8 0.5 4 2 8 - 1 1 0.5 2 - - - - - 
265 1 0.25 1 1 1 - 1 0.5 0.25 1 - - - - - 
266 4 - - - - - - 8 - - - - - - - 
267 2 - 4 - 4 - 8 2 8 4 - - - - - 
268 - 6.25 - - - - - - - - - - - - - 
269 - - - - - - 8 - - - - 2 - - 4 
270 - - - - - - - - - - - 2 - - 8 
271 - - - - 8 - - - - - - - 8 - 8 
272 8 - - 4 2 - 2 - - - - - - - 4 
273 - - - - - - 8 - - - - - - 8 - 
274 8 - 8 8 - - - - - - 8 - 8 - 8 
275 - 2 - 4 4 8 2 - - - 8 - - - 1 
276 - - - - - - - - - - - 4 - - - 
277 2 8 4 - 1 - 4 - - 0.5 - - - - - 
278 2 - 8 - - - - - - - - - - - - 
279 - - - - 8 - 8 - - - - - - - - 
280 - - 4 - 4 - 4 - - 8 - - - - - 
281 - 2 4 - 4 - 8 2 - 4 - - - - - 
282 4 8 - - 8 - 0.5 4 8 8 - - - - - 
283 0.5 - 2 - 0.5 - 2 2 8 0.5 - - - - - 
284 - 2 1 - - - 1 1 4 4 - - - - - 
285 4 - 4 - 2 - 1 2 8 4 - - - - - 
MIC = Minimum inhibitory concentration in µg mL-1; 
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Gram +ve Gram –ve 
 
B. subtilis MRSA M. luteus S. aureus B. proteus E. coli S. dysenteriae 
 
S. enterica P. aeruginosa 
MIC (µg mL-1) 
 
286 - 1 1 - 0.5 0.5 4 4 1 
287 4 - 4 - 4 8 2 - 4 
288 - 0.125 0.5 8 4 2 - 0.5 1 
289 - 2 2 - - 8 - 4 2 
290 - - - - 4 - 1 8 8 
291 8 - 8 8 - - - 8 8 
292 8 0.125 0.25 4 1 1 2 0.25 1 
293 2 8 4 4 - - 4 4 4 
294 0.5 4 4 - 1 2 - 2 2 
295 4 0.5 0.125 8 0.5 0.5 4 0.25 0.125 
296 8 0.25 0.25 - 1 1 4 0.25 2 
297 - 8 - - - - - 4 - 
298 8 4 - - - - - - 8 
299 4 0.125 0.0625 8 0.03 0.125 1 0.03 0.5 









Gram +ve Gram -ve Fungi 
 
B. subtilis S. aureus E. coli K. pneumonia S. abony A. niger C. albicans C. tropicalis P. notatum 
 
MIC (µg mL-1) 
 
301 0.125* 0.016* 0.50* - 0.50* - - - - 
302 0.50* 0.50* - - - - - - - 
303 1* - - - - - - - - 
304 - - - -  6.25 - 6.25 - 
305 - - 6.25 - - - - - - 
306 6.25 - 6.25 - - 3.12 6.25 6.25 - 
307 6.25 6.25 6.25 6.25 - 6.25 6.25 6.25 - 
308 - 6.25 - - - 3.12 - - - 
309 6.25 - 3.12 - - 6.25 - - - 
310 - 6.25 - 6.25 - 3.12 - 6.25 6.25 
311 6.25 - - - - - - - - 
312 - - - - - 6.25 6.25 3.12 - 
313 - - - - - 6.25 - - - 
314 - - - - - 6.25 - - - 
315 3.12 3.12 3.12 6.25 - 3.12 3.12 6.25 6.25 
316 - - 6.25 - - 6.25 - - - 
* = Minimum inhibitory concentration (MIC) in mg mL-1 
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Table 3-7  α-Glucosidase inhibitory enzyme activity 
Comp. 
No. 
IC50 µg mL-1 Comp. 
No. 
IC50 µg mL-1 
318 22.4 326 84.84 
319 8.74 327 23.53 
320 9.99 328 18.30 
321 8.74 329 18.21 
322 12.49 330 24.82 
323 22.36 331 15.06 
324 8.44 332 19.35 
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Chapter 4. Synthesis and structure elucidation using 2D-NMR and thermal 
coefficient investigation on amino acid tethered quinoxalines  
 
* The compounds referred to in the chapter are referred to elsewhere in the thesis with an A preceding the 




A chiral library of amino acid tethered quinoxalines (A6a-A6n) was synthesized via a 4-step 
synthesis using a SNAr reaction mediated by reduction and cyclization steps at ambient 
temperature.  The synthesized compounds were characterized with the use of instrumental 
techniques such as 2D NMR spectroscopy and X-ray crystallography.  Hydrogen bonding in 
the molecules was determined by thermal coefficient investigations and X-ray crystallography.  
We herein report the elucidation of the series of quinoxalines (A6a-n) by NMR spectroscopy 
and X-ray crystallography and report on the thermal coefficient investigations.  Density 
functional theory (DFT) and molecular dynamic (MD) studies were additionally conducted to 
support the experimental hydrogen bonding and conformational flexibility of these 
compounds. 
 






The structure of quinoxalines are characterised by a benzene ring fused to a 6 membered 
heterocyclic ring incorporating two nitrogen atoms, both of which are bonded to the aromatic 
ring.  These compounds play an important role in the field of medicine (Reddy et al., 1999; 
Lu et al., 2011; Cholo et al., 2012; Ajani et al., 2014; Demmer et al., 2015), industrial (Keshtov 
et al., 2015; Podsiadly et al., 2011; Kono et al., 2012).  
 
Quinoxaline units are present in a number of natural and pharmacological compounds and are 
found to display a wide array of biological activity (Deepika et al., 2011), such as anticancer 
(Vázquez et al., 2015; Issa et al., 2015; Parrino et al., 2015), anti-HIV (Ajani et al., 2014; Ramli 
et al., 2014; Balasubramanian et al., 2014), antituberculosis (Vicente et al., 2011; Puratchikody 
et al., 2011; Ramli et al., 2014; Ajani et al., 2014), antibacterial (Chandra Shekhar et al., 2015; 
Raju  et al., 2015; Manchal et al., 2015), fungicidal (Naga Raju  et al., 2015; Zhang  et al., 
2014; Ramli et al., 2014), insecticidal (Gil et al., 2014; Ninfa et al., 2014), anti-inflammatory 
(Achutha et al., 2013; Ingle and Marathe, 2012b; Patidar et al., 2011), antioxidant (Kotra et al., 
2013; Sridevi et al., 2011; Burguete et al., 2011), antimalarial (Gil et al., 2014; Chandra 
Shekhar et al., 2014; Barea et al., 2013), anti-tumor (Neckel et al., 2015; Huang et al., 2015; 
Bříza et al., 2015), and other pharmacological activities.  They have therefore become an 
interesting scaffold to for the synthetic chemists (Ameen et al., 2015; Ingle and Marathe, 
2012a).   
 
Bioactive compounds show enhanced activity when linked to amino acids (Suhas et al., 2011; 
Sharma et al., 2013).  Amino acids are good building blocks to incorporate into quinoxalines 
since they have low toxicity and biocompatibility (Shantharam et al., 2014). Currently there is 
huge tendency of conjugating amino acid/peptide residues with small bioactive heterocyclic 
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motifs in the field of biomedical research (Sharma et al., 2013; Suhas et al., 2012, Suhas et al., 
2011).  
 
We herein report the NMR elucidation of a series of amino acid tethered quinoxalines, of which 
six are novel.  Their structural elucidation is slightly more complicated because of the amino 
acid moiety linked to the quinoxaline, which has an effect on the resonances of the quinoxaline 
moiety.  Extensive 2D NMR studies, X-ray crystallography and thermal coefficient 
investigations were used to provide a full structural elucidation of these amino acid tethered 
quinoxalines.  Additionally, the density functional theory (DFT) and molecular dynamic (MD) 
simulations were employed to explain the hydrogen bonding tendency and conformational 
flexibility of these compounds.  
 
4.2 Experimental 
4.2.1  Chemistry 
All the chemicals were supplied by Sigma-Aldrich via Capital Lab, South Africa.  Organic 
solvents were redistilled and dried according to standard procedure.  Silica gel 60F254 plates 
(Merck) were used for thin layer chromatography.  Purifications were carried out by column 
chromatography using silica gel (60-120 mesh) with an EtOAc : Hexane mobile phase. Melting 
points were recorded using a Stuart Scientific SMP3 apparatus.  UV spectra were obtained on 
a Varian Cary UV-VIS spectrometer in MeOH.  IR spectra were recorded on a Perkin Elmer 
100 FT-IR spectrometer with universal attenuated total reflectance sampling accessory.  1H, 
13C and all 2D NMR spectra were recorded at 298 K with 5- to 10-mg samples dissolved in 0.5 
ml of DMSO-d6 in 5-mm NMR tubes using a Bruker Avance 400 MHz instrument and 1H 
NMR for thermal analysis was performed on a Bruker Avance 600 MHz instrument (9.4 T; 
Bruker, Germany) (400.22 MHz for 1H, 100.63 MHz for 13C). The digital digitizer resolution 
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was set at 22 for both the 1H and 13C NMR experiments.  Chemical shifts are reported in δ 
values (ppm) and coupling constants (J) in Hz relative to the internal standard, 
tetramethylsilane (TMS) and referenced to the solvent line of DMSO-d6 (δH = 2.5, δC = 39.52).  
For the 1H NMR analyses, 16 transients were acquired with a 1-s relaxation delay using 32 K 
data points.  The 90° pulse duration was 10.0 µs, and the spectral width was 8223.68 Hz.  The 
13C NMR spectra were obtained with a spectral width of 24 038.46 Hz using 64 K data points.  
The 90° pulse duration was of 8.40 µs. For the 2D experiments including COSY, NOESY, 
HSQC and HMBC, all data were acquired with 4 K × 128 data points (t2 × t1).  The mixing 
time for the NOESY experiment was 0.3 s, and the long range coupling time for the HMBC 
experiment was 65ms.  All data were analysed using Bruker Topspin 2.1 (2008) software.  
High-resolution mass data were obtained using a Bruker micro TOF-Q II ESI instrument 
operating at ambient temperature.  Optical rotations were recorded using a Perkin ElmerTM 
model 341 polarimeter with a 10 cm flow tube in MeOH.  The purity of the compounds were 
determined by analytical HPLC on a Shimadzu-20A5 fitted with a C8 (150mm x 5µm x 4.6) 
column using a mobile phase (A) of 0.1M KHPO4 buffer and (B) acetonitrile with a linear 
gradient of 0 to 30% over a period of 60 minutes at a flow rate of 1 mL/min.  
 
General procedure for the preparation of amino acid methyl ester hydrochloride (A4) 
Methanol (20 mL) was added to different amino acids (A3a-n) (0.1 mol) followed by the 
gradual addition of thionyl chloride (0.3 mol) at room temperature.  The resulting solution was 
stirred at 70°C for 4h and the reaction mixture concentrated on a rotary evaporator producing 




General procedure for the preparation of methyl 4-fluoro-3-nitrobenzoate (A2) 
4-Fluoro-3-nitrobenzoic acid (5g, 27 mmol) was refluxed in methanol (50 mL) and conc. 
H2SO4 (5 mL) for 8h.  After completion of the reaction (as evident from TLC), the methanol 
was evaporated under reduced pressure and the aqueous layer extracted with ethyl acetate (25 
mL x 3).  The EtOAc layer was dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to yield A2 as a cream-colored powder in a yield of 95%. 
 
General procedure for the preparation of compound (A5) 
Methyl-4-fluoro-3-nitrobenzoate A2 (0.5g, 2.34 mmol), the hydrochloride salt of the amino 
acid ester A4 (3.51 mmol) and NaHCO3 (0.005g, 4.68 mmol) were mixed in THF (10 mL).  
The reaction mixture was stirred overnight at room temperature.  After completion of the 
reaction (monitored by TLC), the reaction mixture was washed with water (10 mL x 2), 
followed by 10% Na2CO3 solution (10 mL).  The organic layer was separated and dried over 
anhydrous Na2SO4 and concentrated under reduced pressure to afford A5, which was purified 
by column chromatography (hexane/ethyl acetate) to afford the desired product in good yields 
(80-90%). 
 
General procedure for the preparation of compound (A6)  
4-(Substituted amino)-3-nitro-methyl benzoate A5 (1 mmol) was added to methanol (10 mL), 
to which 10% Pd/C (50 mg) was added.  The reaction mixture was stirred for 4h at room 
temperature under H2 atmosphere.  The reaction mixture was then filtered through Celite 545 
to remove the catalyst.  The filtrate was evaporated under reduced pressure and the obtained 
solid was purified by column chromatography (hexane/ethyl acetate) to afford the desired 
products (Table 4-1) in moderate to good yield (60-85%).   
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Table 4-1 Physical data of the synthesized compounds 
 





Orange solid 212-214 80 92 
A6b 
 
Cream solid 218-220 77 94 
A6c 
 
Yellow solid 158-160 75 98 
A6d 
 
White solid 216-218 85 98 
A6e 
 
White solid 204-206 83 90 
A6f 
 
White solid 206 75 85 
A6g 
 












































Orange solid 102 84 96 
A6i 
 
Black solid 206-208 76 93 
A6j 
 
Cream solid 140-142 90 98 
A6k** 
 
Yellow solid 135-137 88 97 
A6l 
 
Cream solid 168-170 86 92 
A6m 
 
Cream solid 184-186 78 80 
A6n 
 
Black solid 102-104 75 80 
aPurified sample yield (%);  bPurity determined by HPLC;  **Proline and quinoxaline conjugated together 
  
(S)-Methyl-2-methyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (A6a), UV λmax 
nm (log ε): 316 (3.75), 253 (3.89), 220 (4.01); IR υmax (cm-1):  3342 (NH), 3188 (CH aromatic), 
3098 (NH amide), 1746 (C=O ester), 1670 (C=O amide); [α]25D = +12° (c = 10, MeOH); LRMS 
m/z 243.0843 [M + Na]+. 
 
(S)-Methyl-2-(4-hydroxybenzyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate 







































(NH), 3198 (CH aromatic), 3099 (NH amide), 1776 (C=O ester), 1662 (C=O amide); [α]25D = 
-108.3° (c = 10, MeOH); HRMS m/z 335.0992 [M + Na]+ (calcd.for C17H16N2O4Na 335.1008). 
(S)-Methyl-2-(2-methoxy-2-oxoethyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate 
(A6c), UV λmax nm (log ε): 315 (4.01), 254 (4.18), 220 (4.32); IR υmax (cm-1): 3337 (NH), 3144 
(CH aromatic), 3025 (NH amide), 1776 (C=O ester), 1676 (C=O amide); [α]25D = -49.50° (c = 
10, MeOH); HRMS m/z 301.0786 [M + Na]+ (calcd. for C13H14N2O5Na 301.0800). 
 
(S)-Methyl-2-isobutyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (A6d), UV λmax 
nm (log ε): 317 (3.95), 254 (4.07), 221 (4.17); IR υmax (cm-1):  3344 (NH), 3217 (CH aromatic), 
2958 (NH amide), 1748 (C=O ester), 1696 (C=O amide); [α]25D = +23.50° (c = 10, MeOH); 
LRMS m/z 285.1573 [M + Na]+.  
 
(S)-Methyl-2-isopropyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (A6e), UV 
λmax nm (log ε): 320 (3.84), 257 (3.95), 221 (4.08);  IR υmax (cm-1):  3331 (NH), 3139 (CH 
aromatic), 3017 (NH amide), 1727 (C=O ester), 1678 (C=O amide); [α]25D = +36.50° (c = 10, 
MeOH); LRMS m/z 271.1412 [M + Na]+. 
 
(S)-Methyl-2-((S)-sec-butyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (A6f), 
UV λmax nm (log ε): 321 (3.84), 257 (3.95), 221 (4.22); IR υmax (cm-1):  3338 (NH), 3206 (CH 
aromatic), 2960 (NH amide), 1746 (C=O ester), 1698 (C=O amide); [α]25D = +30.50° (c = 10, 
MeOH); LRMS m/z 285.1579 [M + Na]+. 
 
(S)-Methyl-2-benzyl-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (A6g), UV λmax 
nm (log ε): 319 (3.73), 258 (3.89), 220 (4.11); IR υmax (cm-1):  3342 (NH), 3144 (CH aromatic), 
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3025 (NH amide), 1750 (C=O ester), 1695 (C=O amide); [α]25D = -67.50° (c = 10, MeOH); 
HRMS m/z 319.1057 [M + Na]+ (calcd. for C17H16N2O3Na 319.1059). 
 
(S)-Methyl-2-((1H-indol-3-yl)methyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-arboxylate 
(A6h), UV λmax nm (log ε): 320 (3.79), 258 (3.94), 221 (4.38); IR υmax (cm-1):  3331 (NH), 3170 
(CH aromatic), 2948 (NH amide), 1730 (C=O ester), 1671 (C=O amide); [α]25D = -47.0° (c = 
10, MeOH); HRMS m/z 358.1169 [M + Na]+ (calcd. for C19H17N3O3Na 358.1168). 
 
(S)-Methyl-2-((1H-imidazol-4-yl)methyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-
carboxylate (A6i), UV λmax nm (log ε): 316 (3.61), 255 (3.77), 219 (4.00); IR υmax (cm-1): 3356 
(NH), 3134 (CH aromatic), 2947 (NH amide), 1730 (C=O ester), 1671 (C=O amide); [α]25D = 
-16.0° (c = 10, MeOH); LRMS m/z 309.1420 [M + Na]+. 
 
(S)-Methyl-2-(2-(methylthio)ethyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate 
(A6j), UV λmax nm (log ε): 317 (3.82), 255 (3.95), 220 (4.05);  IR υmax (cm-1): 3345 (NH), 3181 
(CH aromatic), 3089 (NH amide), 1720 (C=O ester), 1683 (C=O amide); [α]25D = -16.25° (c = 
10, MeOH); HRMS m/z 303.0766 [M + Na]+ (calcd. for C13H16N2O3SNa 303.0763). 
 
(S)-Methyl-4-oxo-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoxaline-7-carboxylate (A6k), 
UV λmax nm (log ε): 321 (3.93), 257 (3.94), 224 (4.093);  IR υmax (cm-1): 3189 (CH aromatic), 
3095 (NH amide), 1701 (C=O ester), 1677 (C=O amide); [α]25D = -117.3° (c = 10, MeOH); 
LRMS m/z 269.1239 [M + Na]+. 
 
(S)-Methyl-2-(3-methoxy-3-oxopropyl)-3-oxo-1,2,3,4-tetrahydroquinoxaline-6-
carboxylate (A6l), UV λmax nm (log ε): 317 (3.87), 255 (4.02), 221 (4.19);  IR υmax (cm-1): 
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3348 (NH), 3185 (CH aromatic), 3095 (NH amide), 1734 (C=O ester), 1686 (C=O amide); 




(A6m), UV λmax nm (log ε): 324 (3.50), 264 (3.77), 220 (4.14);  IR υmax (cm-1):  3302 (OH), 
3254 (NH), 3170 (CH aromatic), 2980 (NH amide), 1730 (C=O ester), 1699 (C=O amide); 




UV λmax nm (log ε): 325 (3.45), 265 (3.69), 221 (4.06);  IR υmax  (cm-1): 3244 (OH), 3205 (NH), 
3188 (CH aromatic), 2950 (NH amide), 1720 (C=O ester), 1668 (C=O amide); [α]25D = +24.50° 
(c = 10, MeOH); HRMS m/z 259.0690 [M + Na]+ (calcd. for C11H12N2O4Na 259.0695).  
4.2.2 Single Crystal X-ray Diffraction Analysis of compound A6d 
A cube-shaped single crystal was selected and glued onto the tip of a glass fiber and mounted 
in a stream of cold nitrogen at 173 K and centered in the X-ray beam using a video camera. 
The crystal evaluation and data collection were performed on a Bruker Smart APEX II 
diffractometer with Mo Kα radiation (λ = 0.71073 Å).  The diffractometer to crystal distance 
was set at 4.00 cm.  The initial cell matrix was obtained from three series of scans at different 
starting angles.  Each series consisted of 12 frames collected at intervals of 0.5° in a 6° range 
with the exposure time of 10s per frame.  The reflections were successfully indexed by an 
automated indexing routine built in the APEX II program suite.  The final cell constants were 
calculated from a set of 3387 strong reflections from the actual data collection.  Data collection 
method involved ω scans of width 0.5°.  Data reduction was carried out using the program 
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System Administrator’s Integrated Network Tool (SAINT+).  The structure was solved by 
direct methods using SHELXS and refined.  Non-H atoms were first refined isotropically and 
then by anisotropic refinement with full-matrix least-squares calculations based on F2 using 
SHELXS.  All H atoms were positioned geometrically and allowed to ride on their respective 
parent atoms.  All H atoms were refined isotropically.  The absorption correction was based on 
fitting a function to the empirical transmission surface as sampled by multiple equivalent 
measurements.  The final least-squares refinement of 286 parameters against 5126 data points 
resulted in residuals R (based on F2 for I ≥ 2σ) and wR (based on F2 for all data) of 0.0497 and 
0.1358, respectively.  The final difference Fourier map was featureless.  The programs Olex-2 
and Ortep-3 were used within the WinGX software package to prepare artwork representation 
(Farrugia et al., 2012; Spek et al., 2003).  Crystallographic data (excluding structure factors) 
for the structure in this paper has been deposited with the Cambridge Crystallographic Data 
Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK.  Copies of the data can be obtained 
free of charge on quoting the depository number CCDC 1451681 (Fax: +44-1223-336-033; E-
Mail: deposit@ccdc.cam.ac.uk, http://www.ccdc.cam.ac.uk). 
 
4.2.3 Computational methods 
Different conformations of A6d were obtained using the “Generate Conformation” module in 
the Accelrys Discovery Studio (Accelrys Software, 2013).  Conformation of A6d with lowest 
energy was further optimized using the Becke’s (Becke et al., 1988) three parameter exchange-
functional (B3) and gradient-corrected correlation functional of Lee, Yang ad Parr (LYP) (Lee 
et al., 1988) with implementation of 6-311g+(2d,p) basis sets, with Gaussian 09 software 
(Frisch et al., 2009).  The true energy minima was further verified by frequency calculations 
on the optimized geometry.  HOMO-LUMO visualization was performed using the gauss view.  
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For MD, the optimized structure of A6d was explicitly solvated with water molecules using 
the “Solvation” algorithm embedded in the Discovery Studio (DS).  The system was 
energetically minimized in DS using 1000 steps of the steepest descent algorithm followed by 
1000 steps of Conjugant gradient, until the root mean square (RMS) gradient of 0.1 kcal mol-1 
was achieved in DS.  The temperature of the system was raised to 300 K at constant volume.  
The equilibration step with a length of 10 picoseconds was used to create uniform density of 
the solvent around the compound at constant pressure and temperature.  Finally, the MD 
simulation of 500 ps was performed using default parameters in DS.  
 
4.3 Results and Discussion 
4.3.1 Synthesis 
Quinoxalines with various substituents at C-2 and with an ester group at C-6 were synthesized 
in a four- step reaction involving esterification of 4-fluoro-3-nitrobenzoic acid A1 to methyl 4-
fluoro-3-nitrobenzoate A2, which was then reacted with various amino acid hydrochloride 
esters A4 prepared from amino acids themselves.  This produced an intermediate A5 which 
incorporates both the amino acid and the benzoate moieties.  This intermediate was cyclised to 
the quinoxalines A6a-n following reduction of the nitro group with Pd/C and methanol 
(Scheme 4-1). 
 
Scheme 4-1  Synthesis of amino acids derived quinoxalines; Reagents and conditions: (i) 
SOCl2, MeOH, reflux, 4h; (ii) H2SO4, MeOH, reflux, 8h; (iii) NaHCO3, THF, rt, 8h;  (iv) 10% 
Pd/C, MeOH, rt, 4h 
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The most important step in the reaction sequence was the nucleophilic substitution of the 
fluorine in A2 with the amino acid ester A4a.  In order to determine the optimum conditions 
for step, we first examined the effect of solvent (Table 4-2), followed by base (Table 4-3). 
Various polar, non-polar, protic and non-protic solvents were investigated.  The results 
indicated that the two polar non-protic solvents, THF and DMF reacted in the shortest time (8 
h) and with the highest yield (80 and 68% respectively) (Table 4-2). 
 
The role of the base in step 3 is to deprotonate the hydrochloride amino salt of the ester, 
allowing the amino ester to act as a nucleophile.  From the results in Table 4-3, the moderate 
bases NaHCO3 and Et3N resulted in the best yields (78-80%) in the shortest time (8 h).  From 
these two, NaHCO3 has the advantages of being less expensive, available in the solid form and 
easy to handle as opposed to the pungent odour and comparatively more expensive organic 
liquid base of Et3N. 
 
4.3.2 Structural elucidation  
The full characterization (1H and 13C NMR) of amino acid derived tetrahydroquinoxalines 
A6a-n is presented in Table 4-4, Table 4-5 and Table 4-6 and the 1H and 13C NMR spectra of 
a representative tetrahydroquinoxaline (A6b) is presented in Figure 4-1 and Figure 4-2 
respectively.  With the aid of COSY, NOESY, HSQC and HMBC as well as multiplicity of the 
resonances, unambiguous chemical shift assignments were made. 
 
Compounds A6a-n from this series were derived from various amino acids and hence these 
analogues contain a basic skeleton, 3-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxylate with 
different amino acid side chain functionalities at the chiral carbon C-2.  Compound A6b was 
chosen for discussion, since this compound was the most interesting of the series. 
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Table 4-2  Yields and times of completion of reaction with different solvents for the 
formation of the intermediate A5a 




1 MeOH 16 48 
2 DCM 14 35 
3 Ethanol 12 64 
4 Diethyl ether 18 40 
5 DMF 8 68 
6 THF 8 80 
7 Water 24 NR 
8 ACN 24 NR 
9 EtOAc 24 NR 
10 Toluene 24 NR 
a prepared from methyl-4-fluoro-3-nitrobenzoate (2.34 mmol) and (R)-methyl 2-amino-3-methylbutanoate (3.51 
mmol), base: Et3N (4.68 mmol), room temperature and 10 mL solvent; b Isolated yield, NR = No reaction 
 
 
The core quinoxaline framework 
 The core quinoxaline structure contains seven proton resonances at δ 10.34 for the H-4 amino, 
δ 6.73 for the H-1 amino, δ 4.15 for H-2 (a triplet in this case with J = 4.6 Hz) and a singlet 
methyl resonance at δ 3.73 for the H-12 ester methyl group. The aromatic protons of the core 
skeleton, H-8, H-7 and H-5 appear between δ 6.64 to 7.35, H-8 appearing as a doublet at δ 6.64 
(J = 8.3 Hz), H-7 as a double doublet at δ 7.35 (J = 8.2, 1.5 Hz) and H-5 at δ 7.22 as a doublet 
with J = 1.5 Hz.  For A6a-n, H-2 shows different chemical shifts and splitting patterns, which 
is dependent on the groups at the 2-position.  For A6b H-2 showed a COSY correlation with 
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NH-1, distinguishing it from NH-4.  Furthermore, NH-4 also showed a HMBC correlation to 
C-5 and NH-1 to C-8 confirming these assignments.     
 
Table 4-3  The effect on yields and time of completion of reaction with different bases in the 
formation of the intermediate A5a 






1 Pyridine 5.2 14 67 
2 4-Methyl 
morpholine 
7.38 18 59 
3 DIPEA 40 12 60 
4 DMAP 9.7 10 50 
5 K2CO3 10.25 24 55 
6 NaHCO3 10.3  8 80 
7 Et3N 10.75  8 78 
8 NaOH 13 24 NR 
9 KOH 13.5 24 NR 
a Reaction condition: Methyl-4-fluoro-3-nitrobenzoate (2.34 mmol), (R)-methyl 2-amino-3-methylbutanoate 
(3.51 mmol), solvent: THF (10 mL), room temperature and base (2 eq.); b Isolated yield; NR = No reaction 
 
The two carbonyl resonances in the core skeleton, the amide carbon resonance (C-3) and the 
ester carbonyl resonance (C-11) appear very close to each other in the 13C NMR spectrum at δ 
166.1 and δ 166.0 and are interchangeable.  These resonances also cannot be distinguished in 
compounds A6h, A6k and A6l.  However, in other compounds, for example A6a, these can be 
distinguished due to HMBC correlations between C-2 with H-2, NH-4 and H-1a and C-11 with 
H-7, H-5 and the ester methyl H-12.  The assignment of C-10 at δ 138.3 was made due to an 
HMBC correlation with H-7.  C-9 and C-6 at δ 124.3 and δ 117.1 respectively were 
distinguished by C-9 showing a HMBC correlation to both H-8 and NH-1 and C-6 showing a 
HMBC correlation to H-8 only. 
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Side chain of quinoxaline A6b 
For the benzyl moiety attached to C-2, the two diastereotopic protons of H-1a each appeared 
as a doublet of doublets at δH 2.84 (J = 13.8, 6.2 Hz) and δH 2.80 (J = 13.8, 4.8 Hz).  These 
proton resonances showed a COSY correlation to H-2 and a HMBC correlation to the amide 
carbonyl C-3.  The aromatic protons of benzyl group H-3a/7a and H-4a/6a, each occurred as 
doublets at δH 6.93 and δH 6.59 respectively with coupling constants of 8.2 Hz respectively.  
The assignment of H-3a/7a was made due to a HMBC correlation with C-1a.  The hydroxyl 
proton attached to the para position of benzyl group appeared at δH 9.1 as a singlet.  This 
hydroxyl proton (OH-8a) showed a long range COSY correlation with H-4a/6a.  The singlet 
C-2a and C-5a resonances occurred at δC 126.6 and δC 155.8 respectively.  C-2a showed HMBC 
correlations to H-2 and C-5a showed HMBC correlations to H-3a/7a.  Selected HMBC 
correlations used in the structural elucidation of A6b are provided in Figure 4-3. 
 
 









Figure 4-3  Selected HMBC correlations for (S)-methyl 2-(4-hydroxybenzyl)-3-oxo-1,2,3,4-
tetrahydroquinoxaline-6-carboxylate (A6b) 
 
The structural elucidation of each of the side chains in the quinoxalines are divided into three 
sections, (i) quinoxalines with aromatic side chains, (ii) quinoxalines with non-polar side 




Table 4-4  1H NMR data (δ in ppm) for compounds A6a-g (J is given in Hz)   
 A6a A6b A6c A6d A6e A6f A6g 
1 6.81 s 6.73 s 6.86 s 6.82 s 6.84 s 6.84 s 6.80 s 
2 3.95 (q, 6.6) 4.15 (t, 4.6)1 4.31 (td, 5.7, 1.2)2 3.88 (ddd, 7.4, 
5.5, 1.6) 
3.77 (dd, 4.2, 2.0) 3.84 (dd,4.0, 1.8) 4.25 (ddd, 6.6, 
5.2, 1.6) 
3 - - - - - - - 
4 10.36 s 10.34 s 10.49 s 10.37 s 10.41 s 10.40 s 10.37 s 
5 7.34 (d, 1.8) 7.22 (d, 1.5) 7.34 (d, 1.6) 7.33 (d, 1.6) 7.29 (d, 1.7) 7.29 (d, 1.6) 7.20 (d, 1.9) 
6 - - - - - - - 
7 7.40 (dd, 8.1, 1.8) 7.35 (dd, 8.2, 1.5) 7.40 (dd, 8.2, 1.6) 7.40 (dd, 8.3, 1.6) 7.38 (dd, 8.3, 1.7) 7.38 (dd, 8.2, 1.6) 7.36 (dd, 8.4, 1.9) 
8 6.67 (d, 8.3) 6.64 (d, 8.3) 6.67 (d, 8.3) 6.73 (d, 8.3) 6.73 (d, 8.3) 6.70 (d, 8.3) 6.65 (d, 8.3) 
9 - - - - - - - 
10 - - - - - - - 
11 - - - - - - - 
12 3.75 s (3H) 3.73 s (3H) 3.75 s (3H) 3.74 s (3H) 3.73 s (3H) 3.73 s (3H) 3.72 s (3H) 
1a 1.28 (d, 6.6, 3H) 2.84 (dd, 13.8, 
6.2) 
2.78 (dd, 14.1, 
3.2)   
1.40-1.52 m3 2.06 (sep of d, 6.8, 
2.0) 
1.75-1.83 m 2.97 (13.7, 6.0) 
  2.80 (dd, 13.8, 
4.8) 
2.73 (dd, 14.1, 
3.8) 
    
2a - - - 1.81 (sep, 6.6) 0.94 (d, 6.8, 3H) 1.37-1.44 m  
1.06-1.16 m 
- 
3a - 6.93 (d, 8.2) 3.58 s (3H) 
0.87 (d, 6.6, 6H)4 
0.82 (d, 6.8, 3H) 0.90 (d, 7.0, 3H) 7.15-7.17 m 
4a - 6.59 (d, 8.2) - - 0.81 (t, 7.4, 3H)1 7.20-7.22 m 
5a - - - 0.87 (d, 6.6, 6H)4 - - 7.15-7.17 m 
6a - 6.59 (d, 8.2) - - - - 7.20-7.22 m 
7a - 6.93 (d, 8.2) - - - - 7.15-7.17 m 
8a - 9.1 s - - - - - 





Table 4-5  1H NMR data (δ in ppm) for compounds A6h-n (J is given in Hz) 
 A6h A6i A6j A6k A6l A6m A6n 
1 6.75 s 6.71 s 6.88 s - 6.85 (d, 1.1) 6.84 s - 
2 4.24 (td, 5.6, 1.4)1 4.15 
(ddd,7.7,4.1,1.6) 
4.02 (ddd, 6.2, 
4.4, 1.0) 
3.86 (dd, 9.2, 7.2) 3.95 (td, 6.1, 1.6) 3.93 (dd, 6.4, 3.6) 3.97 (dd, 5.4, 3.5) 
3 - - - - - - - 
4 10.34 s 10.41 s 10.44 s 10.50 s 10.46 s 10.37 s 10.40 s 
5 7.23 (d, 1.6) 7.31 (d, 1.7) 7.33 (d, 1.7) 7.40 (d, 1.8) 7.33 (d, 1.8) 7.26 (d, 1.8) 7.29 (d, 1.8) 
6 - - - - - - - 
7 7.34 (dd, 8.2, 1.7) 7.38 (dd, 8.3, 1.8) 7.41 (dd, 8.3, 1.8) 7.52 (dd, 8.3, 1.8) 7.40 (dd, 8.1, 1.9) 7.36 (dd, 8.2, 1.8) 7.37 (dd, 8.2, 1.7) 
8 6.63 (d, 8.3) 6.69 (d, 8.3) 6.71 (d, 8.3) 6.59 (d, 8.3) 6.70 (d, 8.3) 6.72 (d, 8.3) 6.69 (d, 8.3) 
9 - - - - - - - 
10 - - - - - - - 
11 - - - - - - - 
12 3.72 s (3H) 3.74 s (3H) 3.74 s (3H) 3.76 s (3H) 3.73 s (3H) 3.73 s (3H) 3.73 s (3H) 
1a 3.07 (d, 5.6)2 2.97 (dd, 14.7, 
4.1) 
2.83 (dd, 14.7, 
7.7) 
1.81-1.98 m 2.00-2.20 m 
 
1.81-1.97 m 3.71-3.73 m 3.66 (dd, 10.8, 
5.4)  
3.60 (dd, 10.8, 
3.4) 
2a - - 2.53-2.64 m 1.93-2.00 m 2.39-2.45 m 1.12 (d, 6.4) - 
3a 7.07 (d, 2.1) 6.79 s 2.03 s (3H) 3.25-3.47 m 
 
- - - 
4a 10.82 s 10.90 s - - 3.55 s (3H) - - 
5a - 7.58 s - - - - - 
6a 7.51 (d, 7.8) - - - - - - 
7a 7.03 (t, 7.8)3 - - - - - - 
8a 6.95 (t, 7.5)3 - - - - - - 
9a 7.29 (d, 7.5) - - - - - - 
1actually a ddd collapsed due to 2nd order coupling. 2 both resonances of 1a overlap. Each proton of 1a should be a dd, however this could not be detected since the 2nd order 
coupling is so strong that the outer peaks of the dd were too negligible to be detected. 3 actually a dd appearing as a t since both J values are the same. 
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Table 4-6  13C NMR data (δ in ppm) for compounds A6a-6n 
 A6a A6b A6c A6d A6e A6f A6g A6h A6i A6j A6k A6l A6m A6n 
1 - - - - - - - - - - - - - - 
2 50.4 56.6 51.9 53.3 60.3 59.7 56.3 55.9 55.0 53.8 59.0 54.2 67.4 57.5 
3 167.4 166.1 166.0 167.0 166.1 166.1 166.0 166.4 166.1 166.4 166.2 166.5 166.2 166.1 
4 - - - - - - - - - - - - - - 
5 115.4 115.1 115.5 115.3 115.2 115.2 115.2 115.1 115.4 115.4 114.9 115.7 115.0 115.2 
6 117.8 117.1 117.8 117.6 116.9 116.8 117.3 117.1 117.7 117.8 117.8 118.0 116.5 116.8 
7 125.0 125.1 125.1 125.1 125.2 125.2 125.1 125.1 125.1 125.1 125.3 125.4 125.0 125.1 
8 112.2 111.9 112.1 112.3 111.4 111.4 112.0 111.9 112.4 112.2 110.5 112.5 111.6 111.6 
9 125.2 124.3 124.7 124.8 124.1 124.1 124.3 124.4 124.7 124.7 126.8 124.8 124.3 124.2 
10 138.9 138.3 138.2 138.3 138.9 138.9 138.3 138.3 138.3 138.4 138.5 138.6 139.1 138.8 
11 166.1 166.0 165.4 166.1 165.8 165.7 165.8 166.1 165.9 166.0 166.1 166.3 165.5 165.2 
12 51.4 51.3 51.4 51.4 51.3 51.3 51.4 51.3 51.5 51.4 51.5 51.7 51.3 51.3 
1a 18.2 37.7 37.0 41.4 32.1 39.0  38.5 28.7 29.4 31.8 27.0 27.9 61.3 62.8 
2a - 126.6 170.5 23.3 18.6 24.2 136.8 136.0 131.7 28.7 21.7 29.2 19.8 - 
3a - 130.7 51.5 22.9 17.2 15.1 129.9 124.2 117.3 14.4 46.0 173.1  - - 
4a - 114.8 - 21.7 - 11.6 128.2 - - - - 51.5 - - 
5a - 155.8 - - - - 126.3 127.5 134.4 - - - - - 
6a - 114.8 - - - - 128.2 118.3 - - - - - - 
7a - 130.7 - - - - 129.9 120.8 - - - - - - 
8a - - - - - - - 118.4 - - - - - - 
9a - - - - - - - 111.2 - - - - - - 
10a - - - - - - - 109.0 - - - - - - 
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Quinoxalines with aromatic side chain 
Compounds A6b and A6g-i contained aromatic amino acids, tyrosine (A6b), phenylalanine (A6g), 
tryptophan (A6h) and histidine (A6i).  Tyrosine contains a polar hydroxyl group, tryptophan and 
histidine are basic whereas phenylalanine is non-polar. 
 
All the functional groups of these amino acids contain a methylene group bonded directly to C-2 
and hence, H-2 should appear as a ddd in each case, coupling with the two methylene protons and 
NH-1.  However, this is only seen in two cases, A6g and A6i with J = 6.6, 5.2, 1.6 Hz for A6g and 
J = 7.7, 4.1, 1.6 Hz for A6i.  For A6b we observe a triplet for H-2 at δ 4.15 (J = 4.6 Hz).  This 
could be due to there being no coupling with the NH-1 proton and the protons of the diastereotopic 
methylene group occurring at the same resonance.  For A6h, we observe a triplet of doublets at δ 
4.24 for H-2, due to coupling with equivalent methylene protons (J = 5.6 Hz) and a small coupling 
with the NH-1 proton (J = 1.4 Hz).  The diastereotopic proton resonances are clearly observed in 
A6b at δ 2.84 (J = 13.8, 6.2 Hz) and 2.80 (J = 13.8, 4.8 Hz) and A6i at δ 2.97 (J = 14.7, 4.1 Hz) 
and 2.83 (J = 14.7, 7.7 Hz).  For A6h, this methylene group, H-1a is observed as a doublet at δ 
3.07 (J = 5.6 Hz).  We do not observe geminal coupling here and propose that due to second order 
coupling, the two outer peaks of each of the doublets have disappeared and that the inner peaks 
only are observed 5.6 Hz apart.  Since no other coupling is observed, the dihedral angle between 
the two methylene protons and H-2 must be very close to 90º.  For A6g, the two methylene protons 
overlap at δ 2.97 and both geminal (13.7 Hz) and vicinal (6.0 Hz) coupling is observed. 
 
For the rest of the side chain, expected resonances were seen for A6b, two pairs of doublets at d 
6.93 (H-3a/7a) and 6.59 (H-4a/6a) with J = 8.2 Hz indicative of ortho coupling; for A6g, three 
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proton (at d 7.15-7.17) and two proton (at δ 7.20-7.22) aromatic resonances were seen for the five 
aromatic protons; for A6h the six tryptophan proton resonances can be seen at δ 7.07 (d, J = 2.1 
Hz, H-3a), δ 10.82 (s, NH-4a), δ 7.51 (d, J = 7.8 Hz, H-6a), δ 7.03 (t, J = 7.3 Hz, H-7a), δ 6.95 (t, 
J = 7.5 Hz, H-8a) and δ 7.29 (d, J = 7.5 Hz, H-9a); and for A6i the three imidazole protons can be 
seen at δ 6.79 (s, H-3a), δ 10.90 (s, NH-4a) and δ 7.58 (s, H-5a). 
 
An NMR study on hydrogen bonding (see 4.3.4) indicated that amongst these aromatic side chain 
amino acid quinoxalines, the −∆δ/∆T value of H-2 for compound A6b is much higher at 3.8 than 
for compounds A6g-A6i (0.46, 0.28 and 0.19 respectively) (Table 4-8).  This indicates strong 
hydrogen bonding for A6g-i and only moderate hydrogen bonding for A6b as H-2 in this case 
showed the largest change.  
 
Quinoxalines with aliphatic non-polar side chain  
The side chains of quinoxalines containing alanine (A6a), leucine (A6d), valine (A6e), isoleucine 
(A6f) and proline (A6k) are aliphatic and non-polar in nature.  In the case of A6a (alanine 
quinoxaline) with a methyl group in its side chain, H-2 was observed as a quartet at δ 3.95 and the 
methyl group H-1a appeared at δ 1.28 with a J value of 6.6 Hz.  For A6d (leucine quinoxaline) 
with a 2-methylpropyl side chain, H-2 appears as a ddd (J = 7.4, 5.5, 1.6 Hz), coupling with each 
of the diastereotopic methylene protons and the NH-1 proton.  The two H-1a protons overlap and 
occur as a multiplet at δ 1.40-1.52.  Interestingly, H-2a does not couple with either of the H-1a 
protons and occurs as a septet at δ 1.81 (J = 6.6 Hz) coupling only with the two equivalent methyl 
groups, which appear as a doublet at δ 0.87.  
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In A6e, H-2 appears as a double doublet at δ 3.77 (J = 4.2, 2.0 Hz), coupling with both NH-1 and 
H-1a.  The H-1a resonance occurs as a multiplet at δ 2.03-2.11.  The methyl groups appear as two 
separate doublets at δ 0.94 and 0.82.  These methyl groups appear as separate resonances since 
they are close to the chiral H-2 proton.  In A6f (isoleucine side chain), H-2 appears as a double 
doublet at δ 3.84 (J = 4.0, 1.8 Hz), H-1a and the two H-2a protons as multiplets at δ 1.75-1.83, 
1.06-1.16 and δ 1.37-1.44 respectively.  The methyl groups CH3-3a and CH3-4a appear as a doublet 
and triplet with J = 7.0 and 7.4 Hz respectively.  In A6k with a proline side chain, the H-2 
resonance occurs as a double doublet (J = 9.2, 7.2 Hz) and H-1a to H-3a all appear as multiplets 
at δ 2.00-2.20, δ 1.93-2.00 and δ 3.25-3.47 respectively, the latter resonance being deshielded since 
it is adjacent to nitrogen. 
 
The −∆δ/∆T value of the H-2 proton (Table 4-8) for compounds A6a, A6d-f and A6k indicated 
that A6d, A6f and A6k are more strongly involved in hydrogen bonding than A6a and that A6e 
has the least intermolecular hydrogen bonding from this series.   
 
Quinoxalines with ester, thiomethyl and hydroxyl functionality 
Compounds A6c and A6l both have ester functional groups in its side chain.  In A6c, the H-2 
proton was split into a triplet of doublets (td), since H-2 was first split into a triplet by the H-1a 
protons and then into a td by NH-1.  Even though both H-1a protons are diastereotopic, they behave 
as though they split H-2 equally, thus resulting in a triplet.  Each of the diastereotopic H-1a 
resonances appear separately at δ 2.78 (J = 14.1, 3.2 Hz) and 2.73 (J = 14.1, 3.8 Hz).  A similar 
splitting pattern for H-2 is seen in A6l which appears as a td.  Since A6l has two methylene groups 
adjacent to each other in its side chain, each of H-1a and H-2a appear as two-proton multiplets at 
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δ 1.81-1.97 and  δ 2.39-2.45 respectively.  Each of the ester methyl groups for A6c and A6l appear 
as singlets at δ 3.58 and 3.55 respectively and the ester carbonyl resonances occur at δ 170.5 and 
173.1 respectively.  For A6j with a thiomethyl ester side chain, H-2 appears as a ddd, coupling 
with each of the diastereotopic H-1a protons and then NH-1 with J values of 6.2, 4.4 and 1.0 Hz.  
This is slightly different to H-2 of A6c and A6l above which occur as td.  Both 1a and 2a appear 
as two-proton multiplets similar to A6l at δ 1.81-1.98 and δ 2.53-2.64 respectively and the 
thiomethyl group appears a singlet at δ 2.03. 
 
For A6m and A6n derived from threonine and serine, containing hydroxy groups in its side chain, 
the H-2 splitting pattern and coupling constants were similar in both cases, occurring as dd at δ 
3.93 (J = 6.4, 3.6 Hz) and δ 3.97 (J = 5.4, 3.5 Hz) respectively, even though H-2 in A6m was 
vicinal to a CH-O moiety and in A6n to a CH2-O moiety.  This could be due to there being no 
coupling to NH-1 in A6n and therefore the dd arises from coupling to each of the H-1a protons.  
The H-1a resonance in A6m overlaps with the ester methyl resonance and appears as a deshielded 
multiplet at δ 3.71-3.73.  The methyl group CH3-2a appears as a doublet as expected at δ 1.12 (J 
= 6.4 Hz).  In A6n, each of the H-1a resonances occur separately as dd at δ 3.66 and 3.60 with 
geminal coupling of 10.8 Hz and smaller vicinal coupling to H-2 of 5.4 and 3.4 Hz respectively. 
 
From the thermal study carried out, A6c is seen to have a larger −∆δ/∆T value for H-2 of 2.34 than 
A6m- A6n, A6j and A6l with a −∆δ/∆T value of less than 0.5 (Table 4-8), indicating that A6c has 
weaker intermolecular hydrogen bonding than the other compounds in this series.    
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4.3.3 Structure determination of A6d by single crystal X-Ray diffraction 
 In order to describe the structure of the series of compounds more fully, we obtained the crystal 
structure of A6d as a representative of the series (Figure 4-4).  Compound A6d was solved in the 
orthorhombic space group P21/c, with one molecule in the asymmetric unit.  The crystal structure 
of A6d indicated that the absolute stereochemistry at C-2 was in the S configuration and that the 
benzene and piperazine rings are contained in the same plane (the torsion angle for C5 - C9 - C10 
- N1 is 177.7º and that of N4 - C9 - C10 - C8 is -175.3º) with the isobutyl moiety out of the plane, 
perpendicular to the benzene ring with the dihedral angle between C1a and C10 being 73.8º and 
C1a and N4 being -89.6º (Figure 4-4).  The dihedral angle between the axial H-2 with axial H-1aa 
is 124.8º, whereas the dihedral angle between the axial H-2 with equatorial H-1ab is 4.5º.  The six 
membered rings exist in a twist half boat conformation Φ = 42.1 (3) Å, θ = 64.3 (3)°, Ψ= 0.3703 
(17)°.  As expected the O(3)…. NH(4) distance is 2.44 Å and the O(3)….. H(2) distance is 2.53 
Å, falling within the range of 2.30-3.10 Å required for hydrogen abstraction (Nishio et al., 2005).  
Interestingly the O(3)….H(1ab) distance of 2.89 Å also falls within this range, but the 
O(3)….H(1aa) distance of 3.44 Å falls out of this range.  In general there was intermolecular 
hydrogen bonding between the NH protons and the oxygen of the carbonyl groups as well as 
between the chiral proton H-2 and the oxygen atoms of carbonyl groups (Figure 4-5; Table 4-7).  
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Figure 4-4  ORTEP diagram of compound A6d 
 
Table 4-7  Geometry of hydrogen bonding in molecule A6d (Å,o) 
D - H….A D - H H….A  D….A D - H….A 
N1 – H1….O2 0.88 2.06 2.852 (2) 149 
N4 – H4….O3 0.88 2.26 3.104 (2) 162 
C2 – H2….O3 1.00 2.60 3.597 (2) 179 




Figure 4-5  Intermolecular hydrogen bonding in A6d 
 
4.3.4 Thermal coefficient shift NMR investigation 
Amino acids have the tendency to be involved in hydrogen bonding, both intermolecular and 
intramolecular, especially the ones with polar functional groups.  In order to investigate this 
hydrogen bonding in the molecules synthesized in this work, 1H proton NMR thermal analysis was 
performed starting from 298 K and increasing the temperature in increments of 10 ºC up to 328 K.  
At higher temperatures, the hydrogen bonding would be disrupted and as such the proton 
resonances involved in hydrogen bonding would be more shielded due to the N-H bond now being 
shorter. 
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Upon heating, a significant upfield shift of NH-4 and NH-1 in the tetrahydroquinoxalines was 
observed in the 1H NMR spectra (Figure 4-6).  The chemical shift of the chiral proton H-2 did not 
change much.  In the crystal structure of A6d, intermolecular hydrogen bond interactions were 
evident between NH-1 and the carbonyl oxygen of the ester moiety (O2).  For NH-4 both 
intramolecular and intermolecular hydrogen bonding was present to O3, the amide carbonyl 
oxygen, with greater intermolecular hydrogen bonding being present.  Intramolecular and 
intermolecular hydrogen bonding also occurred with H-2 and O3 with greater intramolecular 
hydrogen bonding being present (Figure 4-5). 
 
In aprotic solvents such as DMSO-d6, −∆δ/∆T < 3 ppb K-1 indicates the presence of hydrogen 
bonding and at −∆δ/∆T > 5 ppb K−1 hydrogen bonding is not possible (Farahani et al., 2014). The 
−∆δ/∆T values for selected protons in A6a-n acquired in DMSO-d6 are summarised in (Table 
4-8).  For the NH-4 proton our results indicate −∆δ/∆T values between 4.12 - 5.04 ppb K-1.  
According to the definition above only A6a with −∆δ/∆T of 5.04 ppb K-1 would have no hydrogen 
bonding.  All the other compounds show weak hydrogen bonding since its values are close to 
−∆δ/∆T of 5.0.  For the NH1 proton resonance, −∆δ/∆T range from 3.90 to 44.77, although only 
three values are in the high end of the range between 41.67-44.77 for A6c (esterified aspartic acid 
derivative), A6d (leucine derivative) and A6e (valine derivative).  All other compounds have 
−∆δ/∆T less than 5.64. In two of the cases, NH1 could not be observed and the −∆δ/∆T was not 
calculated.  For the three compounds with very high −∆δ/∆T values for NH-1 (A6c-e) all hydrogen 
bonding involving this proton was totally absent upon heating.  The fact that these three molecules 
deviated from the norm could be due to the fact that once heated, the interaction between the atoms 
involved in hydrogen bonding were totally absent.  For the chiral proton H-2, hydrogen bonding 
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in A6a-n were conserved upon heating since the −∆δ/∆T values were present in the range of 0.04-
3.80.  This could be due to the conservation of the intramolecular hydrogen bonding between H-2 
and the oxygen of the amide carbonyl group.  NH-4 also had intramolecular hydrogen bonding, 
not as much as H-2, but more than NH1.  This supports our data in that the more intramolecular 
hydrogen bonding present, the smaller the −∆δ/∆T value. 
 
4.3.5 Computational results 
Conformational analysis and structure validation 
The conformational profile with of A6d was explored using the Discovery studio programme, and 
the five lowest energy conformers obtained.  These structures were re-optimized at DFT level 
using Gaussian software (Frisch et al., 2009).  The computed electronic energies of conformer 1-
5 were found to be -879.531657, -879.528114, -879.530716, -879.525673 and -879.529739 
Hartree, respectively, indicating conformer 1 to be the energetically most favourable in 
comparison to other conformers.  The most energetically favourable DFT predicted structure was 
further validated by monitoring the root mean square deviation (RMSD) of all five conformers 
relative to the X-ray structure of A6d considering all their atoms, using the Discovery Studio 
visualizer.  The computed RMSD with values of 0.832 Å, 1.112 Å, 1.125 Å, 1.151 Å and 1.045 Å 
for conformers 1-5 respectively, indicated a close structural correlation between conformer 1 and 
the X-ray structure.  Three dimensional structure comparison of conformer 1 and conformer 2 with 
the X-ray structure of A6d was performed using DS visualizer to indicate the similarity between 
conformer 1 and the X-Ray structure and the deviation from the X-Ray structure by conformer 2 
(Figure 4-7).  Conformer 1 (green) structurally fits very well on the X-ray structure (red). On the 
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other hand, conformer 2 (blue), was slightly more folded bringing the ester and alkyl chain 
inwards, accounting for higher RMSD (1.112Å) compared to conformer 1 (0.832Å).       
 
Table 4-8  −∆δ/∆T values of shielded and deshielded proton from compound A6a-n 
Entry NH-1 NH-4 H-2 OH NH-4a 
A6a 4.50 5.04 1.59 - - 
A6b 5.64 4.57 3.8 5.43 - 
A6c 44.77 4.54 2.34 - - 
A6d 43.81 4.75 0.45 - - 
A6e 41.67 4.79 3.53 - - 
A6f 3.90 4.81 0.25 - - 
A6g 4.51 4.30 0.46 - - 
A6h 5.15 4.27 0.26 - 3.64 
A6i 4.21 4.70 0.19 - - 
A6j 4.03 4.67 0.23 - - 
A6k - 4.68 0.57 - - 
A6l 4.12 4.71 0.04 - - 
A6m 5.09 4.12 0.12 1.28 - 
A6n - 4.42 0.26 - - 
      
 
Natural atomic charges and electronic properties 
The effective atomic charges of chemical entities provide very useful information about their 
interactions in the molecular systems.  Accordingly, the atomic charges of A6d were obtained 
using the Mulliken population analysis procedure, and are depicted in Figure 4-8.  A closer 
inspection of Figure 4-8 revealed that the negative (–ve) charge was predominantly distributed 
over the nitrogen (N4 and N1) and oxygen atoms (O1 and O2), imposing large positive charges on 
the directly bonded carbon atoms (C3, C2, C10, C9 and C11).  Except for the nitrogen bonded 
hydrogen atoms (H4 and H1), no significant charge distribution was observed in the remaining 
hydrogen atoms of the molecule.  The accumulation of a large positive charge on H4 (0.290) and 
H1 (0.258) was attributed to a large negative charge on the nitrogen atoms (N4 and N1, 
respectively).  This indicates the participation of these atoms in hydrogen bonding, in agreement 
with the argument presented above.  
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Figure 4-6  1H spectral traces showing the shift of amide, sec. amine and chiral carbon 
containing proton at variable temperature in DMSO-d6 
 
In order to substantiate these observations, the electron density plots for the highest occupied 
molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) were visualized, 
and are depicted in Figure 4-9 and Figure 4-10 respectively.  The electron density in HOMO was 
preferably localized on the piperazine and phenyl rings, whereas in LUMO it was distributed over 
the oxygens of the ester functionality and phenyl ring. This HOMO-LUMO electronic arrangement 
suggests an electron density exchange between the central part (piperazine and phenyl rings) and 
the edge (ester group) of the molecule, indicating the possibility of hydrogen bonding in these 
regions, in accordance with the X-ray structure. Morever, the computed HOMO-LUMO gap was 
sufficiently low (4.4 eV) reflecting the chemical reactivity of the compound and resulting charge 
transfer interaction.   
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Molecular dynamics (MD) results 
Finally, a molecular dynamics (MD) study was conducted to explain the structural flexibility of 
A6d, observed in NMR experiments (Table 8).  A total of 500 different conformations of A6d 
were explored under explicit solvent conditions using the Standard Dynamics Cascade algorithm 
embedded in the Discovery Studio (Accelrys Software, 2013). 
 
The evolution of four distances; distance 1 [(N1)H..H(C2a)], distance 2 [O3..H(C2a)], distance 3 
[(N1)H..H(C1a)] and distance 4 [(N1)H..O3), was monitored during the progress of MD 
simulation, and is diagrammatically shown in Figure 4-11.  These results revealed that the distance 
1 (in black) fluctuates between 2-5 Å during the first half of simulation, but becomes stable (2.3 
Å) during the next half, suggesting the formation of a hydrogen bond between atoms N1 and HC2a.  
On the other hand, the distance 2 (in red) exhibited an average fluctuation around 5Å after 250 
picoseconds, indicating the unstable nature of this interaction.  The inter-atomic distances, 3 (in 
green) and 4 (in blue), exhibited larger deviations (>3.0 Å) in the majority of the sampled 
conformations.  Overall, the MD results suggested that compound A6d is highly flexible in the 
presence of solvent molecules, and also indicates the role of N1 (quinoxaline) and HC2a in 




Figure 4-7  Overlay of X-ray structure (in red sticks) of A6d with its DFT predicted conformer1 








Figure 4-9  The electron density distribution in HOMO of compound A6d 
 
Figure 4-10  The electron density distribution in LUMO of compound A6d 
 




Fourteen quinoxaline derivatives were successfully synthesized and 1H and 13C NMR assignments 
of tetrahydroquinoxaline were made with the aid of HSQC and HMBC data and will provide a 
reference point for the structural elucidation of other tetrahydroquinoxalines synthesized.  NMR 
studies appear to reveal that atoms on the tetrahydroquinoxaline core enforce intermolecular 
hydrogen bonding interactions.  The stereochemistry of C-2 for A6d was shown to be in the S 
configuration for tetrahydroquinoxaline from X-Ray data.  Thermal coefficient investigation 
studies revealed the presence of hydrogen bonding in these molecules. Additionally, DFT 
calculations of A6d revealed the role of the quinoxaline ring in hydrogen bonding and charge 
transfer.  Moreover, MD studies explained the high flexible nature of A6d in the solvent phase, 
and supported the experimental observations.  From the thermal coefficient shift, NMR 
investigation and X-ray crystal analysis of quinoxalines it can be described that the chiral carbon 
containing proton (H-2) is involved in low to strong hydrogen bonding.  This could be due to 
different side chain functionalities of amino acid precursors, each having a different structure.  
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Chapter 5. Biological evaluation and docking study of synthesized amino acid 
tethered quinoxalines 
 
* The compounds referred to in the chapter are referred to elsewhere in the thesis with an A preceding the number of 
the compound.  For example 6a-n is referred to as A6a-n elsewhere in the thesis. 
 
Abstract 
A total of 14 amino acid-tethered-quinoxalines (A6a-A6n) were evaluated for their antimicrobial, 
anti-oxidant and anti-diabetic activity.  Preliminary structure-activity relationship studies showed 
that compounds with an alanine (A6a), threonine (A6m) and serine (A6n) residues possessed a 
broader spectrum of antimicrobial activity than the other quinoxalines tested.  Compound A6g 
with a benzyl group appeared to have strain specific activity against Escherichia coli and 
Pseudomonas aeruginosa (MBC 0.08 mM and 0.17 mM), compared to the standard ciprofloxacin 
(0.002 mM).  Compounds A6a, A6d and A6f showed the most potent anti-diabetic activity, with 
the A6d derivative (leucine residue) showing the most potent activity against both α-Glucosidase 
(IC50 0.01 mM) and α-amylase (IC50 1.41 mM) enzymes respectively compared to the standard 
acarbose (IC50 0.088 and 0.104 mM).  Five of the molecules (A6a, A6d, A6e, A6h and A6j) 
showed antioxidant activity, with two of the molecules (A6h and A6d) showing good antioxidant 
activity (IC50 0.15 mM) compared to that of ascorbic acid (IC50 0.10 mM).  Furthermore, in silico 
molecular docking simulations were conducted to support the anti-bacterial and anti-diabetic 
activity profiles of the synthesized compounds using the bacterial topoisomerase II (PDB code: 
2XCT) and α-glucosidase proteins.  
 
Keywords: Quinoxaline, amino acids, antimicrobial, antioxidant, anti-diabetic, docking 
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5.1 Introduction  
Quinoxaline is a heterocyclic core structure used as a back-bone for the synthesis of bioactive 
compounds.  It is formed by two aromatic rings, benzene and pyrazine.  This core structure is rare 
in nature but is easy to synthesize chemically.  By varying the functional groups and moieties on 
the quinoxaline scaffold, a wide variety of compounds were synthesized, many of which had good 
biological activity (Ajani et al., 2014; Ramli et al., 2014; Ameen et al., 2015; Padvi et al., 2015).   
 
Various quinoxaline derivatives have shown antibacterial, antifungal, antiviral, anti-HIV, anti-
tuberculosis, antimalarial, leishmanicial, antitumor, antioxidant, anti-inflammatory, analgesic, 
antidepressant, antidiabetic, enzyme inhibitory, kinase inhibitory, receptor antagonist, multi-drug 
resistant antagonist, antithrombotic, antiamoebic, anticonvulsant, antiepileptic and Gonadotropin 
releasing hormone antagonistic activities (Lawrence et al., 2001; Waring et al., 2002; Burguete et 
al., 2011; Noolvi et al., 2011; Kakodkar et al., 2011; Puratchikody et al., 2011; Habib et al., 2012; 
Kulkarni et al., 2012; Kotra et al., 2013; Soliman et al., 2013; Ajani et al., 2014; Ramli et al., 2014; 
Srinivas et al., 2014a, 2014b; Vieira et al., 2014; Ameen et al., 2015; Ismail et al., 2015; Wei et 
al., 2015; Padvi et al., 2015; Anand et al., 2015; Raju et al., 2015).  Their wide range of bioactivity 
makes them a versatile scaffold for pharmaceuticals. 
 
Amino acids are the building blocks of peptides and proteins as well as other naturally occurring 
substances such as alkaloids, antibiotics and heterocyclic peptides (Hughes et al., 2007; Nolan et 
al., 2009; Fester et al., 2010; Albers et al., 2013).  Being a natural ligand, they are water soluble 
and less toxic than other synthetic ligands used in drug design.  Simple α-amino acids were used 
to form conjugated piperazinyl benzoisothiazole complexes with anti-ulcer activity (Sharma et al., 
124 
2013a, 2013b) and conjugated benzisoxazole derivatives with potent antimicrobial activity (Suhas 
et al., 2011), showing that these amino acids have the ability to form bioactive molecules when 
coupled with heterocyclic rings.  Cinnamic acid analogues combined with amino acids showed 
promising anti-diabetic activity (Prakash et al., 2014).   
 
The amino acids themselves, such as 4-hydroxyisoleucine and 3-guanidinopropionic acid and its 
semi-synthetic derivatives, polypeptides such as polypeptide-k and proteins such as ADMc1 from 
the seed extract of Momordica charantia has shown good anti-diabetic properties (Larsen et al., 
2001; Ahmad et al., 2012; Patel et al., 2012; Chhabra and Dixit, 2013; Sridevi et al., 2014; Shukla 
and Rangari, 2015).  Peptides have also been used in the design of antimicrobials (Friedrich et al., 
2000; Laverty et al., 2011; Mojsoska et al., 2015; Kalita et al., 2015).  The beta-defensin-3 peptide 
has shown a broad spectrum of antimicrobial activity (Dhople et al., 2006).  Amino acids are also 
found in thiostrepton-derived thiopeptide antibiotics (Baringo et al., 2014; Wang et al., 2015).  
Copper and cobalt amino acid complexes have shown the ability to be developed into antibiotics 
(Stanila et al., 2011) and amino acids conjugated to thiazole and oxazole moieties showed good to 
moderate antimicrobial activity (Stanchev et al., 1999; Prakasha et al., 2011).  A report on the 
synthesis of quinoxalines with β-amino acid derivatives has shown good antibacterial and 
antifungal activity (Mickeviciene et al., 2015). 
 
Due to the vast range of bioactivity of quinoxalines reported we have synthesized quinoxaline 
amino acid conjugates (A6a-A6n) with the aim of testing them for antimicrobial and antidiabetic 
activities (Thesis chapter 4).  We herein report the antimicrobial, antidiabetic and antioxidant 
activities of some amino acid-tethered-quinoxalines.  
125 
5.2 Experimental 
5.2.1 Test compounds 
The amino acid-tethered-quinoxalines (A6a-A6n) were previously synthesized in our laboratory 
(Thesis chapter 4).  These molecules contain a 1,2,3,4-tetrahydroquinoxaline heterocyclic skeleton 
with an ester group at position 6 and various amino acids at position 2.  These amino acids contain 
aliphatic and aromatic groups and are either polar or non-polar in nature (Table 5-1).  
5.2.2 In vitro antimicrobial studies 
The microbial cultures were grown overnight at 37 °C in nutrient broth (UKZN Biolab, South 
Africa), adjusted to 0.5 McFarland standard using distilled water and lawn inoculated onto 
Mueller-Hinton agar (MHA) plates.  A volume of 10 µL of each sample (29.84 – 45.44 mM, 1 mL 
DMSO) was inoculated onto antibiotic assay discs (6 mm diameter) and placed on the MHA plates 
which were incubated overnight at 37°C for 24 hours.  After the incubation period, zones of 
inhibition were measured in mm.  Compounds showing an inhibition zone of > 9 mm were selected 
to determine their MBC values using the broth dilution assay with ampicillin and ciprofloxacin as 
the controls following the method in Andrews (2001).  Compounds A6a-b, A6d-h, A6j, and A6m-
n were selected to determine their MBC values by the broth dilution method. 
 
In the MBC method, the microbial cultures were prepared as described previously for the disc 
diffusion method and adjusted to a 0.5 McFarland standard.  The test compounds were dissolved 
in DMSO (10 mg/mL) and subject to a 50% serial dilution in 1 mL eppendorf tubes with Mueller-
Hinton Broth (MHB), inoculated with bacterial cultures (20 µL) and then incubated at 37°C for 18 
h.  The total volume in each eppendorf was 200 µL.  A volume of 10 µL of each dilution was 
spotted on MHA plates and incubated at 37°C for 18 h to determine the MBC (in mM).  Ampicillin, 
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ciprofloxacin and tioconazole served as the standard drugs for the antibacterial and antifungal 
studies respectively.  All experiments were performed in duplicate. 
 
5.2.3 In vitro antioxidant studies 
DPPH radical scavenging activity 
The total free radical scavenging activity of the synthesized amino acid-tethered quinoxaline 
compounds (A6a-A6n) was determined and compared to that of ascorbic acid using a slightly 
modified method described by Tuba and Gulcin et al., 2008.  A 0.3 mM solution of DPPH was 
prepared in methanol and 500 µL of this solution added to 50 µL of the compounds (dissolved in 
DMSO) at different concentrations (50-200 µg mL-1).  These solutions were mixed and incubated 
in the dark for 30 min at room temperature.  Absorbance was then measured at 517 nm against a 
blank sample lacking scavenger. 
5.2.4 Anti-diabetic activity 
In vitro α-Glucosidase inhibitory activity 
The α-Glucosidase inhibitory activity of the synthesized amino acid-tethered quinoxaline 
compounds (A6a-n) was determined according to the method described by Ademiluyi et al. 
(2013), with slight modifications.  Briefly, 50 µL of each compound or acarbose dissolved in 
DMSO at different concentrations (50-200 µg mL-1), was incubated with 100 µL of 1.0 U mL–1 α-
glucosidase solution in 100 mM phosphate buffer (pH 6.8) at 37 °C for 15 min.  Thereafter, 50 µL 
of pNPG solution (5 mM) in 100 mmol L–1 phosphate buffer (pH 6.8) was added and the mixture 
was further incubated at 37 °C for 20 min.  The absorbance of the released p-nitrophenol was 
measured at 405 nm and the inhibitory activity expressed as a percentage of the control sample 
without inhibitors.  
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In vitro α-Amylase inhibitory activity  
The α-Amylase inhibitory activity of the compounds A6a-n, was determined according to the 
method described by Shai et al. 2010, with slight modifications.  A volume of 50 µL of each 
compound dissolved in DMSO or acarbose at different concentrations (50-200 µg mL-1) was 
incubated with 100 µL of porcine pancreatic amylase (2 U mL–1 ) in 100 mM phosphate buffer 
(pH 6.8) at 37 °C for 20 min. 50 µL of 1% starch dissolved in 100 mM phosphate buffer (pH 6.8) 
was then added to the reaction mixture and incubated at 37 °C for 1 h. 100 µL of 3,5-
dinitrosalicylic acid (DNS) colour reagent was then added and boiled for 10 min.  The absorbance 
of the resulting mixture was measured at 540 nm and the inhibitory activity was expressed as 
percentage of a control sample without inhibitors.  All assays were carried out in triplicate. 
 
5.2.5 Docking methodology 
Initial structures of the representative compounds (RCs) (A6d, A6f, A6g and A6n) in protein data 
bank (pdb) format were drawn in the Discovery Studio software (DS).  Different isomers of the 
compounds were generated at the physiological pH (7.0) using the “Prepare Ligands” algorithm, 
and further geometrically minimized using the “minimize ligands” module.  The CHARMm force 
field was considered to develop the partial atomic charges of each atom.  The X-ray structure of 
topoisomerase II DNA-gyrase (pdb id: 2xct, resolution 3.5Å) was downloaded from the protein 
data bank (PDB) database (www.rcsb.org).  The bound ligands and water molecules were removed 
from the protein while the manganese ion (Mn+2) present in the active site was retained (Bax et al., 
2010).  The “Prepare Protein” module in DS was used to add missing atoms/loops and protonates 
amino acid residues according the physiological conditions. Since, the X-ray structure of α-
glucosidase is not known, homology modelling method was used to generate it’s 3D structure 
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using the crystal structure of S. cerevisiae from isomaltase (pdb id: 3AJ7) as a template, using 
MODELER algorithm (Eswar et al., 2006) in Discovery Studio (DS). Prior to docking, a binding 
sphere covering the active site residues of proteins was developed.  CDOCKER (Wu et al., 2003), 
a grid-based program, was used to dock RCs in the active site of the protein where a conformational 
profile of the ligands was explored by the molecular dynamics sampling method.  The most 
favourable pose of each RC was chosen based on the CDOCKER energy (CDE), where the most 
negative CDE indicates the strongest interaction with the receptor.   
 
5.3 Results and Discussion 
5.3.1 Chemical structures 
The chemical structures of the compounds used in the structure activity relationship (SAR), have 
a 1,2,3,4-tetrahydroquinoxaline base core moiety which is formed by the fusion of the phenyl 
group and amino acids (Figure 5-1).  Compounds A6a-n contain precursors of different amino 
acids, two secondary amine groups and a methyl ester at position 6.  These functional groups are 
believed to play an important role in antimicrobial and antioxidant activities (Ghorab et al., 2004; 
Shivakumara et al., 2009; Kumar et al., 2011; Abedini et al., 2013; Goszczyn´ska et al., 2015). 
Compounds A6b, A6g, A6h and A6i contain aromatic R groups and A6a, A6c-f and A6j-6n, either 
polar or non-polar aliphatic side chain R groups.  The R groups in A6a-n are tabulated in Table 
5-1.  
 
Figure 5-1  The core structure of amino acid tethered quinoxalines 
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5.3.2 Antimicrobial activity 
The compounds were evaluated for their in vitro antimicrobial activity against two Gram +ve 
strains S. aureus (ATCC 25923) and methicillin resistant S. aureus (MRSA) (ATCC BAA-1683) 
and three Gram -ve strains E. coli (ATCC 25922), K. pneumonia (ATCC 31488) and P. aeruginosa 
(ATCC 27853) as well as one fungal strain, C. albicans (ATCC 10231).  The disc diffusion assay 
was used to screen all the synthesized compounds and to select compounds to determine their 
MBC values.  Compounds with a zone of inhibition between 8-35 mm were selected (Table 5-2). 
 
Compounds A6a, A6m and A6n with alanine, threonine and serine side chains showed a broad 
spectrum of antimicrobial activity with MBCs of between 0.31 to 1.42 mM for both 
Staphylococcus species and MBCs of 0.25 to 5.68 mM against the Gram -ve strains and 0.63 to 
2.84 for C. albicans.  The activity of A6m and A6n could possibly be due to the hydroxy groups 
in the side chain.  The fact that A6a is more active than A6d-f may be due to the branched chains 
hindering interaction between the molecule and the active sites of the enzymes in the bacteria. 
 
Compound A6b with a tyrosine side chain showed strain specific activity to S. aureus, MRSA and 
E. coli with IC50 values of 0.38, 1.00 and 0.38 mM, better than the standard ampicillin.  The other 
compounds with aromatic side chains, A6g (phenylalanine side chain) and A6h (tryptophan 
residue) also showed strain specific activity, A6g being active against E. coli and P. aeruginosa 
with IC50 values of 0.08 and 0.17 mM respectively and A6h being active in all strains except 
MRSA with the best activity being against K. pneumoniae (0.18 mM) and E. coli (0.35 mM). 
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Table 5-1  Side chains of compounds A6a-n 





























**Proline and quinoxaline conjugated together 
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Table 5-2  Minimum Bactericidal Concentration (MBC in mM) of compounds A6a-n 
 
No. 
Gram +ve Gram -ve Fungi 






A6a 1.42 0.71 5.68 5.68 4.26 2.84 
A6b 0.38 1.00 0.38 - 4.01 1.00 
A6c - - - - - - 
A6d 2.89 2.89 0.27 0.72 - 5.78 
A6e - 1.89 2.52 0.24 5.04 - 
A6f 0.60 - 0.34 - 0.15 0.15 
A6g - - 0.08 0.17 - - 
A6h 0.70 - 0.35 1.87 0.18 1.87 
A6i - - - - - - 
A6j - - 0.21 1.12 0.42 - 
A6k - - - - - - 
A6l - - - - - - 
A6m 0.47 0.31 1.25 0.39 0.31 0.63 
A6n 0.41 0.37 0.66 0.25 0.25 0.99 
ampicilin 0.06 1.79 0.89 3.58 0.89 0.89 
ciprofloxacin 0.002 0.007 0.002 0.002 0.004 0.002 
tioconazole - - - - - 25.79 
DMSO - - - - - - 
Highlighted values indicate the best results 
 
Amongst the compounds with branched alkyl side chains (A6d-f), A6d with a leucine side chain 
showed good activity with IC50 values of 0.27 and 0.72 mM against E. coli and P. aeruginosa, A6e 
was active against P. aeruginosa at 0.24 mM and A6f was active against four of the test strains, 
including the fungal strain, with IC50 values of 0.60 and 0.34 mM against S. aureus and E. coli and 
0.15 mM each against both Klebsiella pneumonia and C. albicans.  Compound A6j a methionine 
side chain was active against E. coli, P. aeruginosa and K. pneumonia with IC50 values of 0.21, 
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1.12 and 0.42 mM respectively.  The compounds with the best antifungal activity against C. 
albicans was A6f and A6m with IC50 values of 0.15 and 0.63 mM respectively.   
Compounds A6c, A6i, A6k and A6l with an esterified aspartic acid side chain, a histidine side 
chain, proline side chain and esterified glutamic acid side chain all showed no activity against all 
of the test strains. 
 
5.3.3 Antioxidant Activity 
Antioxidant properties of the synthesized compounds were tested by the DPPH radical scavenging 
activity, which determines the effectiveness of the compounds in scavenging free radicals.  These 
results are presented in Table 5-3.  The antioxidant activity was dependent on the side chain 
attached at C-2.  Compounds A6a, A6d-e, A6h and A6j showed good scavenging activity, with 
IC50 values of 0.20 mM or less in comparison to ascorbic acid (IC50 of 0.10 mM).  Compounds 
A6d and A6h showed the best activity with IC50 values of 0.15 mM each.  Of the active 
compounds, three of these, A6a, A6d and A6e contained aliphatic side chains with one or more 
methyl groups.  The aliphatic side chain of A6j also contained an aliphatic side chain, but with a 













A6a 0.20±0.02bc A6h 0.15±0.01bc 
A6b 0.32±0.02ef A6i 0.40±0.01fg 
A6c 0.30±0.02de A6j 0.18±0.01bc 
A6d 0.15±0.01b A6k 0.50±0.01g 
A6e 0.19±0.02bc A6l 0.30±0.02e 
A6f 0.25±0.03cd A6m 0.24±0.07bc 
A6g 0.38±0.04fg A6n 0.36±0.01e 
Ascorbic acid 0.10±0.02a 
Data are presented as mean ± SD values of triplicate determinations. 
a-d Different letters stand for significantly different values from each other within a column (Tukey’s-HSD multiple 
range post hoc test, p < 0.05);  the same letters stand for non-significant difference.  Highlighted values indicate the 
best results. 
 
5.3.4 Anti-diabetic activity 
In order to investigate the in vitro anti-diabetic activity of the synthesized amino acid tethered 
quinoxalines, two enzymes, α-glucosidase and α-amylase were used.  The results are summarized 
in Table 5-4.  In comparison to acarbose (IC50 of 0.88 mM), A6a, A6d and A6f showed better α-
glucosidase inhibitory activity with IC50 values of 0.056, 0.012 and 0.042 mM respectively.  These 
compounds contained amino acid residues with aliphatic side chains with at least one or two 
methyl groups.  The test compounds were however not as active against the α-amylase enzyme 




Table 5-4  In vitro α-Glucosidase and α-amylase activity of A6a-n (IC50 in mM)  
No α-Glucosidase α-amylase No α-Glucosidase α-amylase 
A6a 0.056±0.002ab 3.564±0.192a A6h 0.114±0.030abc 5.714±2.795a 
A6b 0.332±0.019de 8.558±0.598a A6i 0.415±0.004e 8.959±2.70a 
A6c 0.231±0.024c 33.054±0.101ab A6j 0.159±0.076bc 5.165±0.216a 
A6d 0.012±0.0a 1.414±0.241a A6k 0.482±0.021e 8.026±0.126a 
A6e 0.168±0.016bc 11.417±0.407a A6l 0.203±0.043c 102.295±0.81b 
A6f 0.042±0.021ab 8.729±2.252a A6m 0.190±0.056c 2.206±0.038a 
A6g 0.353±0.031de 2.839±0.824a A6n 0.297±0.008cd 4.644±0.599a 
Ac* 0.088±0.005c 0.104 ±0.028a Ac* 0.088±0.005c 0.104 ±0.028a 
Data are presented as mean ± SD values of triplicate determinations. 
a-d Different letters stand for significantly different values from each other within a column (Tukey’s-HSD multiple 
range post hoc test, p < 0.05);  the same letters stand for non-significant difference. 
Ac* = acarbose standard.  Highlighted values indicate the best results. 
 
5.3.5 Molecular docking  
The inhibition of bacterial type II topoisomerases (topoisomerase IV and DNA-gyrase) is one of 
the mechanisms associated with anti-bacterial action of several drugs including ciprofloxacin, 
enoxacin, and lomefloxacin (Mitscher et al., 2005).  In order to examine the binding modes of the 
synthesized molecules with topoisomerase and DNA-gyrase, compounds A6g and A6n (chosen as 
representative compounds (RCs)), were flexibly docked into the binding cavity of bacterial 
topoisomerase II DNA-gyrase (PDB id: 2XCT) using the CDOCKER module in discovery studio 
(DS) (Wu et al., 2003).  The docking efficiency of the docking protocol was first assessed by re-
docking ciprofloxacin (co-crystallized ligand) into the active site of the bacterial protein. Overlay 
of the sampled conformation of ciprofloxacin and its X-ray structure (Figure 5-2) showed the root 
mean square deviation (RMSD, all atoms) to be <1Å.  This demonstrated the accuracy and good 
predictive efficiency of the docking protocol.  
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The scoring function, -CDOCKER energy (CDE) that includes the receptor interaction energy and 
internal ligand strain energy was computed to assess the binding affinity of ligands with the 
receptor.  A more negative CDE indicates stronger interaction for the receptor.  The CDE of A6g 
was found to be -20.1 kcal mol-1 and A6n -18.5 kcal mol-1, which was not as strong as the standard 
ciprofloxacin which had a CDE of -28.6 kcal mol-1.  Figure 5-3 and Figure 5-4  contain the 
complexes of A6g, A6n and ciprofloxacin with the bacterial protein, which were visualized (using 
DS) to get a deeper understanding of their binding modes and interacting forces.  
 
Generally, hydrogen bonding was found to be essential in locking the conformation of the 
compounds in the binding site of the protein.  Compound A6g, for instance, formed two concurrent 
hydrogen bonds (conventional) with Asp437 (proton acceptor) through its piperazinyl nitrogen 
(proton donor) and another single hydrogen bond with the same amino acid (proton donor) through 
its ester carbonyl (proton acceptor) moiety in addition to three non-conventional hydrogen bonds 
with Glu435 and Gly436 (Figure 5-3).  Compound A6n also displayed prominent hydrogen 
bonding (Figure 5-4) with Ser1084, Arg458, Glu477 and Lys460 amino acids.  Typically, the 
conformation of A6g was more folded in comparison to A6n, and supported its greater interaction 
with the binding cavity of the bacterial protein, as evidenced by its lower CDE (-20.1 kcal mol-1).  
Both compounds, however, missed interaction with Mg2+. Ciprofloxacin (Figure 5-4), on the other 
hand, exhibited two co-ordinate bonds (2.6 and 2.8 Å) with the Mg2+ by its two oxygen atoms, in 
addition to its engagement with Glu477, Lys460 and Arg458 amino acid residues of the protein 
through hydrogen bonding.  Enhanced antibacterial activity of ciprofloxacin, compared to A6g 
and A6n, could be attributed to this additional interaction with the Mg2+ metal which led to its 
tighter binding with the bacterial protein.  
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Since, the synthesized compounds exhibited good potency against α-glucosidase, it was thought 
worthwhile to support their activity profiles by illuminating their binding characteristics into the 
active site of the protein.  However, the 3D structure for α-glucosidase obtained from S. cerevisiae 
used in our study was not available in the protein database.  Literature survey, nonetheless, 
indicated the utilization of its homology models in several publications (Khan et al., 2014; Lee et 
al., 2014; Huang et al., 2015).  Since, these modelled structures are not available publicly, we built 
the 3D structure of α-glucosidase by homology modelling method using the Discovery Studio 
program.    
 
The amino acid sequence for S. cerevisiae α-glucosidase (access code P53341) was downloaded 
from UniProt protein data bank (http://www.uniprot.org/). Different protein templates were 
subsequently identified using BLAST, a program which searches against a query sequence 
database constructed from proteins deposited in PDB repository.  The crystal structure of S. 
cerevisiae from isomaltase (pdb id: 3AJ7) was found to be the best match based on its high 
sequence identity (71.4%) and sequence similarity (86.9%) with the query sequence, and selected 
as a template for homology modelling. 3D structure was generated using MODELER algorithm 
(Eswar et al., 2006) in DS considering default parameters, and verified using Verify Protein 
(Profiles-3D) module.  Finally, the generated model was energetically minimized up to 0.1 RMS 
gradient in DS.   
 
Two most active compounds, A6d (IC50 = 0.012±0.0 mM) and A6f (0.042±0.021mM) (Table 5-
4) were subsequently docked into the active site of modelled structure of the α-glucosidase.  The 
computed scoring function (CDE) suggested the favorable binding of both compounds for the 
137 
protein with the most active compound (A6d) showing comparatively the stronger interaction 
(CDE = -38.0 kcal mol-1) in comparison to A6f (BE = -29.1 kcal mol-1).  Compound A6d 
established a conventional hydrogen bond (2.74Å) with His 280 through its NH (piperazine 
moiety), and three non-conventional hydrogen bonds with Glu 277 and His 240 residues of α-
glucosidase (Figure 5-5).  Additionally, hydrophobic (alkyl and π-alkyl types) interactions 
between A6d and the active site residues (Phe 178, His 240 and Arg 315) of protein were also 
observed.  Compound A6f, on the other hand, displayed predominantly hydrophobic interactions 
with the active site residues e.g., Arg 442, Arg315, Phe 158 and Phe 303, in addition to a non-
conventional hydrogen bond with Asp 411 residues (Figure 5-5).  The presence of strong hydrogen 
bonding network in A6d probably accounts for its stronger binding affinity (lower CDE) for the 
protein and supports its higher anti-diabetic action observed under experimental conditions. 
 
Figure 5-2  Superimposition of the conformation (from docking) of ciprofloxacin (in red sticks) 




Figure 5-3  Docked conformation (in blue sticks) of A6g in the binding cavity of the bacterial 
protein (shown as red lines).  Green dotted lines represent conventional H-bonds whereas red 
dotted lines depict non-conventional H-bonds 
 
5.4 Conclusion 
Compounds A6a, A6m and A6n showed broad spectrum antibacterial activity with several other 
compounds also showing very good strain specific activity to at least one of the bacterial strains 
tested against.  Five of the synthesized compounds A6a, A6d-e, A6h and A6j demonstrated 
antioxidant activity with IC50 values of 0.20 mM or less (good in comparison to ascorbic acid with 
an IC50 of 0.10 mM).  Compounds A6a, A6d and A6f showed better α-glucosidase inhibitory 
activity (IC50 values of 0.056, 0.012 and 0.042 mM respectively) in comparison to acarbose (IC50 
of 0.88 mM).  Docking simulations of A6g and A6n with the bacterial topoisomerase II enzyme 
indicated the significance of Mg2+ interaction in the stability of complexes.  The inability to interact 
with Mg2+ decreased the stability of the RCs, A6g (BE = -20.1 kcal mol-1) and A6n (BE = -18.5 
kcal mol-1) relative the standard ciprofloxacin (BE = -28.6 kcal mol-1), and probably accounts for 
their lower anti-bacterial activity.  The docking of two most active anti-diabetic compounds (A6d, 
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A6f) in the binding site of modelled S. cerevisiae α-glucosidase revealed the predominance of 
hydrophobic and hydrogen bonding interactions in their host-guest relationship. Of all the 
synthesized compounds, A6a was active in all three assays (antibacterial, anti-oxidant and anti-
diabetic) and may be a good pharmaceutical lead compound. 
 
Figure 5-4  Docked conformation (in blue sticks) of A6n (A) and ciprofloxacin (B) in the 
binding cavity of the bacterial protein (shown as red lines).  A green dotted line represents 
conventional H-bonds, red dotted lines non-conventional H-bonds and golden dotted lines 
represent the co-ordinate bonds 
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Figure 5-5  Docked conformation (in blue sticks) of A6d (A) and A6f (B) in the binding cavity 
of the α-glucosidase (red lines).  Conventional H-bonds are shown as green dotted lines, non-
conventional H-bonds (red dotted lines) and hydrophobic forces (blue dotted lines) 
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Chapter 6. Synthesis, in vitro antimicrobial, antioxidant and antidiabetic 
activities of amino acid linked thiazolidine-quinoxaline derivatives 
 
* The compounds referred to in the chapter are referred to elsewhere in the thesis with an B preceding the number of 
the compound.  For example 5a-c and 6a-l is referred to as B5a-c and B6a-l elsewhere in the thesis. 
 
Abstract 
A novel protocol for the rapid assembly of a hybrid framework based on amino acid, thiazolidine 
and quinoxaline scaffolds has been demonstrated by microwave irradiation.  The amino acid 
quinoxalines B5a-B5c were prepared in three steps from 2,4-dinitrofluorobenzene and the amino 
acids, valine, methionine and tyrosine and subsequently reacted with four different aldehydes and 
thioglycolic acid to produce thiazolidine-quinoxaline-amino acid hybrids B6a-B6l.  All 
synthesized compounds were evaluated for their in vitro antimicrobial, antioxidant and antidiabetic 
activities.  Compounds B6f, B6j and B6k showed broad spectrum antimicrobial activity against 
Gram +ve and Gram –ve bacteria, whilst B6h, B6k and B6l showed the best antioxidant activity 
in the same order of magnitude to that of ascorbic acid.  Four of the compounds, B5c, B6d, B6g 
and B6k showed activity against α-glucosidase and α-amylase similar to acarbose.  Those 
compounds showing antibacterial activity possessed 4-fluorophenyl and 4-methoxyphenyl groups 
along with methionine and tyrosine residues while the compounds showing antioxidant, α-
glucosidase and α-amylase activity contained 4-nitrophenyl and 4-methoxyphenyl groups on the 
thiazolidine moiety with mainly methionine and tyrosine amino acid residues.  The α-glucosidase 
and α-amylase inhibitory compound B5c did not have a thiazolidine moiety and B6d was the only 
active compound with a valine amino acid moiety.  Compound B6k with a tyrosine amino acid 
residue and a 4-methoxyphenylthiazolidine moiety on the quinoxaline scaffold showed good 
bioactivity in all three assays.  
 
Keywords: Microwave irradiation, thermal, antimicrobial, antioxidant, antidiabetic, α-




Thiazolidinones consists of a heterocyclic 5-membered ring containing a thioether 
and amide group.  This moiety is found in many highly active natural products (Riego et al., 2005; 
Davyt et al., 2010; Sahoo et al., 2015; Zhang et al., 2015).  Thiazolidine derivatives have been 
studied extensively and found to have diverse chemical reactivities (Teresa et al., 2006; Bayuelo 
et al., 2012; Fernanda et al., 2013; Lobana et al., 2015) and a broad-spectrum of biological 
activities, such as anti-microbial, antidiabetic, anti-obesity, anti-inflammatory, antioxidant, anti-
proliferative, antitumor, anti-HIV, anticancer and anti-tubercular (Siddiqui et al., 2009; Malik et 
al., 2011; Vinay et al., 2011; Singh et al., 2011; Singh et al., 2011; Geronikaki et al., 2013). 
 
Quinoxaline is commonly called 1,4-diazanaphthalene or benzopyrazine.  Quinoxaline and its 
derivatives are mostly of synthetic origin (Baumann et al., 2013; Srivastava et al., 2014; Padvi et 
al., 2015).  They have been described as a part of a bicyclic desipeptide antibiotic having activity 
against Gram +ve bacteria and certain tumours by inhibiting RNA synthesis (Waring et al., 1979; 
Eike et al., 2011; Noorulla et al., 2011; Noolvi et al., 2011; Kotra et al., 2013; Mishra et al., 2013; 
Al-Marhabi et al., 2015).  The quinoxaline moiety can be found in a number of antibiotics such as 
echinomycin, levomycin and actinomycin (Katagiri et al., 1975; Patidar et al., 2011; Pai et al., 
2011; Dhanaraj et al., 2015).   
 
Simple α-amino acids have been known to be converted into complex arrays of heteroaromatic 
rings with interesting and potent biological activities (Suhas et al., 2011; Sharma et al., 2013; 
Hashash et al., 2013; Sharma et al., 2015).  Amino acid coupled to other heterocyclic scaffolds 
(benzo-phenoxazine, indole), or amides of amino acids and metal complexes increased the 
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bioactivity of the molecular scaffolds themselves (Yang et al., 1998; Aiyelabola et al., 2012; 
Saxena et al., 2014; Mickevičienė et al., 2015).  Thus far, there have been two reports on the 
synthesis of quinoxalines using amino acids (Holley et al., 1952; Tung et al., 2004).  Amino acids 
attached to quinoxaline derivatives which have shown antimicrobial, and glutamate receptor 
activity have also been described (Faham et al., 2002; Demmer et al., 2015; Mickevičienė et al., 
2015).  In addition, there have been reports of thiazolidine containing quinoxalines, which showed 
good antibacterial and antitubercular activity (Pawar et al., 2007, 2008; Puratchikody et al., 2011). 
 
We herein report an efficient microwave-assisted synthesis of amino acid linked thiazolidine-
quinoxaline compounds and tested them in antimicrobial, antioxidant and antidiabetic assays.  
 
6.2 Experimental  
6.2.1 Materials and methods 
All chemicals were supplied by Sigma-Aldrich via Capital Lab, South Africa.  All organic solvents 
were redistilled and dried according to standard procedures.  Silica gel 60 F254 plates (Merck) were 
used for thin layer chromatography.  Products were purified by column chromatography using 
silica gel (60-120 mesh) with ethyl acetate : hexane as the eluent.  Melting points were recorded 
using a Stuart Scientific SMP3 apparatus.  UV spectra were obtained on a Varian Cary UV-VIS 
spectrophotometer using MeOH as a solvent.  IR spectra were recorded on a Perkin Elmer 100 FT-
IR spectrophotometer with universal attenuated total reflectance sampling accessory.  Microwave 
reactions were performed using a CEM Discover, Explorer-12 Hybrid microwave instrument.  1H, 
13C NMR and all 2D NMR spectra were recorded on a Bruker Avance instrument operating at 400 
MHz.  Chemical shifts were reported as δ values (ppm) relative to an internal standard of 
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tetramethylsilane (TMS) or to the solvent line of DMSO-d6 (δH = 2.50, δC = 39.52).  High-
resolution mass data were obtained using a Bruker micro TOF-Q II ESI instrument operating at 
ambient temperature. 
 
General procedure for the preparation of amino acid methyl ester hydrochloride (B2) 
Methanol (20 mL) was added to different amino acids (B1a-c) (0.1 mol) followed by gradual 
addition of thionyl chloride (0.3 mol) at room temperature.  The resulting solution was stirred at 
70 °C for 4h and the reaction mixture concentrated on a rotary evaporator producing the respective 
amino acid ester hydrochlorides in yields of > 90 %. 
 
The general scheme for the reaction sequence is shown in Scheme 6-1 below. 
 
 
Scheme 6-1  Synthesis of amino acid linked thiazolidine-quinoxaline compounds 
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General procedure for the preparation of compounds (B4a-c) 
1-Fluoro-2,4-dinitrobenzene B3 (0.50 g, 2.34 mmol), amino acid ester (3.51 mmol) and NaHCO3 
(0.005 g, 4.68 mmol) were mixed in THF (10 mL).  The reaction mixture was stirred overnight at 
room temperature.  After completion of the reaction (monitored by TLC), the reaction mixture was 
washed with water (2 × 10 mL), followed by 10% Na2CO3 solution (10 mL).  The organic layer 
was separated from the aqueous layer by adding a small amount of ethyl acetate to distinguish the 
THF and aqueous layers.  The organic layer was then dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to afford B4a-c, which was subsequently purified by column 
chromatography (hexane/ethyl acetate) to afford the desired product in good yields (80-90%). 
 
General procedure for the preparation of compounds (B5a-c)  
The 2,4-dinitrophenyl amino acid compounds B4a-c (1 mmol) was added to methanol (10 mL), to 
which 10% Pd/C (50 mg) was added.  The reaction mixture was stirred for 4h at room temperature 
under H2 atmosphere.  The reaction mixture was then filtered through Celite 545 to remove the 
catalyst.  The filtrate was evaporated under reduced pressure and the obtained solid was purified 
by column chromatography (hexane/ethyl acetate) to afford the desired product in good yield (80-
85%).   
 
General procedure for the preparation of amino acid linked thiazolidine-quinoxaline 
derivatives (B6a-l) 
A mixture of 3-substituted-7-amino quinoxalin-2(1H)-one (B5a-c) (1.0 mmol), the appropriate 
substituted benzaldehyde (1.5 mmol) and thioglycolic acid (5.0 mmol) was placed in a 10 mL 
reaction vial containing absolute ethanol (3 mL) and a stirring bar.  The vial was sealed tightly 
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with a Teflon septum, placed into the microwave cavity and irradiated at 100 ºC using 100 W as 
the maximum power for 10-45 min.  Upon completion, the reaction mixture was rapidly cooled by 
gas jet cooling to ambient temperature, the contents dissolved in ethyl acetate and washed with 5% 
aqueous citric acid (2 × 5 mL), water and aqueous sodium hydrogen carbonate (2 × 5 mL).  The 
organic layer was then separated and dried over sodium sulphate, evaporated under reduced 
pressure and the solid obtained purified by column chromatography (hexane/ethyl acetate) to 
afford the desired product in good yield (80-90%).   
 
(B5a) 7-Amino-3-isopropylquinoxalin-2(1H)-one, dark brown solid; mp 238-240 ºC; UV λmax 
(MeOH) nm (log ε) 222 (3.40), 282 (2.40), 364 (3.02); IR υmax 3460 (NH2), 3331 (NH), 1650, 1622 
(C=O) cm-1; 1H NMR (400 MHz, DMSO) δH 11.87 (s, 1H, H-1), 7.33 (d, J = 8.0 Hz, 1H, H-5), 
6.51 (dd, J = 8.0, 2.2 Hz, 1H, H-6), 6.32 (d, J = 2.2 Hz, 1H, H-8), 5.80 (s, 2H, H-11), 3.28-3.39 
(m, 1H, H-1a), 1.15 (d, J = 6.8 Hz, 6H, H-2a/H-3a); 13C NMR (400 MHz, DMSO) δC 157.4 (C, C-
3), 154.9 (C, C-2), 150.3 (C, C-7), 133.6 (C, C-9), 129.1 (CH, C-5), 124.0 (C, C-10), 111.5 (CH, 
C-6), 95.9 (CH, C-8), 29.3 (CH, C-1a), 20.3 (2CH3, C-2a/3a); HRMS (m/z): calc. for C11H13N3ONa 
(M + Na)+: 226.0956, found: 226.0956. 
 
(B5b) 7-amino-3-(2-(methylthio)ethyl)quinoxalin-2(1H)-one, brown solid; mp 178-180 ºC; UV 
λmax (MeOH) nm (log ε) 230 (3.14), 283 (2.97), 390 (3.02); IR υmax 3337 (NH), 2809 (C-H), 1671, 
1637 (C=O), 1521 cm-1; 1H NMR (400 MHz, DMSO) δH 12.01 (s, 1H, H-1), 7.34 (d, J = 8.5 Hz, 
1H, H-5), 6.53 (d, J = 8.5 Hz, 1H, H-6), 6.33 (bs, 1H, H-8), 5.89 (s, 2H, H-11), 3.14-3.20 (m, 2H, 
H-2a), 2.97-3.05 (m, 2H, H-1a), 2.58 (s, 3H, H-4a); 13C NMR (400 MHz, DMSO) δC 155.2 (C, C-
3), 150.7 (C, C-2), 150.7 (C, C-7), 133.9 (C, C-10), 129.0 (CH, C-5), 124.0 (C, C-9), 111.7 (CH, 
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C-6), 95.9 (CH, C-8), 49.9 (CH2, C-2a), 38.0 (CH3, C-4a), 25.2 (CH2, C-1a); HRMS (m/z): calc. 
for C11H12N3OS (M + H)+: 234.0701, found: 234.0708. 
 
(B5c) 3-(4-hydroxybenzyl)-7-aminoquinoxalin-2(1H)-one, light yellow solid; mp 164-166 ºC; 
UV λmax (MeOH) nm (log ε) 224 (3.51), 249 (3.0), 279 (2.78), 371 (3.15); IR υmax 3461 (NH2), 
3332 (NH), 1651, 1622 (C=O) cm-1; 1H NMR (400 MHz, DMSO) δH 11.91 (s, 1H, H-1), 9.17 (s, 
1H, H-8a), 7.33 (d, J = 8.6 Hz, 1H, H-5), 7.08 (d, J = 8.2 Hz, 2H, H-3a/7a), 6.65 (d, J = 8.2 Hz, 
2H, H-4a/6a), 6.51 (dd, J = 8.6, 1.6 Hz, 1H, H-6), 6.31 (d, J = 1.6 Hz, 1H, H-8), 5.84 (s, 2H, H-
11), 3.85 (s, 2H, H-1a); 13C NMR (400 MHz, DMSO) δC 155.7 (C, C-3), 155.3 (C, C-5a), 152.6 
(C, C-2), 150.6 (C, C-7), 133.9 (C, C-9), 129.8 (2CH, C-3a/7a), 129.1 (CH, C-5), 128.6 (C, C-10), 
124.2 (C, C-2a), 115.0 (2CH, C-4a/6a), 111.6 (CH, C-6), 95.9 (CH, C-8), 37.6 (CH2, C-1a); HRMS 
(m/z): calc. for C15H13N3O2Na (M + Na)+: 290.0905, found: 290.0910. 
 
(B6a) 3-isopropyl-7-(4-oxo-2-phenylthiazolidin-3-yl)quinoxalin-2(1H)-one, white solid; mp 
280-282 ºC; UV λmax (MeOH) nm (log ε) 231 (3.13), 287 (2.59), 341 (2.81); IR υmax 3151 (NH), 
1683 (C=O), 1652, 1616 cm-1; 1H NMR (400 MHz, DMSO) δH 12.27 (s, 1H, H-1), 7.60 (d, J = 8.8 
Hz, 1H, H-5), 7.38 (dd, J = 7.7,  Hz, 2H, H-2c/6c), 7.31 (d, J = 2.2 Hz, 1H, H-8), 7.26 (dd, J = 7.7, 
7.7 Hz, 2H, H-3c/5c), 7.22 (dd, J = 7.7, 2.2 Hz, 1H, H-4c), 7.20 (dd, J = 8.8, 2.2 Hz, 1H, H-6), 
6.58 (s, 1H, H-5b), 4.06 (d, J = 15.9 Hz, 1H, H-3bi), 3.92 (d, J = 15.9 Hz, 1H, H-3bii), 3.39 (sep, 
J = 6.9 Hz, 1H, H-1a), 1.16 (d, J = 6.9 Hz, 3H, H-2a), 1.15 (d, J = 6.9 Hz, 3H, H-3a); 13C NMR 
(400 MHz, DMSO) δC 170.8 (C, C-2b), 165.5 (C, C-3), 154.1 (C, C-2), 139.7 (C, C-1c), 138.1 (C, 
C-7), 131.7 (C, C-9*), 129.4 (C, C-10*), 128.7 (2CH, C-3c/5c), 128.6 (CH, C-4c), 128.3 (CH, C-
5), 126.9 (2CH, C-2c/6c), 119.3 (CH, C-8), 111.3 (CH, C-6), 63.3 (CH, C-5b), 32.8 (CH2, C-3b), 
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29.8 (CH, C-1a), 19.99 (CH3, C-2a), 19.97 (CH3, C-3a); HRMS (m/z): calc. for C20H19N3O2SNa 
(M + Na)+: 388.1096, found: 388.1096.  *indicates that assignments are interchangeable. 
 
(B6b) 7-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)-3-isopropylquinoxalin-2(1H)-one, white 
solid; mp 252-254 ºC; UV λmax (MeOH) nm (log ε) 230 (3.29), 287 (2.72), 340 (2.95); IR υmax 
3178 (NH), 1657 (C=O), 1615, 1510 cm-1; 1H NMR (400 MHz, DMSO) δH 12.27 (s, 1H, H-1), 
7.61 (d, J = 8.7 Hz, 1H, H-5), 7.45 (dd, J = 8.7, 5.4, Hz, 2H, H-2c/6c), 7.27 (d, J = 2.2 Hz, 1H, H-
8), 7.19 (dd, J = 8.7, 2.2 Hz, 1H, H-6), 7.12 (t, J = 8.8 Hz, 2H, H-3c/5c), 6.59 (s, 1H, H-5b), 4.06 
(d, J = 15.8 Hz, 1H, H-3bi), 3.92 (d, J = 15.8 Hz, 1H, H-3bii), 3.42 (septet, J = 6.8 Hz, 1H, H-1a), 
1.16 (d, J = 6.8 Hz, 3H, H-2a), 1.15 (d, J = 6.8 Hz, 3H, H-3a); 13C NMR (400 MHz, DMSO) δC 
170.7 (C, C-2b), 165.6 (C, C-3), 161.9 (d, JC-F = 243.9 Hz, C, C-4c), 154.1 (C, C-2), 137.9 (C, C-
7), 135.9 (d, J = 2.8 Hz, C, C-1c), 131.7 (C, C-9*), 129.5 (C, C-10*), 129.3 (d, J = 8.6 Hz, 2CH, 
C-2c/6c), 128.4 (CH, C-5), 119.4 (CH, C-6), 115.6 (d, J = 21.7 Hz, 2CH, C-3c/5c), 111.5 (CH, C-
8), 62.6 (CH, C-5b), 32.8 (CH2, C-3b), 29.8 (CH, C-1a), 19.99 (CH3, C-2a*), 19.96 (CH3, C-3a*); 
HRMS (m/z): calc. for C20H18N3O2SFNa (M + Na)+: 406.1001, found: 406.0999.  *indicates that 
assignments are interchangeable. 
 
(B6c) 3-isopropyl-7-(2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)quinoxalin-2(1H)-one, 
brown solid; mp 268-270 ºC; UV λmax (MeOH) nm (log ε) 230 (3.67), 284 (3.03), 341 (3.22); IR 
υmax 3144 (NH), 1682 (C=O), 1657, 1609 cm-1; 1H NMR (400 MHz, DMSO) δH 12.26 (s, 1H, H-
1), 7.59 (d, J = 8.6 Hz, 1H, H-5), 7.31 (d, J = 8.8 Hz, 2H, H-2c/6c), 7.26 (d, J = 2.2 Hz, 1H, H-8), 
7.18 (dd, J = 8.6, 2.2 Hz, 1H, H-6), 6.82 (d, J = 8.8 Hz, 2H, H-3c/5c), 6.52 (s, 1H, H-5b), 4.03 (d, 
J = 15.7 Hz, 1H, H-3bi), 3.91 (d, J = 15.7 Hz, 1H, H-3bii), 3.67 (s, 3H, H-8c), 3.38 (septet, J = 6.8 
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Hz, 1H, H-1a), 1.16 (d, J = 6.8 Hz, 3H, H-2a), 1.15 (d, J = 6.8 Hz, 3H, H-3a); 13C NMR (400 MHz, 
DMSO) δC 171.1 (C, C-2b), 165.9 (C, C-3), 159.5 (C, C-4c), 154.3 (C, C-2), 138.4 (C, C-7), 131.8 
(C, C-1c), 131.2 (C, C-9*), 129.7 (C, C-10*), 129.1 (2CH, C-2c/6c), 128.5 (CH, C-5), 120.2 (CH, 
C-6), 114.3 (2CH, C-3c/5c), 111.9 (CH, C-8), 63.5 (CH, C-5b), 55.3 (CH3, C-8c), 33.2 (CH2, C-
3b), 30.1 (CH, C-1a), 20.2 (2CH3, C-2a/3a); HRMS (m/z): calc. for C21H21N3O3SNa (M + Na)+: 
418.1201, found: 418.1213.  *indicates that assignments are interchangeable. 
 
(B6d) 3-isopropyl-7-(2-(4-nitrophenyl)-4-oxothiazolidin-3-yl)quinoxalin-2(1H)-one, light 
yellow solid; mp 274-276 ºC; UV λmax (MeOH) nm (log ε) 229 (3.48), 341 (3.12); IR υmax 3088 
(NH), 1694, 1664 (C=O), 1624 cm-1; 1H NMR (400 MHz, DMSO) δH 12.28 (s, 1H, H-1), 8.15 (d, 
J = 8.7 Hz, 2H, H-3c/5c), 7.70 (d, J = 8.7 Hz, 2H, H-2c/6c), 7.62 (d, J = 8.8 Hz, 1H, H-5), 7.32 (d, 
J = 2.2 Hz, 1H, H-8), 7.24 (dd, J = 8.8, 2.2 Hz, 1H, H-6), 6.75 (s, 1H, H-5b), 4.13 (d, J = 15.8 Hz, 
1H, H-3bi), 3.96 (d, J = 15.8 Hz, 1H, H-3bii), 3.39 (septet, J = 6.8 Hz, 1H, H-1a), 1.16 (d, J = 6.8 
Hz, 3H, H-2a), 1.15 (d, J = 6.8 Hz, 3H, H-3a); 13C NMR (400 MHz, DMSO) δC 170.7 (C, C-2b), 
165.7 (C, C-3), 154.0 (C, C-2), 147.5 (C, C-4c), 147.4 (C, C-1c), 137.8 (C, C-7), 131.8 (C, C-9*), 
129.5 (C, C-10*), 128.5 (CH, C-5), 128.1 (2CH, C-2c/6c), 124.1 (2CH, C-3c/5c), 118.9 (CH, C-
6), 110.9 (CH, C-8), 62.1 (CH, C-5b), 32.7 (CH2, C-3b), 29.8 (CH, C-1a), 19.98 (CH3, C-2a), 
19.95 (CH3, C-3a); HRMS (m/z): calc. for C20H17N4O4S (M - H)-: 409.0971, found: 409.0966.  
*indicates that assignments are interchangeable. 
 
(B6e) 3-(2-(methylthio)ethyl)-7-(4-oxo-2-phenylthiazolidin-3-yl)quinoxalin-2(1H)-one, 
brown solid; mp 258-260 ºC; UV λmax (MeOH) nm (log ε) 230 (3.34), 294 (2.74), 344 (2.98); IR 
υmax 3173 (NH), 1678 (C=O), 1654, 1618 cm-1; 1H NMR (400 MHz, DMSO) δH 12.32 (s, 1H, H-
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1), 7.61 (d, J = 8.7 Hz, 1H, H-5), 7.38 (d, 1H, J = 7.3 Hz, H-2c/6c), 7.33 (d, 1H, J = 2.2 Hz, H-8), 
7.29 (t, J = 7.3 Hz, 2H, H-3c/5c), 7.23 (t, J = 7.3 Hz, 2H, H-4c), 7.21 (dd, J = 8.7, 2.2 Hz, H-6), 
6.58 (s, 1H, H-5b), 4.06 (d, J = 15.9 Hz, 1H, H-3bi), 3.92 (d, J = 15.9 Hz, 1H, H-3bii), 3.01 (t, J = 
7.7 Hz, 2H, H-2a), 2.82 (t, J = 7.7 Hz, 2H, H-1a), 2.07 (s, 3H, H-4a); 13C NMR (400 MHz, DMSO) 
δC 170.8 (C, C-2b), 160.1 (C, C-3), 154.5 (C, C-2), 139.7 (C, C-1c), 138.3 (C, C-7), 131.9 (C, C-
9*), 129.4 (C, C-10*), 128.7 (2C, C, C-3c/5c), 128.6 (CH, C-5), 128.3 (CH, C-4c), 126.9 (CH, C-
2c/6c), 119.3 (CH, C-6), 111.3 (CH, C-8), 63.3 (CH, C-5b), 32.8 (CH2, C-3b), 32.6 (CH2, C-2a), 
29.9 (CH2, C-1a), 14.6 (CH3, C-4a); HRMS (m/z): calc. for C20H18N3O2S2  (M - H)+: 396.0840, 
found: 396.0856.  *indicates that assignments are interchangeable. 
 
(B6f) 7-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)-3-(2-(methylthio)ethyl)quinoxalin-2(1H)-
one, dark brown solid; mp 264-266 ºC; UV λmax (MeOH) nm (log ε) 231 (3.27), 293 (2.68), 343 
(2.92); IR υmax 3173 (NH), 1679 (C=O), 1655, 1618, 1604, 1508 cm-1; 1H NMR (400 MHz, 
DMSO) δH 12.33 (s, 1H, H-1), 7.62 (d, J = 8.7 Hz, 1H, H-5), 7.46 (dd, J = 8.8, 5.4 Hz, 2H, H-
2c/6c), 7.28 (d, J = 2.0 Hz, 1H, H-8), 7.20 (dd, J = 8.7,  2.0 Hz, 1H, H-6), 7.12 (dd, J = 8.8, 8.8 
Hz, 2H, H-3c/5c), 6.59 (s, 1H, H-5b), 4.07 (d, J = 15.7 Hz, 1H, H-3bi), 3.93 (d, J = 15.7 Hz, 1H, 
H-3bii), 3.01 (t, J = 7.0 Hz, 2H, H-2a), 2.83 (t, J = 7.6 Hz, 2H, H-1a), 2.07 (s, 3H, H-4a); 13C NMR 
(400 MHz, DMSO) δC 170.7 (C, C-2b), 161.9 (d, J = 243.7 Hz, C, C-4c), 160.2 (C, C-3), 154.5 
(C, C-2), 138.2 (C, C-7), 135.9 (d, J = 2.9 Hz, C, C-1c), 131.9 (C, C-9*), 129.5 (C, C-10*), 129.3 
(d, J = 8.4 Hz, 2CH, C-2c/6c), 128.3 (CH, C-5), 119.5 (CH, C-6), 115.7 (d, J = 21.2 Hz, 2CH, C-
3c/5c), 111.5 (CH, C-8), 62.6 (CH, C-5b), 32.8 (CH2, C-3b), 32.6 (CH2, C-2a), 29.9 (CH2, C-1a), 
14.6 (CH3, C-4a); HRMS (m/z): calc. for C20H18FN3O2S2Na (M + Na)+: 438.0722, found: 




2(1H)-one, yellow solid; mp 258-260 ºC; UV λmax (MeOH) nm (log ε) 230 (3.09), 279 (2.95), 389 
(3.06); IR υmax 3321 (NH), 1685 (C=O), 1616, 1525 cm-1; 1H NMR (400 MHz, DMSO) δH 12.36 
(s, 1H, H-1), 7.61 (d, J = 8.7 Hz, 1H, H-5), 7.32 (d, J = 8.6 Hz, 2H, H-2c/6c), 7.28 (d, J = 2.1, 1H, 
H-8), 7.21 (dd, J = 8.7, 2.1 Hz, 1H, H-6), 6.83 (d, J = 8.6 Hz, 2H, H-3c/5c), 6.53 (s, 1H, H-5b), 
4.03 (d, J = 15.9 Hz, 1H, H-3bi), 3.91 (d, J = 15.9 Hz, 1H, H-3bii), 3.67 (s, 3H, H-8c), 3.16-3.10 
(m, 2H, H-2a), 3.06-2.96 (m, 2H, H-1a), 2.57 (s, 3H, H-4a); 13C NMR (400 MHz, DMSO) δC 170.6 
(C, C-2b), 159.4 (C, C-4c), 159.2 (C, C-3), 154.4 (C, C-2), 138.4 (C, C-1c), 138.4 (C, C-7), 131.9 
(C, C-9*), 131.1 (C, C-10*), 128.7 (2CH, C-2c/6c), 128.2 (CH, C-5), 119.6 (CH, C-6), 113.9 
(2CH, C-3c/5c), 111.6 (CH, C-8), 63.1 (CH, C-5b), 55.0 (CH3, C-8c), 49.3 (CH2, C-3b), 37.9 (CH3, 
C-4a), 32.9 (CH2, C-2a), 25.5 (CH2, C-1a); HRMS (m/z): calc. for C21H22N3O3S2 (M-H)+: 
428.1103, found: 428.1084.  *indicates that assignments are interchangeable. 
 
(B6h) 3-(2-(methylthio)ethyl)-7-(2-(4-nitrophenyl)-4-oxothiazolidin-3-yl)quinoxalin-2(1H)-
one, reddish brown solid; mp 240-242 ºC; UV λmax (MeOH) nm (log ε) 233 (2.92), 344 (2.60); IR 
υmax 3175 (NH), 1681 (C=O), 1655, 1619, 1515 cm-1; 1H NMR (400 MHz, DMSO) δH 12.34 (s, 
1H, H-1), 8.16 (d, J = 8.7 Hz, 2H, H-3c/5c), 7.70 (d, J = 8.7 Hz, 2H, H-2c/6c), 7.63 (d, J = 8.8 Hz, 
1H, H-5), 7.34 (d, J = 2.2 Hz, 1H, H-8), 7.25 (dd, J = 8.8, 2.2 Hz, 1H, H-6), 6.76 (s, 1H, H-5b), 
4.13 (d, J = 15.9 Hz, 1H, H-3bi), 3.96 (d, J = 15.9 Hz, 1H, H-3bii), 3.01 (t, J = 7.6 Hz, 2H, H-2a), 
2.82 (t, J = 7.6 Hz, 2H, H-1a), 2.06 (s, 3H, H-4a); 13C NMR (400 MHz, DMSO) δC 170.8 (C, C-
2b), 160.3 (C, C-3), 154.5 (C, C-2), 147.5 (C, C-4c), 147.4 (C, C-1c), 137.9 (C, C-7), 132.0 (C, C-
9*), 129.5 (C, C-10*), 128.5 (CH, C-5), 128.1 (2CH, C-2c/6c), 124.1 (2CH, C-3c/5c), 119.0 (CH, 
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C-6), 111.0 (CH, C-8), 62.1 (CH, C-5b), 32.7 (CH2, C-3b), 32.6 (CH2, C-2a), 29.9 (CH2, C-1a), 
14.6 (CH3, C-4a); HRMS (m/z): calc. for C20H17N4O4S2 (M + H)+: 441.0691, found: 441.0696.  
*indicates that assignments are interchangeable. 
 
(B6i) 3-(4-hydroxybenzyl)-7-(4-oxo-2-phenylthiazolidin-3-yl)quinoxalin-2(1H)-one, yellow 
solid; mp 134-136 ºC; UV λmax (MeOH) nm (log ε) 228 (3.39), 346 (3.01); IR υmax 3177 (NH), 
1656 (C=O), 1614, 1510 cm-1; 1H NMR (400 MHz, DMSO) δH 12.31 (s, 1H, H-1), 9.19 (s, 1H, H-
8a), 7.60 (d, J = 8.5 Hz, 1H, H-5), 7.38 (d, 2H,  J = 7.0 Hz, H-2c/6c), 7.32 (s, 1H, H-8), 7.28 (dd, 
2H, J = 7.0, 7.0, H-3c/5c), 7.19-7.23 (m, 2H, H-4c, H-6), 7.07 (d, J = 7.6 Hz, 2H, H-3a/7a), 6.64 
(d, J = 7.6 Hz, 2H, H-4a/6a), 6.57 (s, 1H, H-5b), 4.06 (d, J = 15.8 Hz, 1H, H-3bi), 3.93 (bs, 2H, 
H-1a), 3.91 (d, J = 15.8 Hz, 1H, H-3bii); 13C NMR (400 MHz, DMSO) δC 170.8 (C, C-2b), 160.6 
(C, C-3), 155.9 (C, C-2), 154.4 (C, C-5a), 139.7 (C, C-1c), 138.3 (C, C-7), 132.0 (C, C-9*), 130.0 
(2C, CH, C-3a/7a), 129.5 (C, C-10*), 128.8 (2C, CH, C-2c/6c), 128.6 (CH, C-5), 128.3 (CH, C-
4c), 127.2 (C, C-2a), 126.9 (2C, CH, C-3c/5c), 119.3 (CH, C-6), 115.1 (2CH, C-4a/6a), 111.2 (CH, 
C-8), 63.3 (CH, C-5b), 38.0 (CH2, C-1a), 32.8 (CH2, C-3b); HRMS (m/z): calc. for 




one, yellow solid; mp 268-270 ºC; UV λmax (MeOH) nm (log ε) 230 (3.03), 286 (2.52), 345 (2.75); 
IR υmax 3384 (OH), 3125 (NH), 1678 (C=O), 1615, 1509 cm-1; 1H NMR (400 MHz, DMSO) δH 
12.31 (s, 1H, H-1), 9.18 (s, 1H, H-8a), 7.61 (d, J = 8.7 Hz, 1H, H-5), 7.44 (dd, J = 8.6, 5.4 Hz, 2H, 
H-2c/6c), 7.27 (d, J = 2.2 Hz, 1H, H-8), 7.19 (dd, J = 8.7, 2.2 Hz, 1H, H-6), 7.11 (dd, J = 8.6, 8.6 
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Hz, 2H, H-3c/5c), 7.08 (d, J = 8.5 Hz, 2H, H-3a/7a), 6.64 (d, J = 8.5 Hz, 2H, H-4a/6a), 6.58 (s, 
1H, H-5b), 4.07 (d, J = 15.7 Hz, 1H, H-3bi), 3.93 (bs, 2H, H-1a), 3.92 (d, J = 15.7 Hz, 1H, H-
3bii); 13C NMR (400 MHz, DMSO) δC 170.7 (C, C-2b), 161.9 (d, J = 238.8 Hz, C, C-4c), 160.6 
(C, C-3), 155.9 (C, C-5a), 154.4 (C, C-2), 138.2 (C, C-7), 135.9 (d, J = 2.8 Hz, C, C-1c), 132.0 (C, 
C-10*), 130.0 (2C, CH, C-3a/7a), 129.5 (C, C-9*), 129.2 (2C, CH, d, J = 8.4 Hz, C-2c/6c), 128.4 
(CH, C-5), 127.2 (C, C-2a), 119.4 (CH, C-6), 115.6 (2C, CH, d, J = 21.7 Hz, C-3c/5c), 115.1 (2C, 
CH, C-4a/6a), 111.4 (CH, C-8), 62.6 (CH, C-5b), 38.0 (CH2, C-1a), 32.8 (CH2, C-3b); HRMS 
(m/z): calc. for C24H18FN3O3SNa (M + Na)+: 470.0951, found: 470.0947.  *indicates that 
assignments are interchangeable. 
 
(B6k) 3-(4-hydroxybenzyl)-7-(2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)quinoxalin-2(1H)-
one, yellow solid; mp 194-196 ºC; UV λmax (MeOH) nm (log ε) 232 (2.91), 348 (2.56); IR υmax 
3200 (NH), 1659 (C=O), 1609, 1510 cm-1; 1H NMR (400 MHz, DMSO) δH 12.32 (s, 1H, H-1), 
9.21 (d, J = 3.5 Hz, 1H, H-8a), 7.60 (d, J = 8.3 Hz, 1H, H-5), 7.30 (d, J = 8.4 Hz, 2H, H-3a/7a), 
7.27 (bs, 1H, H-8), 7.17 (d, J = 8.3 Hz, 1H, H-6), 7.06 (d, J = 8.3 Hz, 2H, H-2c/6c), 6.81 (d, J = 
8.4 Hz, 2H, H-4a/6a), 6.63 (d, J = 8.3 Hz, 2H, H-3c/5c), 6.52 (s, 1H, H-5b), 4.02 (d, J = 15.8 Hz, 
1H, H-3bi), 3.93 (d, J = 8.3 Hz, 2H, H-1a), 3.92 (d, J = 15.8 Hz, 1H, H-3bii), 3.67 (s, 3H, H-8c); 
13C NMR (400 MHz, DMSO) δC 170.7 (C, C-2b), 160.6 (C, C-3), 159.3 (C, C-4c), 155.9 (C, C-
5a), 154.4 (C, C-2), 138.4 (C, C-7), 131.9 (C, C-9*), 131.1 (C, C-10*), 130.0 (2C, CH, C-2c/6c), 
129.5 (C, C-1c), 128.5 (2C, CH, C-3a/7a), 128.3 (CH, C-5), 127.3 (C, C-2a), 119.7 (CH, C-6), 
115.1 (2C, CH, C-3c/5c), 114.1 (2C, CH, C-4a/6a), 111.5 (CH, C-8), 63.1 (CH, C-5b), 55.1 (CH3, 
C-8c), 38.1 (CH2, C-1a), 32.9 (CH2, C-3b); HRMS (m/z): calc. for C25H20N3O4S (M + H)+: 




yellow solid; mp 260-262 ºC; UV λmax (MeOH) nm (log ε) 233 (2.58), 344 (2.37); IR υmax 3185 
(NH), 1660 (C=O) cm-1; 1H NMR (400 MHz, DMSO) δH 12.33 (s, 1H, H-1), 9.18 (s, 1H, H-8a), 
8.14 (d, J = 8.1 Hz, 2H, H-3c/5c), 7.68 (d, J = 8.1 Hz, 2H, H-2c/6c), 7.62 (d, J = 8.4 Hz, 1H, H-
5), 7.32 (bs, 1H, H-8), 7.23 (d, J = 8.4 Hz, 1H, H-6), 7.05 (d, J = 7.7 Hz, 2H, H-3a/7a), 6.74 (s, 
1H, H-5b), 6.63 (d, J = 7.7 Hz, 2H, H-4a/6a), 4.12 (d, J = 15.8 Hz, 1H, H-3bi), 3.94 (d, J = 15.8 
Hz, 1H, H-3bii), 3.92 (bs, 2H, H-1a); 13C NMR (400 MHz, DMSO) δC 170.8 (C, C-2b), 160.8 (C, 
C-3), 155.9 (C, C-2), 154.4 (C, C-5a), 147.5 (C, C-4c), 147.3 (C, C-1c), 137.9 (C, C-7), 132.1 (C, 
C-9*), 129.9 (2C, CH, C-3a/7a), 129.6 (C, C-10*), 128.6 (CH, C-5), 128.0 (2C, CH, C-2c/6c), 
127.2 (C, C-2a), 124.1 (2C, CH, C-3c/5c), 118.9 (CH, C-6), 115.1 (2C, CH, C-4a/6a), 110.9 (CH, 
C-8), 62.1 (CH, C-5b), 38.0 (CH2, C-1a), 32.6 (CH2, C-3b); HRMS (m/z): calc. for 
C24H17N4O5S (M + H)+: 473.0920, found: 473.0935.  *indicates that assignments are 
interchangeable. 
 
6.2.2 In vitro antimicrobial studies 
The microbial cultures were grown overnight at 37 °C in nutrient broth (UKZN Biolab, South 
Africa), adjusted to 0.5 McFarland standard using distilled water and lawn inoculated onto 
Mueller-Hinton agar (MHA) plates.  A volume of 10 µL of each sample (21.08 - 49.20 µM, 1 mL 
DMSO) was inoculated onto antibiotic assay discs (6 mm diameter) and placed on the MHA plates 
which were incubated overnight at 37 °C for 24 hours.  After the incubation period, zones of 
inhibition were measured in mm.  Compounds showing an inhibition zone of > 9 mm were selected 
to determine their MBC values using the broth dilution assay with ampicillin and ciprofloxacin as 
160 
the controls following the method in Andrews (2001).  Compounds B5a-c, B6a-c, B6f-h, B6j and 
B6k were chosen for the broth dilution method to determine their MBCs. 
 
For the broth dilution method, the microbial cultures (adjusted to 0.5 McFarland) were prepared 
as described previously for the disc diffusion method.  The test compounds were dissolved in 
DMSO (10 mg mL-1) and subject to a 50% serial dilution in 1 mL Eppendorf tubes with Mueller-
Hinton Broth (MHB), inoculated with bacterial cultures (20 µL) and then incubated at 37°C for 18 
h.  The total volume in each Eppendorf was 200 µL.  A volume of 10 µL of each dilution was 
spotted on MHA plates and incubated at 37°C for 18 h to determine the MBC (µM).  Ampicillin, 
ciprofloxacin and tioconazole served as the standard drugs for the antimicrobial and antifungal 
studies respectively.  All experiments were performed in duplicate. 
 
6.2.3 DPPH radical scavenging activity (in vitro antioxidant activity) 
 The total free radical scavenging activity of the tested compounds was determined and compared 
to that of ascorbic acid using a slightly modified method described by Tuba and Gulcin (2008).  A 
0.3 mM solution of DPPH was prepared in methanol and 500 µL added to 50 µL of the compounds 
(dissolved in DMSO) at different concentrations (50-200 µg mL-1).  These solutions were mixed 
and incubated in the dark for 30 min at room temperature.  Absorbance was then measured at 517 
nm against a blank sample lacking scavenger. 
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6.2.4 Antidiabetic activity 
In vitro α-glucosidase inhibitory activity 
The α-glucosidase inhibitory activity was determined according to the method described by 
Ademiluyi et al. (2013) with slight modifications.  Briefly, 50 µL of each compound or acarbose 
dissolved in DMSO at different concentrations (50-200 µg mL-1), was incubated with 100 µL of 
1.0 U mL–1 α-glucosidase solution in 100 mM phosphate buffer (pH 6.8) at 37 °C for 15 min. 
Thereafter, 50 µL of pNPG solution (5 mM) in 100 mM phosphate buffer (pH 6.8) was added and 
the mixture incubated at 37 °C for 20 min.  The absorbance of the released p-nitrophenol was 
measured at 405 nm and the inhibitory activity expressed as a percentage of the control sample 
without inhibitors.  
 
In vitro α-amylase inhibitory activity  
The α-amylase inhibitory activity was determined according to the method described by Shai et 
al. (2010) with slight modifications.  A volume of 50 µL of each compound dissolved in DMSO 
or acarbose at different concentrations (50-200 µg mL-1) was incubated with 100 µL of porcine 
pancreatic amylase (2 U mL–1 ) in 100 mM phosphate buffer (pH 6.8) at 37 °C for 20 min. 50 µL 
of 1 % starch dissolved in 100 mM phosphate buffer (pH 6.8) was then added to the reaction 
mixture and incubated at 37 °C for 1 h. 100 µL of DNS colour reagent was then added and boiled 
for 10 min.  The absorbance of the resulting mixture was measured at 540 nm and the inhibitory 
activity expressed as a percentage of the control sample without inhibitors.  All assays were carried 
out in triplicate. 
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6.3 Results and discussion 
Our synthetic design incorporates two fundamental methodologies; microwave irradiation and 
conventional synthesis.  This project was aimed at synthesizing hybrid molecules of quinoxaline, 
amino acid and thiazolidine core structures.  Variation was introduced in the molecules at the 
thiazolidine ring by varying the aromatic aldehydes used to form the thiazolidine moiety and in 
the amino acid side chains at position 3 on the quinoxaline ring by using different amino acids.  
The phenyl ring on the thiazolidine moiety was either unsubstituted or substituted at the para 
position with an electron donating methoxy group or electron withdrawing groups (F and NO2).  




The quinoxaline-thiazolidine-amino acid hybrids were synthesized in a four-step reaction.  This 
reaction series first involved esterification of the amino acids B1a-c with thionyl chloride and 
methanol and then an aromatic nucleophilic substitution of the fluorine on 1-fluoro-2,4-
dinitrobenzene B3 with the various amino acid esters B2a-c under mildly basic conditions forming 
the amino acid ester 2,4-dinitrobenzene intermediates B4a-c.  Reduction of the nitro groups and 
formation of the quinoxalines were carried out in a single step with Pd/C in the presence of H2 and 
methanol.  Under microwave irradiation, the thiazolidine ring was formed with the primary amino 
group in the quinoxaline intermediates with thioglycolic acid and the four different aldehydes 
forming the target molecules as racemic mixtures B6a-l (Scheme 6-1).   
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Formation of the Schiff base with aldehydes and further cyclisation to thiazolidines with 
thioglycolic acid was carried out in a single step under microwave conditions.  An attempt to form 
the product by the conventional method, first forming the Schiff base with aldehydes and 
subsequent cyclisation with thioglycolic acid did not work.  However, the microwave reaction was 
carried out within 10-45 minutes depending on the different substituents used (Table 6-1). 
 
6.3.2 Structural elucidation   
The synthesized products were characterized using NMR and MS analysis. Using B6j as a 
representative sample, 1H and 13C NMR resonances were unambiguously assigned as indicated 
below.  The quinoxaline core structure contained four proton resonances at δH 12.31 for the H-1 
amino group.  The aromatic protons H-5, H-6 and H-8 appeared at δH 7.61 (d, J = 8.7 Hz), δH 7.19 
(dd, J = 8.7, 2.2 Hz) and δH 7.27 (d, J = 2.2 Hz) respectively.  The NH-l resonance was 
distinguished from the OH-8a resonance at δH 9.18 since it showed a NOESY correlation to H-8.  
The resonances at δC 138.2, 132.0 and 129.5 all showed correlations to H-5 and were assigned to 
carbon resonances on the same ring.  The most deshielded resonance (δC 138.2) was assigned to 
C-7 and the resonance at δC 129.5 was assigned to C-9 due to a HMBC correlation with H-6.  The 
remaining resonance at δC 132.0 was assigned to C-10.  
 
There were five deshielded carbon resonances between δC 154.4 and 170.7.  The resonances at δC 
154.4 and 160.6 both showed HMBC correlations to H-1a at δH 3.93 and were assigned to C-2 and 
C-3 respectively, the latter assigned due to an HMBC correlation to H-5.  The resonance at δC 
170.7 showed HMBC correlations to H-3bi, H-3bii and H-5b and was assigned to C-2b.  The H-
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3bi and H-3bii resonances appeared as a pair of doublets with geminal coupling of 15.7 Hz and H-
5b occurred as a singlet.  C-5a was assigned to δC 155.9 due to an HMBC correlation with H-4a/6a 
and H-3a/7a.  The remaining carbon resonance of the five between δC 154.4 and 170.7 was a 
doublet carbon resonance with J = 238.8 Hz and was assigned to the carbon bearing the fluorine 
atom (C-4c).   
 
Table 6-1  Yields and duration of microwave synthesis for the amino acid linked quinoxaline-
thiazolidinones 





B5a val - - - 
B5b met - - - 
B5c tyr - - - 
B6a val Ph 90 10 
B6b val 4-F Ph 85 10 
B6c val 4-OMe Ph 82 30 
B6d val 4-NO2 Ph 80 45 
B6e met Ph 90 10 
B6f met 4-F Ph 86 10 
B6g met 4-OMe Ph 83 30 
B6h met 4-NO2 Ph 80 45 
B6i tyr Ph 87 10 
B6j tyr 4-F Ph 90 10 
B6k tyr 4-OMe Ph 82 30 
B6l tyr 4-NO2 Ph 85 45 
NR: no reaction;  * amino acid side chain;  






The aromatic protons of the benzyl group H-3a/7a and H-4a/6a each occurred as doublets at δH 
7.08 and δH 6.64 respectively with coupling constants of 8.5 Hz.  The singlet C-2a and C-5a 
resonances occurred at δC 127.2 and δC 155.9 respectively.  The H-3c/5c and H-2c/6c proton 
resonances each occurred as doublet doublets with coupling constants of JH-3c/H-5c,F = JH-3c/H5c,H-
2c/6c = 8.6 Hz, JH-2c/6c,H-3c/5c = 8.6 Hz and JH-2c/6c,F = 5.4 Hz, typical for a para fluorinated aromatic 
moiety (Gopaul et al., 2016).  
 
Selected HMBC correlations used in the structural elucidation of B6j are provided in Figure 6-1.  
 
 
Figure 6-1  Selected HMBC correlations of compound B6j (H→C) 
 
6.3.3 Antimicrobial activity 
The tested compounds were evaluated for their antifungal activity against Candida albicans 
(ATCC 10231) with tioconazole as the reference drug and antibacterial activity against two Gram 
+ve strains, S. aureus (ATCC 25923) and methicillin resistant S. aureus (MRSA)(ATCC BAA-
1683) and three Gram -ve strains (Escherichia coli (ATCC 25922), K. pneumonia (ATCC 31488) 
and Pseudomonas aeruginosa (ATCC 27853)) using ciprofloxacin and ampicillin as standards.  
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The disc diffusion assay was used as an initial screen to select potentially active compounds.  
Compounds showing a zone of inhibition >8 mm were chosen to determine their MBC values.  
Compounds B5a-c, B6a-c, B6f-h, B6j and B6k all satisfied this criterion and their MBC values 
were further explored. 
 
Table 6-2  Antimicrobial activity of the synthesized compounds, MBCs in µM 
Compound Gram +ve 
bacteria 
Gram -ve bacteria Fungi 






B5a - - - - 658.6 164.7 
B5b 249.0 498.0 - - - 62.3 
B5c 73.1 - - - - 438.5 
B6a - - 851.2 - - - 
B6b 101.4 38.0 202.9 405.7 811.4 50.7 
B6c 49.2 393.4 - 196.7 786.9 - 
B6f 23.4 93.7 46.8 70.3 11.7 35.1 
B6g 90.9 34.1 181.9 136.4 363.8 545.6 
B6h - - - - 706.2 353.1 
B6j 43.5 87.0 32.6 21.7 87.0 65.2 
B6k 15.9 63.8 21.2 680.1 - 85.0 
Ampicillin 55.9 894.4 447.2 1788.7 447.2 447.2 
Ciprofloxacin 1.8 7.4 1.8 1.8 3.7 1.8 
Tioconazole - - - - - 100.8 
- denotes that the compounds were inactive at the highest concentration tested.  The shaded values indicate activity < 
100 µM.  Highlighted values indicate the best results. 
 
Compounds B6b, B6f- B6g and B6j showed broad-spectrum antimicrobial activity, being active 
against all bacterial strains tested against (Table 6-2).  Of these active compounds, B6b, B6f and 
B6j contained a 4-fluorobenzaldehyde moiety on the thiazolidinone ring and were active 
regardless of the amino acid residue present at C-3 on the core structure.  When a 4-
methoxybenzaldehyde moiety was present at the same position, only B6g containing a methionine 
residue showed broad spectrum activity.  Compounds B6f and B6j with methionine and tyrosine 
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residues were particularly active having MBC values < 100 µM against all the strains tested 
against.  It is worth noting that B6b and B6g were active at concentrations < 40 µM against MRSA.  
The best activity was seen with B6f, being active against K. pneumonia at three times that of 
ciprofloxacin. In general, the activity of the synthesized compounds was better than that of 
ampicillin, but 10 fold or greater than that of ciprofloxacin. 
 
Compounds B6b, B6f and B6j discussed above also showed good antifungal activity, being active 
at < 100 µM against C. albicans better than the control, tioconazole, active at 100.8 µM against C. 
albicans.  The other quinoxaline-thiazolidine hybrid showing activity at < 100 µM against C. 
albicans was B6k with a 4-methoxybenzaldehyde moiety on the thiazolidine ring and a tyrosine 
unit at C-3.  The quinoxaline core structure with a methionine residue at C-3 (B5b) also showed 
good antifungal activity, being active at 62.3 µM. 
 
The antibacterial and antifungal activity of the synthesized hybrid compounds showed better 
activity than compounds with either quinoxaline or thiazolidine in its core structure (Ali et al., 
2015; Anh et al., 2015; Issa et al., 2015; Krishna et al., 2015; Liu et al., 2011).  
 
Antioxidant activity 
The free radical scavenging activity of all synthesized amino acid linked thiazolidine-quinoxaline 
compounds B5a-5c and B6a- B6l was carried out in presence of the stable free radical (1,1-
diphenyl-2-picrylhydrazyl) DPPH using ascorbic acid (AA), as a positive control. Although a 
number of methods are available for the determination of the antioxidant activity, the DPPH 
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method is very common, rapid and has been shown to be one of the most appropriate (Bondet et 
al., 1997).  
 
There was no real trend in the structure of the compounds and their antioxidant activity.  Two of 
the four compounds with a tyrosine residue and para methoxybenzaldehyde (B6k) or para 
nitrobenzaldehyde moiety (B6l) on the thiazolidine ring and a third compound with a methionine 
residue and a para nitrobenzaldehyde moiety (B6h) on the thiazolidine ring showed very good 
results with IC50 values of 19.60, 10.53 and 28.95 µM respectively compared to the standard, 
ascorbic acid at 16.86 µM (Table 6-3). 
 





B5a 469.68±304.64abc B6f 155.74±3.99ab 
B5b 756.87±9.95bc B6g 1307.26±594.08d 
B5c 131.10±27.23ab B6h 28.95±6.28a 
B6a 220.84±2.60abc B6i 550.05±14.72cd 
B6b 320.09±4.11abc B6j 239.16±9.44abc 
B6c 163.64±23.18ab B6k 19.60±3.23a 
B6d 162.19±23.69ab B6l 10.53±1.20a 
B6e 47.82±4.34ab - - 
Ascorbic acid 16.86±9.26a 
Data are presented as mean ± SD values of triplicate determinations. 
a-d Different letters stand for significantly different values from each other within a column (Tukey’s-HSD multiple 
range post hoc test, p < 0.05); the same letters stand for non-significant difference.  The shaded cells indicate IC50 
values of < 30 µM.  Highlighted values indicate the best results. 
 
6.3.4 Antidiabetic activity (α-glucosidase and α-amylase activity) 
Among the synthesized compounds, B5c, B6d, B6g and B6k showed in vitro enzymatic inhibitory 
activity (Table 4).  Compounds B6d and B6k showed significant α-glucosidase activity with 
IC50 values of 301.15 and 276.27 µM respectively.  Compound B6d contains a para 
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nitrobenzaldehyde group on the thiazolidinone moiety and a valine amino acid side chain at C-3 
and B6k contains a para methoxybenzaldehyde moiety on the thiazolidinone portion with a 
tyrosine side chain at C-3. 
 
The quinoxaline core structure with a tyrosine moiety at C-3 and a primary amine at C-7 (B5c) 
and B6g with a methionine residue at C-3 and a para methoxybenzaldehyde moiety on the 
thiazolidinone ring showed moderate α-glucosidase activity compared to acarbose, the reference 
drug, active in the same assay with a IC50 value of 135.34 µM against α-glucosidase.  
 
Compounds B6d and B6k whose structures are discussed above showed significant in vitro α-
amylase inhibitory activity with IC50 values of 356.32 and 301.59 µM respectively, approximately 
twice that of acarbose (IC50 149.11 µM) (Table 6-4).  
 
Table 6-4  α- Glucosidase and α-amylase inhibition of the synthesized compounds, IC50 (µM) 
Compounds α-Glucosidase α-Amylase 
 IC50 (µM) 
B5c 411.67±0.21b - 
B6d 301.15±0.86bc 356.32±3.32a 
B6g 428.72±1.64d - 
B6k 276.27±2.90c 301.59±2.27a 
Acarbose 135.34±0.09a 149.11±4.28a 
Data are presented as mean ± SD values of triplicate determinations. 
a-d Different letters stand for significantly different values from each other within a column (Tukey’s-HSD multiple 
range post hoc test, p < 0.05);  the same letters stand for non-significant difference. 
 
6.4 Conclusion 
This is the first report of a new synthetic procedure to synthesize a new class of amino acid linked 
thiazolidine-quinoxaline hybrid molecules.  These molecules were synthesized by developing an 
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efficient, cost effective and short reaction via microwave methods.  Compounds B6f and B6j were 
the most potent antimicrobials, B6k and B6l the most potent antioxidants and B6d and B6k were 
significant antidiabetic agents.  Compound B6k showing good results in all three assays could be 
a good starting point for the design of lead compounds for the pharmaceutical industry.  
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Chapter 7. Expedient synthesis, antimicrobial, antioxidant activities and 
docking study of 2-substituted methyl 1-(4-fluorophenyl)-1H-
benzimidazole-5-carboxylates 
 
* The compounds referred to in the chapter are referred to elsewhere in the thesis with an C preceding the number of 
the compound.  For example 5a-v is referred to as C5a-v elsewhere in the thesis. 
 
Abstract 
A library of 2-substituted fluorinated benzimidazoles (C5a-C5v) was synthesized by an easy, 
efficient, rapid and inexpensive route for the synthesis of benzimidazoles using microwave 
conditions.  The synthesized compounds were tested for their antimicrobial and antioxidant 
behaviour.  The benzimidazoles C5p and C5r showed strong antimicrobial (MBCs: 14-555 and 
25-446 µM respectively) and antioxidant activities (IC50: 386.55 and 306.71 µM respectively) 
compared to the standards used for comparison.  Docking studies of C5h and C5r (one inactive 
and one active compound) into the active site of topoisomerase II DNA-gyrase were used to 
explain the crucial interaction with the Mn2+ ion in the active site of the enzyme for anti-bacterial 
activity.   
 





The development of new, robust, efficient and environmentally friendly chemical processes for 
the synthesis of bis-heterocyclic compounds is needed in the pharmaceutical and chemical 
industries (Dua et al., 2011; Jain s et al., 2013).  Greener and more sustainable chemical syntheses 
focus on minimal or no use of solvents or the use of water as a solvent, reduction of waste, use of 
ambient conditions, shortening of reaction times, and developing easy methods of product 
separation and purification.  
 
Nitrogen containing compounds are important chemical compounds due to their numerous 
applications.  The benzimidazole moiety has gained importance in recent years having anticancer, 
antiviral, antibacterial, antioxidant, antifungal, anthelmintic, antiparasitic, antimycobacterial, 
antidiabetic, antihypertensive, analgesic, antipsychotic, anticoagulant, cardiovascular, and anti-
inflammatory properties (Vazquez et al., 2001; Tomic et al., 2004; Biron et al., 2006; Kuş et al., 
2009; Narasimhan et al., 2010; Vyas et al., 2010; Kalyankar et al., 2012; Barot et al., 2013; 
Gurvinder et al., 2013; Jain S et al., 2013; Yoon et al., 2014; Keri et al., 2015; Singla et al., 2015). 
 
Benzimidazoles are generally synthesized by coupling reactions between o-phenylenediamines 
with carboxylic acids, carboxylic acid chlorides or aldehydes and in some cases esters and amides 
(Panda et al., 2012; Khanna et al., 2012; Prajapti et al., 2015; Saberi et al., 2015; Saleh et al., 2015; 
Rithe et al., 2015; Kattimani et al., 2015; Keri et al., 2015; Carvalho et al., 2015; Azizian et al., 
2016).  They are also synthesized from o-phenylenediamines and reagents other than acid 
derivatives or aldehydes (Khanna et al., 2012).  When two moles of o-phenylenediamines are 
reacted with dicarboxylic acid derivatives, symmetric bisbenzimidazoles are formed (Khanna et 
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al., 2012).  These symmetric bisbenzimidazoles are also formed with o-phenylenediamines and 
hexachloro-2-propanone (Rezende et al., 2001) or with symmetric diacids or dialdhehydes 
(Khanna et al., 2012).  Symmetric bisbenzimidazoles are also synthesized with [1,1'-biphenyl]-
3,3',4,4'-tetraamines and a number of different reagents (Khanna et al., 2012).  
 
There have been numerous reports of benzimidazoles being synthesized using classical organic 
chemistry in the presence of Lewis acid catalysts containing Sn, Ti,
 
Zr, Bi, In, Co, Ce, B, Zn and 
Hf (Zhang et al., 2007), Ir (Tateyama et al., 2016), La (Kamal et al., 2014), acetic acid (Jain et al., 
2013) and p-toluenesulfonic acid (Xiangming et al., 2007; Funel et al., 2014), basic catalysts such 
as NaOH (Rajasekhar et al., 2010), KOH (Al-Mohammed et al., 2013), or inorganic salts for 
example NaHSO3 (Jain et al., 2013) and Na2S2O5 (Yoon et al., 2015).  Although benzimidazoles 
are synthesized widely with the use of a catalyst, several of these catalysts are quite costly such as 
(TiCl4, Ir, HfCl4, Bi(NO3)5 and ZrCl4) (Zhang et al., 2007).  Although several synthetic procedures 
to the benzimidazoles use non-environmentally friendly solvents such as DMF (Yoon et al., 2015), 
CHCl3 (Gupta Atyam et al., 2010) and toluene (Funel et al., 2014), other reported procedures have 
made use of greener solvents such as methanol and water (Borhade et al., 2012; Chen et al., 2012; 
Rao et al., 2014). 
 
The grinding method (Banerjee et al., 2014), ultrasound (Patil et al., 2014) and visible light 
promoted (Park et al., 2014) were all used to synthesize benzimidazoles without the use of a 
catalyst.  In recent years there has been much interest in microwave syntheses (Das et al., 2012; 
Gawande M et al., 2014; Jacob et al., 2012).  Using microwave synthesis, benzimidazoles were 
synthesized without the use of catalysts and organic solvents (Abdullah et al., 2012; Eren et al., 
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2014;).  Its advantages are therefore that it is a green technique, cheaper, carried out in shorter 
times and uses less energy than conventional synthesis.  Benzimidazoles were also synthesized 
under microwave conditions using NaHSO3 as a catalyst (López et al., 2009). 
 
In our study, we have synthesized fluorinated benzimidazole derivatives from the o-
phenylenediamine (methyl 3-amino-4-(4-fluorophenylamino)benzoate) and various substituted 
aldehydes using three methods, conventional organic synthesis with a sodium metabisulphite 
catalyst and ethanol as solvent, the grinding method with iodine as a catalyst and under microwave 
conditions with no catalyst or solvent, and compared the yields and reaction times of these 
methods.  We synthesized a total of twenty-two 2-substituted fluorinated benzimidazoles (C5a- 
C5v) and tested them for their antimicrobial and antioxidant activity. 
 
7.2 Experimental  
7.2.1 General experimental procedures 
All chemicals were supplied by Sigma-Aldrich via Capital Lab, South Africa.  Organic solvents 
were redistilled and dried according to standard procedures. Silica gel 60 F254 plates (Merck) were 
used for thin layer chromatography.  Crude compounds were purified by column chromatography 
using silica gel (60-120 mesh) and a mobile phase of varying ratios of EtOAc : Hexane.  Melting 
points were recorded using a Stuart Scientific SMP3 apparatus.  UV spectra were obtained on a 
Varian Cary UV-VIS spectrometer in MeOH.  IR spectra were recorded on a Perkin Elmer 100 
FT-IR spectrometer with universal attenuated total reflectance sampling accessory.  
 
178 
Microwave assisted reaction: All reactions which involved microwave irradiation were performed 
using a CEM Discover, Explorer-12 Hybrid microwave. 1H, 13C and all 2D NMR spectra were 
recorded on a Bruker Avance instrument operating at 400 MHz. Chemical shifts are reported in δ 
values (ppm) relative to an internal standard of tetramethylsilane (TMS) and referenced to the 
solvent line of CDCl3 (7.24 ppm for 1H; 77.0 ppm for 13C), CD3OD (3.31 ppm for 1H; 49.0 ppm 
for 13C) or DMSO-d6 (2.5 ppm for 1H; 39.5 ppm for 13C). High-resolution mass data were obtained 
using a Bruker micro TOF-Q II ESI instrument operating at ambient temperature.  The purity of 
the compounds were determined by analytical HPLC on a Shimadzu-20A5 fitted with a C8 
(150mm x 5µm x 4.6) column using a mobile phase (A) of 0.1M KHPO4 buffer and (B) methanol, 
with a linear gradient of 0 to 70% over a period of 60 minutes at a flow rate of 1 mL min-1.  
 
The general scheme for the reaction is shown below in Scheme 7-1. 
 
 
Scheme 7-1  Synthesis of fluorinated benzimidazoles C5a-v; a MW 110 ºC, 3-8 min; b grinding, 




General procedure for the preparation of methyl 4-fluoro-3-nitrobenzoate (C2)  
4-Fluoro-3-nitrobenzoic acid (0.5 g, 2.7 mmol) was dissolved in methanol (5 mL) and conc. H2SO4 
(0.5 mL) at room temperature.  The reaction mixture was heated with stirring in a 10 mL 
microwave process vial for 10 min at 80 ºC.  After completion of the reaction (as evident from 
TLC), the solvent was evaporated under reduced pressure, the reaction mixture basified by sodium 
bicarbonate and the aqueous layer extracted into ethyl acetate (3 × 5 mL).  The organic layer was 
dried over anhydrous Na2SO4 and concentrated under reduced pressure to yield C2 as a cream-
colored powder (95%). 1H NMR (CDCl3, 400 MHz) δ 8.73 (1H, dd, J = 7.2, 2.2 Hz, H-2), 8.31 
(1H, m, H-6), 7.38 (1H, dd, J = 10.2, 8.8 Hz, H-5), 3.95 (3H, s, H-8); 13C NMR (CDCl3, 100 MHz) 
δ 164.1 (C-7), 158.1 (d, JCF = 270.0 Hz, C-4), 137.3 (C-3), 136.5 (d, J = 9.7 Hz, C-6), 127.8 (C-
2), 127.2 (d, J = 4.2 Hz, C-1), 118.8 (d, J = 21.2 Hz, C-5), 52.9 (C-8); 19F NMR (CDCl3, 376.5 
MHz) δ -110.55. 
 
General procedure for the preparation of methyl 4-(4-fluorophenylamino)-3-nitrobenzoate 
(C3) 
Methyl-4-fluoro-3-nitrobenzoate C2 (0.5 g, 2.34 mmol) and 4-fluorophenyl aniline (0.36 mL, 2.34 
mmol) were mixed in DMF (2 mL).  The reaction mixture was subject to microwave irradiation 
with stirring in a 10 mL microwave process vial for 5 min at 80 ºC. After completion of the reaction 
(monitored by TLC), the reaction mixture was washed with water (2 × 10 mL) followed by 10% 
Na2CO3 (10 mL).  The organic layer was dried over anhydrous Na2SO4 and concentrated under 
reduced pressure to afford C3 as a crude product.  The solid was purified by column 
chromatography (30% ethyl acetate in hexane) to afford the desired product as a vermilion 
(reddish) solid in good yields (90%).  1H NMR (CDCl3, 400 MHz) δ 9.67 (1H, s, NH-10), 8.90 
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(1H, d, J = 2.0 Hz, H-2), 7.95 (1H, dd, J = 9.0, 2.0 Hz, H-6), 7.29 (2H, dd, J =8.8, 4.7 Hz, H-
2a/6a), 7.18 (2H, t, J = 8.8 Hz, H-3a/5a), 7.03 (1H, d, J = 9.0 Hz, H-5), 3.89 (3H, s, H-8); 13C 
NMR (CDCl3, 100 MHz) δ 165.3 (C-7), 161.2 (d, JCF = 245.8 Hz, C-4a), 146.4 (C-4), 136.0 (C-
2), 133.5 (d, J = 3.3 Hz, C-1a), 132.1 (C-3), 129.24 (C-6), 127.5 (d, J = 8.5 Hz, 2C, C-2a/6a), 
119.2 (C-1), 116.9 (d, J = 22.7 Hz, 2C, C-3a/5a), 115.3 (C-5), 52.2 (C-8); 19F NMR (CDCl3, 376.5 
MHz) δ -114.14. 
 
General procedure for the preparation of methyl 3-amino-4-(4-fluorophenylamino) benzoate 
(C4) 
Methyl 4-(4-fluorophenylamino)-3-nitrobenzoate C3 (0.5 g, 1 mmol), Zn (0.06 g, 0.5 mmol) and 
ammonium formate (0.54 g, 5 mmol) were added to methanol (5 mL).  The reaction mixture was 
stirred at room temperature for 10 min.  Upon completion of the reaction (monitored by TLC), it 
was filtered through Celite 545 to remove the zinc.  The filtrate was evaporated under reduced 
pressure and the solid purified by column chromatography (30% ethyl acetate in hexane) to afford 
the desired product as a brown solid in good yield (92%).  1H NMR (CDCl3, 400 MHz) δ 7.50 
(1H, d, J = 1.7 Hz, H-2), 7.47 (1H, dd, J = 8.2, 1.7 Hz, H-6), 7.03 (1H, d, J = 8.2 Hz, H-5), 6.99 
(d, J = 8.3 Hz, 2H, H-2a/6a), 6.95 (2H, dd, J = 9.0, 8.3 Hz, H-3a/5a), 5.55 (s, 1H, NH-10), 3.85 
(3H, s, H-8), 3.16 (2H, s, NH-9); 13C NMR (CDCl3, 100 MHz) δ 167.0 (C-7), 158.3 (d, JCF = 239.4 
Hz, C-4a), 138.3 (C-1a), 137.1 (C-4), 136.0 (C-3), 123.6 (C-1), 122.6 (C-6), 120.6 (d, J = 7.7 Hz, 
2C, C-2a/6a), 118.4 (C-2), 116.7 (C-5), 116.1 (d, J = 22.5 Hz, 2C, C-3a/5a), 51.8 (C-8); 19F NMR 
(CDCl3, 376.5 MHz) δ -121.46. 
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General procedure for the preparation of fluorinated benzimidazole (C5a- C5v) 
Microwave method 
The mixture of methyl 3-amino-4-(4-fluorophenylamino) benzoate C4 (1 mmol) and various 
aldehydes (1 mmol) were heated in a 5 mL microwave process vial for 5-10 min at 110 ºC to obtain 
compounds (C5a-C5v).  After completion of the reaction (monitored by TLC), the reaction 
mixture was washed with water (2 × 5 mL) followed by brine solution (10 mL).  The aqueous layer 
was extracted into ethyl acetate (3 × 5 mL).  The organic layer was dried over anhydrous Na2SO4, 
concentrated under reduced pressure and the obtained solid purified by column chromatography 
(30-50% ethyl acetate in hexane) to afford the desired product in good yield (85-96%).   
 
Grinding (Mechanochemical) method 
A mixture of methyl 3-amino-4-(4-fluorophenylamino) benzoate C4 (1 mmol), various aldehydes 
(1 mmol), and iodine (10 mol %) were ground together using a mortar and pestle at room 
temperature between 5-45 min (Table 1).  After completion of the reaction (confirmed by TLC), 
the mixture was treated with aqueous Na2S2O3.  The aqueous layer was extracted with ethyl acetate 
(3 × 5 mL), and the organic layer dried over anhydrous Na2SO4 and concentrated under reduced 
pressure.  The solid obtained was purified by column chromatography (hexane/ethyl acetate) to 
afford the desired product (C5a-C5v) in moderate to good yields (10-56%).   
 
Conventional method 
3-Amino-4-(4-fluorophenylamino) benzoate C4 (1 mmol), various aldehydes (1 mmol) and 
Na2S2O5 (20 mol%) was refluxed in ethanol (20 mL) between 8-18h.  After completion of the 
reaction (as evident from TLC), the solvent was evaporated under reduced pressure and the crude 
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mass washed with water (2 × 10 mL).  The aqueous layer was extracted with ethyl acetate (3 × 25 
mL), and the organic layer dried over anhydrous Na2SO4 and concentrated under reduced pressure 
to afford C5a-C5v as crude products.  The solid obtained was purified by column chromatography 
(hexane/ethyl acetate) to afford the desired product in good yields (60-90%). 
 
(C5a) methyl 1-(4-fluorophenyl)-2-phenyl-1H-benzo[d]imidazole-5-carboxylate, white solid 
(90% yield); Purity 99%; mp 160-162 oC; UV λmax (MeOH) nm (log ε) 247 (2.63), 302 (2.19); IR 
υmax 3069 (CH), 1713 (C=O), 1357 (C-F), 1185 (C-O) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.58 
(1H, bs, H-4), 7.98 (1H, d, J = 8.6 Hz, H-6), 7.54 (2H, d, J = 7.4 Hz, H-2b/6b), 7.38 (1H, m, H-
4b), 7.32 (2H, m, H-2a/6a), 7.29 (2H, m, H-3b/5b), 7.23 (1H, m, H-7), 7.20 (2H, m, H-3a/5a), 3.94 
(3H, s, H-11); 13C NMR (CDCl3, 100 MHz) δ 167.4 (C-10), 162.4 (d, JCF = 248.6 Hz, C-4a), 154.0 
(C-2), 142.2 (C-8), 140.2 (C-9), 132.2 (d, J = 3.3 Hz, C-1a), 130.0 (C-4b), 129.2 (C-6b), 129.1 (d, 
J = 8.7 Hz, 2C, C-2a/6a), 129.07 (C-2b), 129.0 (C-1b), 128.5 (2C, C-3b/5b), 125.4 (C-5), 125.1 
(C-6), 122.2 (C-4), 117.1 (d, J = 22.7 Hz, 2C, C-3a/5a), 109.3 (C-7), 52.1 (C-11); 19F NMR 
(CDCl3, 376.5 MHz) δ -108.08; HRMS (m/z): 347.1198 M+ (calculated for C21H16FN2O2: 
347.1196). 
 
(C5b) methyl 1,2-bis(4-fluorophenyl)-1H-benzo[d]imidazole-5-carboxylate, yellow solid 
(90% yield); Purity 98%; mp 130-132 oC; UV λmax (MeOH) nm (log ε)  247 (2.7), 301 (2.4); IR 
υmax 3071 (CH), 1711 (C=O), 1379 (C-F), 1157 (C-O) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.56 
(1H, bs, H-4), 7.99 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.54 (2H, dd, J = 8.8, 5.2 Hz, H-2b/6b), 7.29 
(2H, dd, J = 8.9, 4.8 Hz, H-2a/6a), 7.23 (2H, m, H-3a/5a), 7.19 (1H, d, J = 8.6 Hz, H-7), 7.02 (2H, 
t, J = 8.8 Hz, H-3b/5b), 3.95 (3H, s, H-11); 13C NMR (CDCl3, 100 MHz) δ 167.3 (C-10), 163.7 (d, 
183 
JCF = 250.4 Hz, C-4b), 162.5 (d, JCF = 249.2 Hz, C-4a), 153.0 (C-2), 142.1 (C-8), 140.2 (C-9), 
132.2 (d, J = 3.2 Hz, C-1a), 131.5 (d, J = 8.6 Hz, 2C, C-2b/6b), 129.2 (d, J = 8.7 Hz, 2C, C-2a/6a), 
125.6 (C-5), 125.2 (C-6), 122.1 (C-4), 117.3 (d, J = 23.0 Hz, 2C, C-3a/5a), 115.8 (d, J = 21.8 Hz, 
C-3b/5b), 110.0 (C-7), 52.2 (C-11); 19F NMR (CDCl3, 376.5 MHz) δ -110.71, -109.46; HRMS 
(m/z): 365.1111 M+ (calculated for C21H15F2N2O2: 365.1102). * C-1b could not be detected. 
 
(C5c) methyl 2-(4-chlorophenyl)-1-(4-fluorophenyl)-1H-benzo[d]imidazole-5-carboxylate, 
yellow solid (86% yield); Purity 96%; mp 185-187 oC; UV λmax (MeOH) nm (log ε) 251 (3.23), 
304 (2.85); IR υmax 3059 (CH), 1708 (C=O), 1357 (C-F), 1181 (C-O), 729 (C-Cl ) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.58 (1H, bs, H-4), 8.01 (1H, d, J = 8.5 Hz, H-6), 7.51 (2H, d, J = 8.4 Hz, H-
2b/6b), 7.31 (4H, d, J = 8.5 Hz, H-2a/6a, H-3b/5b), 7.25 (2H, d, J = 6.44 Hz, H-3a/5a), 7.20 (1H, 
d, J = 8.8 Hz, H-7), 3.95 (3H, s, H-11); 13C NMR (CDCl3, 100 MHz) δ 167.3 (C-10), 162.5 (d, JCF 
= 249.2 Hz, C-4a), 152.8 (C-2), 142.0 (C-8), 140.1 (C-9), 136.5 (C-4b), 132.1 (d, J = 3.0 Hz, C-
1a), 130.7 (2C, C-2b/6b), 129.1 (d, J = 8.7 Hz, 2C, C-2a/6a), 128.9 (C-3b), 127.4 (C-1b), 125.7 
(C-5), 125.3 (C-6), 122.2 (C-4), 117.3 (d, J = 22.8 Hz, 2C, C-3a/5a), 110.1 (C-7), 52.2 (C-11); 19F 
NMR (CDCl3, 376.5 MHz) δ -110.35; HRMS (m/z): 381.0818 M+ (calculated for C21H15ClFN2O2: 
381.0806). 
 
(C5d) methyl 2-(4-bromophenyl)-1-(4-fluorophenyl)-1H-benzo[d]imidazole-5-carboxylate, 
cream coloured solid (82% yield); Purity 97%; mp 203-205 oC; UV λmax (MeOH) nm (log ε) 253 
(3.28), 305 (2.92); IR υmax 3072 (CH), 1707 (C=O), 1357 (C-F), 1153 (C-O), 523 (C-Br) cm-1; 1H 
NMR (CDCl3, 400 MHz) δ 8.57 (1H, s, H-4), 8.00 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.47 (2H, d, J = 
8.6 Hz, H-3b/5b), 7.42 (2H, d, J = 8.6 Hz, H-2b/6b), 7.29 (2H, dd, J = 9.0, 4.8 Hz, H-2a/6a), 7.23 
184 
(2H, t, J = 10.8 Hz, H-3a/5a), 7.19 (1H, d, J = 8.6 Hz, H-7), 3.95 (3H, s, H-11); 13C NMR (CDCl3, 
100 MHz) δ 167.3 (C-10), 162.6 (d, JCF = 249.2 Hz, C-4a), 152.8 (C-2), 142.1 (C-8), 140.2 (C-9), 
132.2 (d, J = 3.3 Hz, C-1a), 131.9 (2C, C-3b/5b), 130.9 (2C, C-2b/6b), 129.1 (d, J = 8.7 Hz, 2C, 
C-2a/6a), 127.9 (C-5), 125.7 (C-1b), 125.4 (C-6), 124.9 (C-4b), 122.2 (C-4), 117.4 (d, J = 22.8 
Hz, 2C, C-3a/5a), 110.1 (C-7), 52.2 (C-11); 19F NMR (CDCl3, 376.5 MHz) δ -110.53; HRMS 
(m/z): 425.0310 M+ (calculated for C21H15BrFN2O2: 425.0301). 
 
(C5e) methyl 1-(4-fluorophenyl)-2-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole-5-
carboxylate, white solid (84% yield); Purity 98%; mp 171-173 oC; UV λmax (MeOH) nm (log ε) 
250 (2.83), 304 (2.5); IR υmax 3081 (CH), 1712 (C=O), 1358 (C-F), 1196 (C-O) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.59 (1H, bs, H-4), 8.01 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.68 (2H, d, J = 8.3 
Hz, H-3b/5b), 7.58 (2H, d, J = 8.3 Hz, H-2b/6b), 7.30 (2H, dd, J = 8.9, 4.8 Hz, H-2a/6a), 7.24 (2H, 
t, J = 10.5 Hz, H-3a/5a), 7.21 (1H, d, J = 8.6 Hz, H-7), 3.95 (3H, s, H-11); 13C NMR (CDCl3, 100 
MHz) δ 167.2 (C-10), 162.6 (d, JCF = 249.4 Hz, C-4a), 152.3 (C-2), 142.3 (C-8), 140.3 (C-9), 
132.6 (C-1b), 132.1 (d, J = 3.16 Hz, C-1a), 131.8 (q, JCF = 260.0 Hz, C-7b), 129.7 (2C, C-3b/5b), 
129.1 (d, J = 8.7 Hz, 2C, C-2a/6a), 125.8 (C-5), 125.6 (C-6), 125.5 (q, J = 3.9 Hz, 2C, C-2b/6b), 
122.5 (C-4), 117.5 (d, J = 22.8 Hz, 2C, C-3a/5a), 110.2 (C-7), 52.2 (C-11); 19F NMR (CDCl3, 
376.5 MHz) δ - 62.98; HRMS (m/z): 415.1078 M+ (calculated for C22H15F4N2O2: 415.1070). 
 
(C5f) methyl 1-(4-fluorophenyl)-2-(4-nitrophenyl)-1H-benzo[d]imidazole-5-carboxylate, 
yellow solid (70% yield); Purity 98%; mp 214-216 oC; UV λmax (MeOH) nm (log ε) 229 (2.84), 
320 (2.47); IR υmax 3078 (CH), 1714 (C=O), 1510 (N-O), 1380 (C-F), 1204 (C-O) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.60 (1H, bs, H-4), 8.18 (2H, d, J = 8.1 Hz, H-3b/5b), 8.04 (1H, d, J = 8.4 
185 
Hz, H-6), 7.76 (2H, d, J = 8.1 Hz, H-2b/6b), 7.32 (2H, m, H-2a/6a), 7.27 (2H, m, H-3a/5a), 7.23 
(1H, d, J = 8.4 Hz, H-7), 3.96 (3H, s, H-11); 13C NMR (CDCl3, 100 MHz) δ 167.1 (C-10), 162.9 
(d, JCF = 250.2 Hz, C-4a), 151.2 (C-4b), 148.4 (C-2), 142.0 (C-8), 140.3 (C-9), 134.9 (C-1b), 131.8 
(d, J = 3.1 Hz, C-1a), 130.3 (2C, C-2b/6b), 129.2 (d, J = 8.7 Hz, 2C, C-2a/6a), 126.2 (C-5), 126.1 
(C-6), 123.7 (2C, C-3b/5b), 122.6 (C-4), 117.7 (d, J = 22.8 Hz, 2C, C-3a/5a), 110.4 (C-7), 52.3 
(C-11); 19F NMR (CDCl3, 376.5 MHz) δ -109.63; HRMS (m/z): 392.1055 M+ (calculated for 
C21H15FN3O4: 392.1047). 
 
(C5g) methyl 1-(4-fluorophenyl)-2-p-tolyl-1H-benzo[d]imidazole-5-carboxylate,  white solid 
(80% yield); Purity 96%; mp 156-158 oC; UV λmax (MeOH) nm (log ε) 214 (3.21), 250 (3.36), 304 
(2.93); IR υmax 3074 (CH), 1711 (C=O), 1381 (C-F), 1185 (C-O) cm-1; 1H NMR (CDCl3, 400 MHz) 
δ 8.57 (1H, bs, H-4), 7.98 (1H, dd, J = 8.5, 1.3 Hz, H-6), 7.43 (2H, d, J = 8.1 Hz, H-2b/6b), 7.29 
(2H, dd, J = 8.7, 4.8 Hz, H-2a/6a), 7.21 (2H, t, J = 8.7 Hz, H-3a/5a), 7.18 (1H, d, J = 8.5 Hz, H-
7), 7.13 (2H, d, J = 8.1 Hz, H-3b/5b), 3.94 (3H, s, H-11), 2.34 (3H, s, H-7b); 13C NMR (CDCl3, 
100 MHz) δ 167.3 (C-10), 162.5 (d, JCF = 248.7 Hz, C-4a), 154.0 (C-2), 140.6 (C-8), 140.1 (2C, 
C-4/4b), 132.4 (d, J = 3.6 Hz, C-1a), 129.4 (2C, C-3b/5b), 129.3 (2C, C-2b/6b), 129.2 (d, J = 8.7 
Hz, 2C, C-2a/6a), 125.7 (C-1b), 125.5 (C-5), 125.1 (C-6), 121.8 (C-4), 117.2 (d, J = 22.8 Hz, 2C, 
C-3a/5a), 110.0 (C-7), 52.2 (C-11), 21.4 (C-7b); 19F NMR (CDCl3, 376.5 MHz) δ -111.18; HRMS 
(m/z): 361.1354 M+ (calculated for C22H18FN2O2: 361.1352). 
 
(C5h) methyl 1-(4-fluorophenyl)-2-(4-methoxyphenyl)-1H-benzo[d]imidazole-5-carboxylate, 
white solid (78% yield); Purity 98%; mp 138-140 oC; UV λmax (MeOH) nm (log ε) 225 (2.9), 258 
(3.0), 307 (2.75); IR υmax 3080 (CH), 1710 (C=O), 1385 (C-F), 1180 (C-O) cm-1; 1H NMR (CDCl3, 
186 
400 MHz) δ 8.54 (1H, d, J = 1.5 Hz, H-4), 7.96 (1H, dd, J = 8.5, 1.5 Hz, H-6), 7.48 (2H, d, J = 8.9 
Hz, H-2b/6b), 7.29 (2H, dd, J = 8.7, 4.8 Hz, H-2a/6a), 7.21 (2H, t, J = 8.7 Hz, H-3a/5a), 7.16 (1H, 
d, J = 8.5 Hz, H-7), 6.83 (2H, d, J = 8.9 Hz, H-3b/5b), 3.94 (3H, s, H-11), 3.79 (3H, s, H-7b); 13C 
NMR (CDCl3, 100 MHz) δ 167.6 (C-10), 162.5 (d, JCF = 248.6 Hz, C-4a), 161.0 (C-4b), 154.0 (C-
2), 142.3 (C-8), 140.3 (C-9), 132.6 (d, J = 3.3 Hz, C-1a), 131.0 (2C, C-2b/6b), 129.2 (d, J = 8.7 
Hz, 2C, C-2a/6a), 125.3 (C-5), 124.8 (C-6), 121.8 (C-4), 121.3 (C-1b), 117.2 (d, J = 22.7 Hz, 2C, 
C-3a/5a), 114.1 (2C, C-3b/5b), 109.9 (C-7), 55.3 (C-7b), 52.1 (C-11); 19F NMR (CDCl3, 376.5 
MHz) δ -111.23; HRMS (m/z): 377.1310 M+ (calculated for C22H18FN2O3: 377.1301). 
 
(C5i) methyl 2-(4-aminophenyl)-1-(4-fluorophenyl)-1H-benzo[d]imidazole-5-carboxylate, 
orange solid (75% yield); Purity 97%; mp 225-227 oC; UV λmax (MeOH) nm (log ε) 233 (3.51), 
327 (3.41); IR υmax 3473 (NH), 3077 (CH), 1710 (C=O), 1382 (C-F), 1197 (C-O) cm-1; 1H NMR 
(DMSO-d6, 400 MHz) δ 8.26 (1H, d, J = 1.3 Hz, H-4), 7.83 (1H, dd, J = 8.5, 1.3 Hz, H-6), 7.52 
(2H, dd, J = 8.7, 5.0 Hz, H-2a/6a), 7.44 (2H, t, J = 8.7 Hz, H-3a/5a), 7.21 (2H, d, J = 8.6 Hz, H-
2b/6b), 7.17 (1H, d, J = 8.5 Hz, H-7), 6.49 (2H, d, J = 8.6 Hz, H-3b/5b), 5.61 (2H, s, H-7b), 3.88 
(3H, s, H-11); 13C NMR (DMSO-d6, 100 MHz) δ 166.7 (C-10), 161.8 (d, JCF = 244.9 Hz, C-4a), 
155.1 (C-2), 150.6 (C-4b), 142.4 (C-8), 140.5 (C-9), 132.9 (d, J = 3.0 Hz, C-1a), 130.4 (2C, C-
2b/6b), 129.9 (d, J = 8.9 Hz, 2C, C-2a/6a), 123.9 (C-5), 123.6 (C-6), 120.0 (C-4), 117.0 (d, J = 
22.9 Hz, 2C, C-3a/5a), 115.4 (C-1b), 113.1 (2C, C-3b/5b), 110.0 (C-7), 52.0 (C-11); 19F NMR 




(C5j) methyl 1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate, 
white solid (80% yield); Purity 96%; mp 252-254 oC; UV λmax (MeOH) nm (log ε) 226 (2.88), 259 
(2.92), 308 (2.74); IR υmax 3058 (CH), 1710 (C=O), 1384 (C-F), 1196 (C-O) cm-1; 1H NMR 
(MeOH- d4, 400 MHz) δ 8.41 (1H, d, J = 1.4 Hz, H-4), 7.97 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.42 
(2H, dd, J = 8.7, 4.9 Hz, H-2a/6a), 7.38 (2H, d, J = 8.7 Hz, H-2b/6b), 7.33 (2H, t, J = 8.7 Hz, H-
3a/5a), 7.27 (1H, d, J = 8.6 Hz, H-7), 6.76 (2H, d, J = 8.7 Hz, H-3b/5b), 3.94 (3H, s, H-11); 13C 
NMR (MeOH- d4, 100 MHz) δ 168.8 (C-10), 164.1 (d, JCF = 246.7 Hz, C-4a), 161.1 (C-4b), 156.6 
(C-2), 143.0 (C-8), 141.5 (C-9), 133.8 (d, J = 3.4 Hz, C-1a), 132.4 (2C, C-2b/6b), 130.9 (d, J = 9.0 
Hz, 2C, C-2a/6a), 126.5 (C-5), 125.9 (C-6), 121.7 (C-4), 120.8 (C-1b), 118.1 (d, J = 23.2 Hz, 2C, 
C-3a/5a), 116.5 (2C, C-3b/5b), 111.5 (C-7), 52.7 (C-11); 19F NMR (MeOH- d4, 376.5 MHz) δ -
113.54; HRMS (m/z): 385.0970 M+ Na+ (calculated for C21H15FN2O3 Na: 385.0964). 
 
(C5k) methyl 2-(4-(dimethylamino)phenyl)-1-(4-fluorophenyl)-1H-benzo[d]imidazole-5-
carboxylate, brown solid (90% yield); Purity 87%; mp 184-186 oC; UV λmax (MeOH) nm (log ε) 
205 (3.18), 235 (3.30), 337 (3.23); IR υmax 3049 (CH), 1707 (C=O), 1363 (C-F), 1196 (C-O) cm-1; 
1H NMR (CDCl3, 400 MHz) δ 8.54 (1H, bs, H-4), 7.94 (1H, dd, J = 8.5, 1.4 Hz, H-6), 7.45 (2H, 
d, J = 8.9 Hz, H-2b/6b), 7.34 (2H, dd, J = 8.8, 4.8 Hz, H-2a/6a), 7.24 (2H, t, J = 8.8 Hz, H-3a/5a), 
7.13 (1H, d, J = 8.5 Hz, H-7), 6.59 (2H, d, J = 8.9 Hz, H-3b/5b), 3.95 (3H, s, H-11), 2.98 (6H, s, 
H-7b/8b); 13C NMR (CDCl3, 100 MHz) δ 167.5 (C-10), 162.3 (d, JCF = 248.0 Hz, C-4a), 154.8 (C-
4b), 151.1 (C-2), 142.4 (C-8), 140.4 (C-9), 133.1 (d, J = 3.2 Hz, C-1a), 130.5 (2C, C-2b/6b), 129.3 
(d, J = 8.7 Hz, 2C, C-2a/6a), 124.9 (C-1b), 124.3 (C-6), 121.3 (C-4), 117.0 (d, J = 22.8 Hz, 2C, C-
3a/5a), 115.7 (C-5), 111.4 (C-3b/5b), 109.4 (C-7), 52.0 (C-11), 40.0 (2C, C-7b/8b); 19F NMR 
188 




carboxylate, yellow solid (90% yield); Purity 90%; mp 182-184 oC; UV λmax (MeOH) nm (log ε) 
207 (3.16), 238 (3.21), 277 (2.96), 316 (3.14); IR υmax 3059 (CH), 1697 (C=O), 1377 (C-F), 1155 
(C-O) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.55 (1H, d, J = 1.4 Hz, H-4), 7.97 (1H, dd, J = 8.5, 
1.4 Hz, H-6), 7.46 (2H, d, J = 8.5 Hz, H-2b/6b), 7.30 (2H, dd, J = 7.2, 4.8 Hz, H-2a/6a), 7.22 (2H, 
t, J = 7.2 Hz, H-3a/5a), 7.19 (1H, d, J = 7.3 Hz, H-7), 7.14 (2H, d, J = 8.5 Hz, H-3b/5b), 3.94 (3H, 
s, H-11), 2.46 (3H, s, H-7b); 13C NMR (CDCl3, 100 MHz) δ 167.3 (C-10), 162.5 (d, JCF = 249.1 
Hz, C-4a), 153.5 (C-2), 142.2 (2C, C-9/4b), 140.1 (C-9), 132.3 (d, J = 3.2 Hz, C-1a), 129.6 (2C, 
C-2b/6b), 129.2 (d, J = 8.7 Hz, 2C, C-2a/6a), 125.6 (C-1b), 125.5 (2C, C-3b/5b), 125.2 (C-6), 
124.8 (C-5), 121.8 (C-4), 117.3 (d, J = 22.8 Hz, 2C, C-3a/5a), 109.9 (C-7), 52.2 (C-11), 14.9 (C-
7b); 19F NMR (CDCl3, 376.5 MHz) δ -110.83; HRMS (m/z): 415.0885 M+ + Na+ (calculated for 
C22H17FN2O2SNa: 415.0892). 
 
(C5m) methyl 1-(4-fluorophenyl)-2-(naphthalen-2-yl)-1H-benzo[d]imidazole-5-carboxylate, 
marigold solid (85% yield); Purity 99%; mp 169-171 oC; UV λmax (MeOH) nm (log ε) 210 (3.33), 
252 (3.62), 311 (3.10); IR υmax 3064 (CH), 1701 (C=O), 1362 (C-F), 1156 (C-O) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.61 (1H, bs, H-4), 8.09 (1H, s, H-2b), 8.01 (1H, dd, J = 8.6, 1.2 Hz, H-6), 
7.80 (1H, d, J = 8.2 Hz, H-9b), 7.75 (2H, t, J = 8.8 Hz, H-4b/7b), 7.58 (1H, dd, J = 8.2, 1.6 Hz, H-
10b), 7.51 (1H, t, J = 7.0 Hz, H-5b*), 7.47 (1H, t, J = 7.0 Hz, H-6b*), 7.33 (2H, dd, J = 8.2, 4.7 
Hz, H-2a/6a), 7.22 (1H, d, J = 8.6 Hz, H-7), 7.20 (2H, t, J = 8.2 Hz, H-3a/5a), 3.96 (3H, s, H-11); 
189 
13C NMR (CDCl3, 100 MHz) δ 167.4 (C-10), 162.5 (d, JCF = 248.8 Hz, C-4a), 154.0 (C-2), 142.4 
(C-8), 140.3 (C-9), 133.7 (C-3b), 132.8 (C-1b), 132.6 (d, J = 3.2 Hz, C-1a), 130.0 (C-2b), 129.2 
(d, J = 8.7 Hz, 2C, C-2a/6a), 128.7 (C-7b), 128.2 (C-4b), 127.5 (C-9b#), 127.7 (C-6b#), 126.7 (C-
5b), 126.4 (C-5), 125.8 (C-10b), 125.5 (C-8b), 125.2 (C-6), 122.2 (C-4), 117.2 (d, J = 22.8 Hz, 
2C, C-3a/5a), 110.0 (C-7), 52.2 (C-11); 19F NMR (CDCl3, 376.5 MHz) δ -110.01; HRMS (m/z): 
397.1349 M+ (calculated for C25H18FN2O2: 397.1352).  * and # assignments may be interchanged. 
 
(C5n) (E)-methyl 1-(4-fluorophenyl)-2-styryl-1H-benzo[d]imidazole-5-carboxylate, white 
solid (87% yield); Purity 97%; mp 210-212 oC; UV λmax (MeOH) nm (log ε) 227 (3.21), 268 (3.04), 
332 (3.06); IR υmax 3078 (CH), 1704 (C=O), 1635 (C=C), 1392 (C-F), 1154 (C-O) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.52 (1H, bs, H-4), 8.05 (1H, d, J = 16.0 Hz, H-1b), 7.95 (1H, dd, J = 8.5, 
1.0 Hz, H-6), 7.46 (2H, m, H-4b/8b), 7.43 (2H, m, H-2a/6a), 7.31-7.35 (5H, m, H-5b, H-6b, H-7b, 
H-3a/5a), 7.13 (1H, d, J = 8.5 Hz, H-7), 6.74 (1H, d, J = 16.0 Hz, H-2b), 3.94 (3H, s, H-11); 13C 
NMR (CDCl3, 100 MHz) δ 167.4 (C-10), 162.8 (d, JCF = 249.1 Hz, C-4a), 152.5 (C-2), 142.3 (C-
8), 139.6 (C-9), 138.9 (C-1b), 135.5 (C-3b), 130.9 (d, J = 3.1 Hz, C-1a), 129.5 (2C, C-5b/7b), 
129.4 (2C, d, J = 8.8 Hz, C-2a/6a), 128.8 (C-6b), 127.4 (2C, C-4b/8b), 125.6 (C-5), 124.9 (C-6), 
121.5 (C-4), 117.3 (d, J = 23.9 Hz, 2C, C-3a/5a), 112.8 (C-2b), 109.6 (C-7), 52.2 (C-11); 19F NMR 




carboxylate, marigold solid (85% yield); Purity 98%; mp 228-230 oC; UV λmax (MeOH) nm (log 
ε) 257 (3.43), 321 (2.94), 336 (2.98); IR υmax 3068 (CH), 1702 (C=O), 1386 (C-F), 1190 (C-O), 
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750 (C-Cl) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.64 (1H, bs, H-4), 8.47 (1H, d, J = 8.6 Hz, H-
9b), 8.21 (1H, d, J = 8.6 Hz, H-10b), 8.03 (1H, dd, J = 8.6, 1.3 Hz, H-6), 7.72 (1H, d, J = 9.2 Hz, 
H-4b), 7.46 (2H, m, H-5b/7b), 7.38 (2H, dd, J = 9.2, 4.8 Hz, H-2a/6a), 7.24 (2H, t, J = 9.2 Hz, H-
3a/5a), 7.19 (1H, d, J = 8.6 Hz, H-7), 3.96 (3H, s, H-11); 13C NMR (CDCl3, 100 MHz) δ 167.3 (C-
10), 162.5 (d, JCF = 247.3 Hz, C-4a), 151.2 (C-2), 149.2 (C-1b), 147.3 (C-8b), 141.9 (C-8), 141.2 
(C-9), 136.5 (C-10b), 135.8 (C-6b), 133.7 (d, J = 3.1 Hz, C-1a), 129.6 (d, J = 8.7 Hz, 2C, C-2a/6a), 
128.8 (C-7b*), 128.6 (C-5b*), 128.5 (C-4b), 126.2 (C-3b), 126.0 (C-6), 125.8 (C-5), 122.7 (C-4), 
121.6 (C-9b), 116.3 (d, J = 22.8 Hz, 2C, C-3a/5a), 110.7 (C-5), 52.2 (C-11); 19F NMR (CDCl3, 
376.5 MHz) δ -112.10; HRMS (m/z): 432.0931 M+ (calculated for C24H16ClFN3O2: 432.0915). 
*assignments may be interchanged. 
 
(C5p) methyl 1-(4-fluorophenyl)-2-(2-hydroxy-4,6-dimethoxyphenyl)-1H-
benzo[d]imidazole-5-carboxylate,  white solid (65% yield); Purity 99%; mp 68-70 oC; UV λmax 
(MeOH) nm (log ε) 229 (2.86), 267 (2.33), 297 (3.93); IR υmax 3398 (O-H), 3074 (CH), 1712 
(C=O), 1359 (C-F), 1153 (C-O) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.51 (1H, bs, H-4), 8.00 (1H, 
dd, J = 8.5, 1.0 Hz, H-6), 7.31 (1H, d, J = 8.5 Hz, H-7), 7.26 (2H, dd, J = 8.6, 4.9 Hz, H-2a/6a), 
7.16 (2H, t, J = 8.6 Hz, H-3a/5a), 6.32 (1H, d, J = 1.9 Hz, H-3b), 5.77 (1H, d, J = 1.9 Hz, H-5b), 
3.94 (3H, s, H-11), 3.77 (3H, s, H-8b), 3.15 (3H, s, H-9b); 13C NMR (CDCl3, 100 MHz) δ 167.2 
(C-10), 163.1 (C-4b), 162.2 (d, JCF = 247.1 Hz, C-4a), 160.1 (C-2b), 157.6 (C-6b), 151.8 (C-2), 
140.4 (C-8), 138.5 (C-9), 133.8 (d, J = 2.8 Hz, C-1a), 126.9 (d, J = 8.5 Hz, 2C, C-2a/6a), 125.5 
(C-5), 125.0 (C-6), 120.7 (C-4), 116.3 (d, J = 22.8 Hz, 2C, C-3a/5a), 110.0 (C-7), 96.2 (C-1b), 
94.0 (C-3b), 90.8 (C-5b), 55.4 (C-8b), 54.3 (C-9b), 52.2 (C-11); 19F NMR (CDCl3, 376.5 MHz) δ 
-112.41; HRMS (m/z): 445.1168 M+ Na+ (calculated for C23H19FN2O5 Na: 445.1176). 
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(C5q) methyl 2-(3,4-dihydroxyphenyl)-1-(4-fluorophenyl)-1H-benzo[d]imidazole-5-
carboxylate, cream solid (65% yield); Purity 97%; mp 230-232 oC; UV λmax (MeOH) nm (log ε) 
226 (3.17), 264 (2.91), 313 (2.85); IR υmax 3501 (O-H), 3062 (CH), 1712 (C=O), 1377 (C-F), 1177 
(C-O) cm-1; 1H NMR (MeOH- d4, 400 MHz) δ 8.40 (1H, d, J = 1.5 Hz, H-4), 7.97 (1H, dd, J = 8.5, 
1.5 Hz, H-6), 7.42 (2H, dd, J = 8.7, 4.9 Hz, H-2a/6a), 7.33 (2H, t, J = 8.7 Hz, H-3a/5a), 7.26 (1H, 
d, J = 8.5 Hz, H-7), 7.01 (1H, d, J = 2.1 Hz, H-2b), 6.86 (1H, dd, J = 8.2, 2.2 Hz, H-6b), 6.7 (1H, 
d, J = 8.2 Hz, H-5b), 3.95 (3H, s, H-11); 13C NMR (MeOH- d4, 100 MHz) δ 168.8 (C-10), 164.1 
(d, JCF = 246.8 Hz, C-4a), 156.9 (C-2), 149.2 (C-3b), 146.6 (C-4b), 143.0 (C-8), 141.5 (C-9), 133.8 
(d, J = 2.8 Hz, C-1a), 130.9 (d, J = 8.9 Hz, 2C, C-2a/6a), 126.5 (C-5), 125.9 (C-6), 123.1 (C-6b), 
121.6 (C-4), 121.2 (C-1b), 118.1 (2C, d, J = 23.2 Hz, C-3a/5a), 117.7 (C-2b), 116.3 (C-5b), 111.5 
(C-7), 52.7 (C-11); 19F NMR (MeOH- d4, 376.5 MHz) δ -113.67; HRMS (m/z): 379.1094 M+ 
(calculated for C21H16FN2O4: 379.1110). 
 
(C5r) methyl 1-(4-fluorophenyl)-2-(2,3,4-trihydroxyphenyl)-1H-benzo[d]imidazole-5-
carboxylate, green solid (85% yield); Purity 99%; mp 214-216 oC; UV λmax (MeOH) nm (log ε) 
230 (3.27), 322 (3.0); IR υmax 3483 (O-H), 3069 (CH), 1709 (C=O), 1345 (C-F), 1152 (C-O) cm-1; 
1H NMR (MeOH- d4, 400 MHz) δ 8.34 (1H, d, J = 1.4 Hz, H-4), 7.92 (1H, dd, J = 8.5, 1.4 Hz, H-
6), 7.46 (2H, dd, J = 8.7, 4.9 Hz, H-2a/6a), 7.36 (2H, t, J = 8.7 Hz, H-3a/5a), 7.12 (1H, d, J = 8.5 
Hz, H-7), 6.35 (1H, d, J = 8.9 Hz, H-6b), 6.15 (1H, d, J = 8.9 Hz, H-5b), 3.93 (3H, s, H-11); 13C 
NMR (MeOH- d4, 100 MHz) δ 168.9 (C-10), 164.4 (d, JCF = 247.2 Hz, C-4a), 155.2 (C-2), 149.5 
(C-4b), 149.4 (C-2b), 141.5 (C-8), 141.0 (C-9), 134.6 (C-3b), 134.2 (d, J = 3.3 Hz, C-1a), 131.1 
(d, J = 8.9 Hz, 2C, C-2a/6a), 126.5 (C-5), 125.8 (C-6), 121.0 (C-4), 120.4 (C-6b), 118.3 (d, J = 
23.3 Hz, 2C, C-3a/5a), 111.0 (C-7), 107.8 (C-5b), 106.5 (C-1b), 52.7 (C-11); 19F NMR (MeOH- 
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d4, 376.5 MHz) δ -113.12; HRMS (m/z): 417.0874 M+ + Na+ (calculated for C21H15FN2O5Na: 
417.0863). 
 
(C5s) methyl 1-(4-fluorophenyl)-2-(thiophen-2-yl)-1H-benzo[d]imidazole-5-carboxylate, 
white solid (74% yield); Purity 90%; mp 156-158 oC; UV λmax (MeOH) nm (log ε) 219 (3.26), 254 
(3.28), 322 (3.18); IR υmax 3073 (CH), 1711 (C=O), 1386 (C-F), 1192 (C-O) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.53 (1H, bs, H-4), 7.95 (1H, dd, J = 8.5, 1.0 Hz, H-6), 7.41 (2H, dd, J = 8.2, 
4.8 Hz, H-2a/6a), 7.39 (1H, d, J = 4.4 Hz, H-3b), 7.30 (2H, t, J = 8.2 Hz, H-3a/5a), 7.03(1H, d, J 
= 8.5 Hz, H-7), 7.02 (1H, bs, H-5b), 6.95 (1H, t, J = 4.4 Hz, H-4b), 3.93 (3H, s, H-11); 13C NMR 
(CDCl3, 100 MHz) δ 167.3 (C-10), 163.2 (d, JCF = 249.6 Hz, C-4a), 149.0 (C-2), 142.2 (C-8), 
142.1 (C-1b), 140.6 (C-9), 131.7 (d, J = 3.4 Hz, C-1a), 130.2 (d, J = 8.8 Hz, 2C, C-2a/6a), 129.4 
(C-3b), 129.2 (C-5b), 127.7 (C-4b), 125.5 (C-5), 125.1 (C-6), 121.7 (C-4), 117.5 (d, J = 22.8 Hz, 
2C, C-3a/5a), 109.7 (C-7), 52.1 (C-11); 19F NMR (CDCl3, 376.5 MHz) δ -109.62; HRMS (m/z): 
353.0761 M+ (calculated for C19H14FN2O2S: 353.0760). 
 
(C5t) methyl 1-(4-fluorophenyl)-2-(furan-2-yl)-1H-benzo[d]imidazole-5-carboxylate, dark 
brown solid (76% yield); Purity 98%; mp 139-141 oC; UV λmax (MeOH) nm (log ε) 258 (3.15), 
313 (3.11), 326 (3.01); IR υmax 3069 (CH), 1711 (C=O), 1359 (C-F), 1195 (C-O) cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.53 (1H, d, J = 1.4 Hz, H-4), 7.96 (1H, dd, J = 8.5, 1.4 Hz, H-6), 7.48 (1H, 
bs, H-3b), 7.40 (2H, dd, J = 8.5, 4.7 Hz, H-2a/6a), 7.29 (2H, td, J = 8.5 Hz, H-3a/5a), 7.06 (1H, d, 
J = 8.5 Hz, H-7), 6.39-6.40 (2H, m, H-4b/5b), 3.93 (3H, s, H-11); 13C NMR (CDCl3, 100 MHz) δ 
167.3 (C-10), 163.0 (d, JCF = 249.2 Hz, C-4a), 145.7 (C-2), 144.9 (C-3b), 143.6 (C-8), 140.0 (C-
9), 131.7 (d, J = 3.2 Hz, C-1a), 129.8 (d, J = 8.8 Hz, 2C, C-2a/6a), 125.7 (C-5), 125.4 (C-6), 122.0 
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(C-4), 117.2 (d, J = 22.8 Hz, 2C, C-3a/5a), 113.6 (C-5b), 111.8 (C-4b), 109.8 (C-7), 52.1 (C-11); 
19F NMR (CDCl3, 376.5 MHz) δ -110.00; HRMS (m/z): 337.0994 M+ (calculated for 
C19H14FN2O3: 337.0988). 
 
(C5u) methyl 1-(4-fluorophenyl)-2-propyl-1H-benzo[d]imidazole-5-carboxylate, cream solid 
(70% yield); Purity 100%; mp 102-104 oC; UV λmax (MeOH) nm (log ε) 227 (3.16), 267 (2.40); 
IR υmax 3083 (CH), 1715 (C=O), 1360 (C-F), 1166 (C-O) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.49 
(1H, d, J = 1.4 Hz, H-4), 7.94 (1H, dd, J = 8.5, 1.4 Hz, H-6), 7.34 (2H, dd, J = 8.2, 5.2 Hz, H-
2a/6a), 7.29 (2H, t, J = 8.2 Hz, H-3a/5a), 7.05 (1H, d, J = 8.5 Hz, H-7), 3.92 (3H, s, H-11), 2.76 
(2H, t, J = 7.5 Hz, H-1b), 1.76-1.86 (2H, sestet, H-2b), 0.94 (3H, t, J = 7.5 Hz, H-3b); 13C NMR 
(CDCl3, 100 MHz) δ 167.4 (C-10), 162.8 (d, JCF = 249.3 Hz, C-4a), 156.9 (C-2), 141.7 (C-8), 
139.5 (C-9), 131.2 (d, J = 2.8 Hz, C-1a), 129.2 (d, J = 8.8 Hz, 2C, C-2a/6a), 125.1 (C-5), 124.8 
(C-6), 121.2 (C-4), 117.3 (d, J = 22.8 Hz, 2C, C-3a/5a), 109.6 (C-7), 52.1 (C-11), 29.4 (C-1b), 
21.1 (C-2b), 13.9 (C-3b); 19F NMR (CDCl3, 376.5 MHz) δ -110.53; HRMS (m/z): 335.1161 M+ + 
Na+ (calculated for C18H17FN2O2Na: 335.1172). 
 
(C5v) methyl 1-(4-fluorophenyl)-2-hexyl-1H-benzo[d]imidazole-5-carboxylate, brown solid 
(70% yield); Purity 61%; mp 66-68 oC; UV λmax (MeOH) nm (log ε) 227 (3.53), 264 (2.81); IR 
υmax 3075 (CH), 1708 (C=O), 1399 (C-F), 1156 (C-O) cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.48 
(1H, bs, H-4), 7.94 (1H, dd, J = 8.5, 1.2 Hz, H-6), 7.36 (2H, dd, J = 8.6, 5.0 Hz, H-2a/6a), 7.30 
(2H, t, J = 8.6 Hz, H-3a/5a), 7.06 (1H, d, J = 8.5 Hz, H-7), 3.94 (3H, s, H-11), 2.76 (2H, t, J = 7.5 
Hz, H-1b), 1.77 (2H, quintet, J = 7.5 Hz, H-2b), 1.25-1.35 (2H, m, H-3b), 1.23-1.26 (2H, m, H-
5b), 0.88-0.90 (2H, m, H-4b), 0.84 (3H, t, J = 6.8 Hz, H-6b); 13C NMR (CDCl3, 100 MHz) δ 167.6 
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(C-10), 162.9 (d, JCF = 249.0 Hz, C-4a), 157.2 (C-2), 141.7 (C-8), 139.6 (C-9), 131.5 (d, J = 3.1 
Hz, C-1a), 129.2 (d, J = 8.8 Hz, 2C, C-2a/6a), 124.8 (C-5), 124.5 (C-6), 121.3 (C-4), 117.2 (d, J = 
22.8 Hz, 2C, C-3a/5a), 109.4 (C-7), 52.0 (C-11), 31.3 (C-4b), 28.9 (C-3b), 27.6 (C-1b), 27.6 (C-
2b), 22.4 (C-5b), 13.9 (C-6b); 19F NMR (CDCl3, 376.5 MHz) δ -110.80; HRMS (m/z): 355.1816 
M+ (calculated for C21H24FN2O2: 355.1822). 
1bs-broad singlet. 
 
7.2.2 Single Crystal X-ray Diffraction Analysis 
Crystals suitable for X-ray diffraction were obtained by slow evaporation in a combination of ethyl 
acetate and n-hexane at room temperature.  A cube-shaped single crystal was selected and glued 
onto the tip of a glass fiber and mounted in a stream of cold nitrogen at 173 K and centered in the 
X-ray beam using a video camera.  The crystal evaluation and data collection were performed on 
a Bruker Smart APEX II diffractometer with Mo Kα radiation (λ = 0.71073 Å). The diffractometer 
to crystal distance was set at 4.00 cm.  The initial cell matrix was obtained from three series of 
scans at different starting angles.  Each series consisted of 12 frames collected at intervals of 0.5° 
in a 6° range with the exposure time of 10s per frame.  The reflections were successfully indexed 
by an automated indexing routine built in the APEX II program suite.  The final cell constants 
were calculated from a set of 4762 strong reflections from the actual data collection.  Data 
collection method involved ω scans of width 0.5°.  Data reduction was carried out using the 
program System Administrator’s Integrated Network Tool+. The structure was solved by direct 
methods using SHELXS and refined. Non-H atoms were first refined isotropically and then by 
anisotropic refinement with full-matrix least-squares calculations based on F2 using SHELXS.  All 
H atoms were positioned geometrically and allowed to ride on their respective parent atoms.  All 
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H atoms were refined isotropically.  The absorption correction was based on fitting a function to 
the empirical transmission surface as sampled by multiple equivalent measurements.  The final 
least-squares refinement of 265 parameters against 4762 data resulted in residuals R (based on F2 
for I ≥ 2σ) and wR (based on F2 for all data) of 0.0465 and 0.1048, respectively.  The final 
difference Fourier map was featureless.  The programs Olex-2 and Ortep-3 were used within the 
WinGX software package to prepare artwork representation (Spek et al., 2003; Farrugia et al., 
2012).  Crystallographic data (excluding structure factors) for the structure in this paper has been 
deposited with the Cambridge Crystallographic Data Centre, CCDC, 12 Union Road, Cambridge 
CB21EZ, UK.  Copies of the data can be obtained free of charge on quoting the depository number 
CCDC 1454700 (Fax: +44-1223-336-033; E-Mail: deposit@ccdc.cam.ac.uk, 
http://www.ccdc.cam.ac.uk). 
 
7.2.3 In vitro antimicrobial studies 
The microbial cultures were grown overnight at 37 °C in nutrient broth (UKZN Biolab, South 
Africa), adjusted to 0.5 McFarland standard using distilled water and lawn inoculated onto 
Mueller-Hinton agar (MHA) plates.  A volume of 10 µL of each sample (23.20 - 32.04 µM in 1 
mL DMSO) was inoculated onto antibiotic assay discs (6 mm diameter) and placed on the MHA 
plates which were incubated overnight at 37°C for 24 hours. After the incubation period, zones of 
inhibition were measured in mm.  Compounds showing an inhibition zone of > 9 mm were selected 
to determine their MBC values using the broth dilution assay with ampicillin and ciprofloxacin as 
the controls following the method in Andrews (2001).  Compounds C5b, C5e, C5h, C5k-l, and 
C5o-t were chosen for the broth dilution method to determine their MBCs. 
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For the broth dilution method the microbial cultures (adjusted to 0.5 McFarland) were prepared as 
described previously for the disc diffusion method.  The test compounds were dissolved in DMSO 
(10 mg mL-1) and subject to a 50% serial dilution in 1 mL Eppendorf tubes with Mueller-Hinton 
Broth (MHB), inoculated with bacterial cultures (20 µL) and then incubated at 37 °C for 18 h.  The 
total volume in each Eppendorf was 200 µL.  A volume of 10 µL of each dilution was spotted on 
MHA plates and incubated at 37 °C for 18 h to determine the MBC (µM). Ampicillin, ciprofloxacin 
and tioconazole served as the standard drugs for the antimicrobial and antifungal studies 
respectively.  All experiments were performed in duplicate. 
 
7.2.4 In vitro antioxidant studies 
The scavenging activity (antioxidant capacity) of the synthesized fluorinated benzimidazole 
compounds (C5a-v) on the stable radical, DPPH was evaluated according to a method by Murthy 
(Murthy et al., 2012) with some modifications.  A volume of 150 µL of methanolic solution of the 
test compounds at different concentrations (1000, 500, 200, 50, 20 and 10 µg mL-1) was mixed 
with 2850 µL of the methanolic solution of DPPH (0.1 mM). An equal amount of MeOH and 
DPPH without sample served as a control.  After 30 min of reaction at room temperature in the 
dark, the absorbance was measured at 517 nm against methanol as a blank using a UV 
spectrophotometer as mentioned above.  The percentage free radical scavenging activity was 
calculated according to the following equation: 
% Scavenging activity = [(Acontrol – Asample) / Ablank] x 100 
Where 'Acontrol' is the absorbance of the control reaction (containing all reagents except the test 
compound) and 'Asample' is the absorbance of the reagents with a particular test compound. 
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7.2.5 Docking methodology 
The “Prepare Protein” module was used to protonate the amino acid residues of the X-ray structure 
of topoisomerase II DNA-gyrase (PDB ID: 2XCT, resolution 3.35Å).  The native ligand and water 
molecules were removed from the protein, while the manganese ion (Mn+2) present in the active 
site was retained.  Different isomers of the representative compounds (RCs) (C5h and C5r) were 
generated at physiological pH using the “Prepare Ligands” module and subsequently minimized.  
The partial atomic charges on each atom were developed using the CHARMm force field.  A 
binding sphere of diameter 7.6 Å was developed around the active site residues.  The automated 
docking was performed using the CDocker algorithm (Wu et al., 2003) by generating new 
conformations of the ligands using the molecular dynamics method.  The best pose of each RC 
was chosen based on the scoring function (-CDOCKER energy), and subjected further to the 
binding energy calculations.  
 
7.3 Results and Discussion 
7.3.1 Chemistry 
Three fundamental methodologies were used in this study: microwave, conventional and 
mechanochemical synthesis.  A series of 22 benzimidazole molecules (C5a-v) were synthesized 
employing these synthetic methods with different substituents at C-2 on the benzimidazole 
skeleton.  The different substituents were all aldehyde derived and are indicated in Table 7-1.  
These contained para halogenated phenyl groups, phenyl groups with para substituted electron 
donating and withdrawing groups as well as other heterocyclic ring moieties such as quinoline, 
furan, naphthalene and thiophene and the alkyl chains butane and heptane.  In addition to the 
different substituents present on the aromatic ring attached to C-2, an ester moiety was present at 
C-5 and a p-fluoro benzyl moiety at N-1 (Scheme 7-1). 
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The synthesis started with the esterification of 4-fluoro-3-nitrobenzoic acid (C1), since the 
subsequent nucleophilic step is easier to perform with esters rather than acids due to the acidic 
nature of benzoic acids.  The conversion to the ester (C2) occurred in 95% yield.  The fluoro 
substituent on the ester was then substituted with 4-fluoroanilne producing C3 in a 90% yield.  
Prior to the aldehyde being added, the nitro group of the methyl benzoate (C3) was reduced (92% 
yield) with zinc and ammonium formate forming the o-diamino phenyl precursor (C4) to the 
benzimidazoles (Scheme 7-1). 
 
In the last step of the synthesis, different aldehydes were added to the precursor C4 using three 
methods: (i) without the use of solvents or catalysts in a microwave at 110 ºC, (ii) grinding 
equimolar amounts of C4 and the aldehydes in the presence iodine as a catalyst at room 
temperature and (iii) refluxing the amino benzoate (C4) and various aldehydes with ethanol in the 
presence of Na2S2O5 to produce 22 benzimidazoles (C5a-v).  The probable mechanism of the final 
step is imine formation of the aldehyde with the primary amino group followed by nucleophilic 
attack by the secondary amine to the imine carbon.  Proton transfer from one nitrogen to the other 
followed by loss of H2 resulted in the formation of the benzimidazoles C5a- C5v (Scheme 7-2).  
Their structures were confirmed by NMR spectroscopy (1D and 2D NMR) and single crystal X-




Scheme 7-2  The proposed mechanism for the final step of the benzimidazole synthesis 
 
Three different methods (microwave, mechanochemical and conventional reflux) were employed 
to synthesize the benzimidazoles (C5a-v) to investigate the best possible method for the final step 
of the synthesis.  Using microwave synthesis, the reaction was carried out without the use of 
solvents and a catalyst and performed at 110 ºC for 3-8 minutes with overall yields of between 85-
96% (Table 7-1).  In the grinding method, the reaction was carried out at room temperature in the 
presence of iodine.  This process lasted for between 10-40 minutes.  The yields obtained for this 
reaction was 10-56%.  The conventional reflux method containing ethanol as a solvent and 
Na2S2O5 as the catalyst produced yields of 60-90%.  The time taken for the reaction to occur was 
the longest in the conventional reflux method (8-18 h) followed by the grinding method (10-45 
min) and then the microwave method (3-8 min).  The yields of the microwave reaction were by 
far the best (85-97%) followed by the reflux method (60-90%) and lastly the grinding method (10-
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56%).  In the grinding method starting material was still detected after the reactants were ground 
together in a mortar and pestle, accounting for the low yields of the reaction.  In terms of economy, 
the microwave method was the best, using only the starting materials.  A solvent and catalyst was 
not needed to produce the products in high yields.   
 
7.3.2 Structural elucidation  
Using C5i (methyl 2-(4-aminophenyl)-1-(4-fluorophenyl)-1H-benzo[d]imidazole-5-carboxylate) 
as a representative fluorinated benzimidazole, H-7, H-6 and H-4 on the benzimidazole core 
skeleton occurs at δΗ 7.17 (d, J = 8.5 Hz), δΗ 7.83 (dd, J = 8.5, 1.5 Hz) and δΗ 8.26 (d, J = 1.3 Hz) 
respectively.  The ester methyl resonance (H-11) occurred as a singlet at δΗ 3.89.  The ester 
carbonyl resonance (C-10) was identified from the HMBC correlation to H-11 and appeared at δC 
166.7.  The two aromatic C-N singlet resonances C-8 and C-9 were assigned to δC 142.4 and 
δC 140.5.  The C-8 resonance was distinguished from C-9 due to an HMBC correlation with H-6.   
The C-5 resonance to which the ester group was attached was assigned to δC 123.9.  This resonance 
showed an HMBC correlation to H-7.  The C-2 carbon on the imidazole core skeleton was present 
at δC 155.1.    
 
The aromatic protons of phenyl group H2a/6a appeared as a dd at δΗ 7.52 Hz with J = 9.8, 5.0 Hz), 
coupling to both F and H3a/5a, which resonated at δΗ  7.44 Hz, appearing as a triplet due to the 
same J values (8.6 Hz) for both coupling to the F and to H-2a/6a.  The C-4a fluorinated carbon 
resonance occurred as a doublet at δ 161.8 (J = 244.9 Hz).  These assignments were supported by 
HMBC correlations between C-4a and H-2a/6a as well as H-3a/5a and C-1a which occurred at δ 
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132.9 (d, J = 3.0 Hz).  C-2a/6a appeared as a doublet at δ 129.9 (J = 8.9 Hz) and C-3a/5a appeared 
as a doublet at δ 117.0 (J = 22.9 Hz). 
 
Table 7-1  Comparison of the yields and duration of the final step in the benzimidazole synthesis 
using three methods 
No. R Microwave Grinding Conventional 











C5a Ph 3 96 10 55 10 90 
C5b 4-F Ph 3 93 10 53 8 85 
C5c 4-Cl Ph 3 89 10 50 10 75 
C5d 4-Br Ph 3 85 10 48 10 74 
C5e 4-CF3 Ph 5 90 10 45 8 70 
C5f 4-NO2 Ph 8 85 45 20 18 60 
C5g 4-CH3 Ph 6 88 20 30 12 72 
C5h 4-OCH3 Ph 6 90 25 25 16 60 
C5i 4-NH2 Ph 5 85 20 10 18 65 
C5j 4-OH Ph 5 90 10 20 16 70 
C5k 4-N(CH3)2 Ph 5 90 20 35 12 87 
C5l 4-S(CH3) Ph  4 90 20 40 16 85 
C5m 2-Naphthyl 5 95 20 56 12 80 
C5n α-(E)-prop-1-en-1-yl Ph  5 97 25 50 12 75 
C5o 2-(6-Chloroquinolinyl) 6 92 25 50 12 73 
C5p 2-OH-4,6-(OCH3)2 Ph 5 90 30 30 16 60 
C5q 3,4-(OH)2 Ph 4 85 35 20 16 60 
C5r 2,3,4-(OH)3 Ph 8 85 40 20 16 76 
C5s 2-Thiophenyl 3 95 30 50 15 75 
C5t 2-Furanyl 3 95 30 50 15 75 
C5u n-Butyl 6 90 25 30 18 70 
C5v n-Heptyl 6 90 25 30 18 70 
aIsolated yield after column chromatography,  bStarting material was not consumed totally and yield was after 
purification; Some amount starting materials and imine were also isolated.  
 
For the phenyl group (B) attached to C-2, the aromatic proton resonance of H2b/6b appeared as a 
doublet at δΗ 7.21 (J = 8.6 Hz) and H3b/5b appeared at δH 6.49 (d, J = 8.6 Hz).  An HMBC 
correlation between the corresponding C-3b/5b carbon resonance at δ 113.1 and the proton 
resonance at δH 5.61 confirmed the assignment of C-3b/5b and allowed the NH2 proton resonance 
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to be assigned to δH 5.61.  The assignment of H-2b/6b was confirmed by a HMBC correlation with 




Figure 7-1  Selected HMBC correlations of compound C5i (H→C) 
7.3.3 Antimicrobial activity 
The synthesized compounds were tested for their antibacterial and antifungal activity in vitro 
against the Gram +ve bacterial strains: Staphylococcus aureus (ATCC 25923) and methicillin 
resistant S. aureus (MRSA) (ATCC BAA-1683) and Gram -ve strains (Escherichia coli (ATCC 
25922), Klebsiella pneumonia (ATCC 31488) and Pseudomonas aeruginosa (ATCC 27853)) 
using ciprofloxacin and ampicillin as the standards.  For the antifungal assay C. albicans (ATCC 
10231) was tested against with tioconazole as the reference drug.  A disc diffusion assay was used 
as an initial screening test to select potentially active compounds.  The results were expressed as 
the mean zone of inhibition in mm using a concentration of 10 mg mL-1 of the test samples.  The 
test samples that showed a zone of inhibition between 8-35 mm was selected for further tests using 
the Minimum Bactericidal Concentration (MBC) assay.  The samples chosen were C5b, C5e, C5h, 
C5k-l and C5o-t. 
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Compounds C5r and C5p showed broad spectrum activity against all strains of bacteria with the 
exception of MRSA (Table 7-2).  Their MBC values ranged between 14.45-115.65 µM (C5p) and 
25.55-74.32 µM (C5r).  The activity of both these compounds were 10 fold or greater, higher than 
that of ampicillin in the same assay.  Compound C5r was 2b,3b,4b-trisubstituted with hydroxyl 
groups at each of the positions on the aromatic B ring and C5p was 2b,4b,6b-trisubstituted with a 
hydroxy group at the 2b-position and methoxy groups at the 4b and 6b positions.  Consequently, 
these were the only two trioxygenated molecules from the 22 compounds that was synthesized.  It 
is likely that this oxygenation has something to do with its broad spectrum activity.  However, the 
test compounds were not as active as ciprofloxacin whose MBC was at least one order of 
magnitude better than the test compounds, including C5r and C5p. 
 
The other compound worth mentioning is C5e with a trifluoromethane moiety at the para position 
of the aromatic B ring.  This compound was active against MRSA with an MBC of 70.73 µM and 
against K. pneumonia (24.32 µM) and C. albicans (94.33 µM).  With regard to antifungal activity, 
only C5e showed comparable activity to Tioconozole (MBC of 100.84 µM) against C. albicans. 
 
7.3.4 Antioxidant activity 
For antioxidant activity, the DPPH radical scavenging activity assay was used.  The DPPH radical 
scavenging assay measures the ability to scavenge free radicals in situ (Murthy et al., 2012).  The 
trioxygenated compounds C5r (306.71 µM, IC50) and C5p (386.55 µM, IC50) with hydroxy and 
methoxy groups showed antioxidant activity comparable to ascorbic acid (264.50 µM, IC50) (Table 
7-3).  Two other compounds, C5q (1129.01 µM, IC50) with dihydroxy moieties and C5j with a 
monohydroxy group (1326.93 µM, IC50) was five times worse than ascorbic acid.   All the other 
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compounds were greater than five times worse than ascorbic acid.  Thus, the only compounds that 
could be considered as having antioxidant potential were C5r and C5p.  Other methods to test for 
antioxidant activity was not carried out as this was only a preliminary antioxidant test for these 
compounds. 
 
Table 7-2  Antimicrobial activity of the synthesized compounds, MBCs in µM 
Compound Gram-positive 
bacteria 
Gram-negative bacteria Fungus 
 S. aureus MRSA E. coli P. aeruginosa K. pneumoniae C.albican
s 
C5b 268.19 536.42 321.83 536.42 107.28 214.56 
 C5e 141.49 70.73 282.98 565.98 24.32 94.33 
 C5h 2492.54 1661.69 103.85 623.12 830.85 1246.27 
 C5k 803.02 401.51 200.76 250.93 301.11 803.02 
 C5l 398.18 1992.48 149.43 199.24 149.43 398.18 
 C5o 1087.38 906.13 407.76 362.46 724.92 362.46 
 C5p 115.65 555.21 92.53 115.65 14.45 369.85 
 C5q 206.61 439.06 232.45 - - 3305.99 
 C5r 74.32 446.03 49.56 37.15 25.55 421.24 
 C5s - - 1109.50 - - 443.81 
 C5t - - 348.66 - - 1859.62 
Ampicilin 55.89 894.36 447.18 1788.73 447.18 447.18 
Ciprofloxacin 1.84 7.36 1.84 1.84 3.68 1.84 
Tioconazole - - - - - 100.84 
Highlighted values indicate the best acitivty 
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Table 7-3  Antioxidant activity of the synthesized compounds from the DPPH assay, IC50 in µM 
Compound IC50 (µM) Compound IC50 (µM) 
C5j 1326.93 C5q 1129.01 
C5p 386.55 C5r 306.71 
Ascorbic Acid (AA)  264.50  
Highlighted values indicate the best activity 
7.3.5 Docking discussion 
Several drugs including ciprofloxacin and lomefloxacin exhibit their antibacterial action by 
inhibition of bacterial type II topoisomerases (topoisomerase IV and DNA-gyrase) (Mitscher et 
al., 2005).  In order to support the antibacterial results and to gain some insight into the binding 
characteristics of the compounds with bacterial proteins, two representative compounds (RCs), 
C5r (most potent) and C5h (least potent) were docked into the empty active site of the 
topoisomerase II DNA-gyrase enzyme. 3D-coordinates of the enzyme co-crystallized with its 
inhibitor ciprofloxacin (pdb id: 2XCT (Bax B et al., 2010)) were downloaded from the RCSB 
protein data bank.  A binding sphere covering the active site was generated and docking of the 
RCs was performed using the CDOCKER module (Wu G et al., 2003) implemented in the 
Discovery Studio ver 4.0 (Accelrys) along with ciprofloxacin.  
 
The binding affinity of the docked compounds was assessed by computing their binding energies 
(BEs) [Ecomplex-(Eprotein+Eligand)].  The more negative the BE, the stronger the interaction with the 
enzyme. Compound C5r exhibited stronger interaction (BE = -124.2 kcal mol-1) with the enzyme 
in comparison to C5h (BE = -24.3 kcal mol-1).  This consequently supports the experimental results 
as C5r showed the highest MBC in the experimental assay performed.  The BE of C5r showed a 
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difference of approximately 30 kcal mol-1 compared to the computed BE of ciprofloxacin (-156 
kcal mol-1).  
 
The best docked pose of C5r and C5h in the active site of topoisomerase II DNA-gyrase (Figure 
7-2) showed that both the RCs interacted with similar amino acid residues (Arg458, Lys460 and 
Glu477).  This was also observed for ciprofloxacin (Figure 7-3).  Compound C5r (Figure 7-2), 
which was the most active antibacterial agent formed a classical hydrogen bond with Ser 1084 
(1.98 Å) and four non-classical hydrogen bonds with Arg458 (2.61Å), Lys460 (2.45Å) and Glu477 
(2.71Å, 2.76 Å).  The least active compound (C5h) displayed three hydrogen bonds with Glu477 
(2.61Å) and Lys460 (3.03Å, 3.05 Å) in addition to hydrophobic interactions with Arg458 (Figure 
7-2).  The fewer and relatively longer hydrogen bond distances in C5h could have led to its weaker 
binding with the enzyme and in turn lower activity.  Ciprofloxacin (the native ligand) fitted nicely 
into the active site of the enzyme through five hydrogen bonds with Glu477 (2.78Å, 2.80Å), 
Lys460 (2.34Å, 2.40Å) and Arg458 (2.14Å) amino residues and formed another two co-ordinate 
bonds with Mn2+ (Figure 7-3).  
 
Overall, the present docking result revealed that the interaction with the Mn+2 in the active site is 
crucial for the antibacterial activity.  Both compounds failed to show any interaction with Mn2+, 
which may be responsible for them not being as active as ciprofloxacin.   
 
7.3.6 Crystal structure 
The crystal structure of the parent compound, methyl 2-(4-(dimethylamino)phenyl)-1-(4-
fluorophenyl)-1H-benzo[d]imidazole-5-carboxylate (C5k) was obtained and the refinement data 
207 
are contained in the supplementary file (Table 7-S1*).  C5k crystallized in the monoclinic P 21/c 
space group with two molecules in the asymmetric unit.  The ester group and N-dimethyl group 
point away from each other and all groups are in the plane except the 4-fluoro phenyl group, which 
is perpendicular to the benzimidazole moiety on N-1.  Weak hydrogen bond interactions (C-H…O, 
C-H…F and C-H…N) were observed in the crystal structure (Table 7-4).  Further selected bond 
length were described in the supplementary file (Table 7-S2*).  An ortep diagram of C5k is given 
in Figure 7-4. 
* Present in the supplementary material 
 
Table 7-4  Hydrogen bond interactions for C5k 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 C(5b)-H(5b)...O(2)#1 0.95 2.49 3.4101(14) 162.3 
 C(8b)-H(8bi)...O(2)#1 0.98 2.63 3.3278(15) 128.3 
 C(7)-H(7)...F(1)#2 0.95 2.59 3.1002(13) 113.6 
 C(2a)-H(2a)...N(3)#3 0.95 2.46 3.2737(14) 143.3 





Figure 7-2  The orientation of C5r (A) and C5h (B) in the active site of topoisomerase II DNA-
gyrase. Ligands are shown as sticks (lemon color) and amino acids of the protein as lines.  Green 
dotted lines represent classical H-bonds, yellow dotted lines, non-classical H-bonds and red dotted 




Figure 7-3  The orientation of ciprofloxacin in the active site of topoisomerase II DNA-gyrase. 
Ligand is shown in sticks (lemon) and amino acids of protein are depicted in the lines format. 
classical H-bonds (green), non-classical H-bonds (yellow) and co-ordinate bonds (gold) 
 
 




We have developed an efficient, cost effective and faster route for 2-substituted fluorinated 
benzimidazoles via a solvent and catalyst free microwave method.  The synthesized compounds 
were screened for their antibacterial and antioxidant activities.  Of the twenty-two compounds 
tested, eleven compounds showed good antimicrobial activity and two showed good antioxidant 
activity.  Compounds C5p and C5r showed better activity than ampicillin against the microbial 
strains used in the assays.  These two compounds could be good leads for antimicrobial agents.  
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Chapter 8. Conclusion 
Seventeen derivatives of chiral amino acid tethered quinoxalines (A6a-A6n and B5a-c), 12 
derivatives of quinoxaline-amino acid-thiazolidines (B6a-l) and 22 derivatives of benzimidazole 
(C5a-v) were successfully synthesized with yields in excess of 75%.  Each of the synthesized 
compounds were fully characterised using NMR and mass spectrometry along with crystal 
structures of selected compounds.  The synthesis of quinoxaline-amino acid-thiazolidines and 
benzimidazoles under microwave conditions is a quick and efficient way of synthesizing these 
molecules.  In addition, the benzimidazole synthesis under microwave is a solvent free reaction, 
which can be considered a green method for the synthesis of these compounds.  Thermal studies 
supported by DFT and MD calculations on A6d indicated that H-2 was capable of hydrogen 
bonding interactions. 
 
Of the three classes that were synthesized, the best antimicrobial activity was seen by several 
compounds in the quinoxaline-amino acid-thiazolidine class.  Compounds B6b-c, B6f-g and B6j-
k all showed good broad spectrum activity with several MBC values <100 µM against the strains 
tested against.  B6f and B6j were the best overall antimicrobial agents with a broad spectrum of 
activity, being active at <100 µM against all of the strains tested against.  In addition, B6k was 
active at <100 µM against both S. aureus and MRSA with MBC values of 15.9 and 63.8 µM 
respectively.  Both B6f and B6j have a 4-fluorophenyl moiety on the thiazolidine group, but a 
methionine and tyrosine amino acid residue respectively.  B6b also has a 4-fluorophenyl group as 
B6f and B6j, however it has a valine residue instead, indicating that the amino acid interaction is 
also essential for activity since B6b is not as active as B6f and B6j.  The thiazolidine group is 
essential for activity, since the quinoxalines with only amino acids coupled to it (A6a-n and B5a-
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c) did not show as good antimicrobial activity as the thiazolidine hybrids.  In general the 
benzimidazoles were not as active as the quinoxaline-amino acid-thiazolidine hybrids with only 
two compounds (C5p and C5r) showing strain specific activity to Klebsiella pneumoniae with 
MBC values of 14.45 and 25.55 µM respectively.  Thus, the quinoxaline-amino acid-thiazolidine 
core structure with a 4-fluorophenyl moiety on the thiazolidine ring is a good lead for antimicrobial 
activity.  Further work can be explored where different amino acids can be coupled to this core 
structure to identify the amino acid that shows the best activity.  The results can be compared to 
the core structure with valine, methionine and tyrosine, which was carried out in this work. 
 
In general, the quinoxaline-amino acids were more active than the quinoxaline-amino acid-
thiazolidine derivatives in that all of the synthesized compounds of the series A6a-n were active 
in both the α-glucosidase and α-amylase assays.  Specifically, A6a, A6d and A6f have better 
activity than acarbose (IC50 of 88 µM) in the α-glucoside enzyme inhibition assay with IC50 values 
of 56, 12 and 42 µM respectively.  Combining a thiazolidine group to this core structure decreased 
activity as only three compounds were now active in these antidiabetic assays with high IC50 values 
of between 276 to 428 µM. 
 
Two quinoxaline-amino acid-thiazolidine hybrids, B6k and B6l showed IC50 values of 19.60 and 
10.53 µM respectively in the antioxidant assay carried out, comparable to ascorbic acid (IC50 16.86 
µM).  These compounds and their scaffolds, containing a tyrosine residue could be a lead for other 
antioxidant compounds, which have the potential to be anticancer agents.  Future work will involve 
making a series of quinoxaline-tyrosine-thiazolidine hybrids with a variety of substituted phenyl 
rings on the thiazolidine group and testing them for their antioxidant and anticancer activity. 
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Adding a thiazolidine moiety on the quinoxaline-amino acid scaffold only increased the 
antimicrobial activities of the compounds and not the antidiabetic activity.  Future work will 
involve reacting the amino group on the quinoxaline-amino acid scaffold and generate other 
classes of hybrid molecules or other derivatives at this position, for example carboxamides, Schiff 
bases and β-lactams to determine whether or not they have a positive effect in increasing the 
antimicrobial and antidiabetic activity of the compounds. 
 
